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ATM: Ataxia Telangiectasia Mutated 
bFGF:  Basic fibroblast growth factor  
BIN1: Bridging Integrator 1 
BMP: Bone Morphogenetic Protein  
BRCA2: Breast Cancer Type 2 susceptibility protein 
CCD1: Cyclin D1 
CCL2: Chemokine (C-C motif) ligand 2 
CDK: Cyclin Dependent Kinase 
CM: Cardiomyocytes 
CML: Chronic myelogenous leukemia 
CNS: Central Nervous System 
CNV: Copy Number Variation 
CTLs: Cytotoxic T Lymphocytes  
DH iPSC: Cyclin D1 made human iPSC 
DHFR: Dihidroxifolate reductase 
DNA-PKcs: DNA dependent protein kinases 
DSB: Double Strand Break 
ENDO: Endoderm cells 
ESC: Embryonic Stem Cells  
FGF2: Fibroblast Growth Factor 2 
GFP: Green Fluorescent Protein 
hESC: human embryonic Stem Cells 
HFFs: Human Foreskin Fibroblasts 
HLA: human leukocyte antigen  
HR: Homologous Recombination 
ICM: inner cell mass 
IL-10: Interleukin 10 
IL-15: Interleukin 15 
IL-6: Interleukin 6 
IPSC: induced Pluripotent Stem Cells 
KLF4: Krupple-Like Factor 4 
LIF: Leukaemia inhibitory factor 
LIG3: Ligase 3 
LPS: Lypopolysaccharides 
MCP1: Monocyte Chemotactic Protein 1  
MEFs: Mouse Embryonic Fibroblasts 
mESC: mouse Embryonic Stem Cells  
MH iPSC: C-Myc made human iPSC 
MHC: Major Histocompatibility Complex  
MN: Motor Neuron 
MRN: Mre11-Rad50-NBS1 
mRNA: messenger RNA  
MSC: Mesenchymal Stem Cells  
NBS1: Nijmegen Breakage Syndrome 1 
NHEJ: Non-Homologous End Joining 
NSC: Neural Stem Cells 
OCT4: Octamer-binding Transcription Factor 4 
OSKM: Oct4, Sox2, Klf4 and c-Myc  
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PAMP: Pathogen Associated Molecular Pattern 
PARP1: Poly (ADP-ribose) polymerase-1  
PI3K: Phosphoinositide 3-kinase 
Pol µ: Polimerase µ 
Pol λ: Polimerase λ 
POLQ or Pol θ: Polymerase θ 
Poly(I:C): Polyinosinic:polycytidylic acid 
ROS: Reactive Oxigen Species 
RPA: Replication Protein A 
RPE: Retinal Pigmented Epithelial 
SCI: Spinal Cord Injury 
SNP: Single Nucleotide Polymorphism  
SIRT1: Silent mating-type information regulation 2 homologue 1 
SMA: Spinal Muscle Atrophy 
SNP: Single Nucleotide Polymorphism 
SOX2: SRY (sex determining region Y)-Box 2 
TCR: T Cell Receptor 
TGFβ: Transforming Growth Factor β  
TLRs: Toll-Like Receptors 
TLR3: Toll-Like Receptor 3 
TLR4: Toll-Like Receptor 4 
TSS: Transcription Start Site 
VPA: Valproic Acid 
XRCC4: X-ray Repair Cross Complementing 4 
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Induced pluripotent stem cells (iPSC) can be made from adult somatic cells by 
reprogramming them with Oct4, Sox2, Klf4 and c-Myc. IPSC have given rise to a new 
technology to study and treat human disease (Takahashi et al., 2007). However, before 
iPSC clinical application, we need to step back and address two main challenges:  
(i) Genetic stability of iPSC. 
(ii) Immune response of iPSC-derived cells. 
 
To address these key issues, the overall mission of this PhD thesis is to advance iPSC 
technology by addressing two objectives. First, is to replace c-Myc with Cyclin D1 in 
the reprogramming cocktail (Oct4, Sox2, Klf4 and c-Myc or Cyclin D1) and second, to 
study the immune response of iPSC-derived cells. 
 
The quality of the starting iPSC determines the quality of the differentiated cells to be 
transplanted for clinical applications. In terms of genetic stability, aberrant cell 
reprogramming leads to genetic and epigenetic modifications that are the most 
significant barriers to clinical applications of patient iPSC derivatives (Gore et al., 
2011). Such aberrations can result from the cellular stress that accompanies 
reprogramming or from the reprogramming factors themselves (Lee et al., 2012a). IPSC 
made with c-Myc are neoplastic in mouse models and have a higher tumorigenic 
potential than embryonic stem cells, prompting a search for new pluripotency factors 
that can replace the oncogenic factors Klf4 and c-Myc (Huangfu et al., 2008; Miura et 
al., 2009; Okita et al., 2007). We chose Cyclin D1 to replace c-Myc because of previous 
observation it can be used to reprogram cells to iPSC (Edel et al., 2010) and because of 
its DNA repair function (Chalermrujinanant et al., 2016). In this thesis we adopt a 
synthetic mRNA method to demonstrate that Cyclin D1 and c-Myc made iPSC have 
equal pluripotency using standard methods of characterisation. Moreover, no significant 
changes in copy number variation were found between starting skin cells and iPSC 
highlighting it is the method of choice for generating high quality iPSC. Further in-
depth analysis revealed that Cyclin D1 made iPSC have reduced genetic instability 
assessed by: (i) reduced DNA double strand breaks (DSB), (ii) higher nuclear amount of 
the homologous recombination key protein Rad51, (iii) reduced multitelomeric signals 
(MTS) and (iv) reduced teratoma growth kinetics in vivo, compared to c-Myc made 
iPSC. Moreover, we demonstrate that Cyclin D1 iPSC derived neural stem cells engraft 
successfully, survive long term and differentiate into mature neuron cell types with high 
efficiency, with no evidence of pathology in a spinal cord injury rat model.  
 
As we move towards the clinic with iPSC-derived cells for cell transplantation, the 
immunogenic response is thought to be one of the main advantages of iPSC technology 
for clinical application, because of its perceived lack of immune rejection of autologous 
cell therapy. We hypothesize that iPSC derived cells are unlikely to provoke an immune 
response. Here we have performed an analysis of the innate and adaptive immune 
response of human skin cells (termed F1) reprogramed to iPSC and then compared to 
iPSC-derived cells (termed F2) using proteomic and methylome arrays. We found little 
differences between MHCI expression and function; however, we discovered a short 
isoform of the Toll-like receptor 3 (TLR3), essential for viral dsRNA innate immune 
recognition, which is predominantly upregulated in all iPSC derived cells analysed and 
not seen in normal endogenous cells. High levels of the TLR3 isoform is associated 
with unresponsiveness to viral stimulation measured by lack of IL6 secretion in iPSC 
derived neural stem cells. We propose a new model that TLR3 short isoform competes 
with the full length wild type isoform destabilizing the essentially required TLR3 
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dimerization process. These differences could result in supressed inflammatory effects 
for transplanted human iPSC-derived cells in response to viral or bacterial insult. 
Further work to determine the in vivo effects is warranted and calls for screening of 
iPSC lines for TLR3 isoform expression levels before clinical use. In conclusion, this 
thesis has advanced iPSC technology by defining a new method that is a significant 
advance with novel insights that has immediate impact on current methods to generate 
iPSC for clinical application and more accurate disease modelling.  
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1. STEM CELLS 
 
Stem cells are cells with self-renewing capability and the ability to differentiate into 
various cell types. They can be classified according to their capacity to differentiate and 
their origin.  
 
 
Depending on their capacity to differentiate into other cell types stem cells are classified 
as: 
 
Totipotent:  
 
Stem cells with the ability to differentiate into all possible cell types. They have a self-
organizing ability to generate a whole organism (Niwa et al., 2007). Only the zygote 
and early blastomere are totipotent in mammals.  
 
Pluripotent: 
 
Stem cells that can give rise to cell types from the three germ layers: ectoderm, 
mesoderm and endoderm. They differ from totipotent cells as pluripotent cells cannot 
give rise to the trophectoderm, which will form the placenta in a developing embryo. 
For instance, inner cell mass (ICM) cells that are specific to the early embryo are 
pluripotent (Pera et al, 2010). 
 
Multipotent:  
 
Stem cells that can give rise to all cell types within a particular lineage. For instance, 
mesenchymal stem cells can give rise to bone, muscle or adipose cells. Neural stem 
cells and Hematopoietic stem cells are other examples.  
 
Unipotent:  
 
Stem cells that can only generate one type of cell. For example spermatogonial stem 
cells can only form sperm (Jaenisch et al., 2008).  
 
 
 
Depending on their origin, stem cells are classified into: 
 
 
Embryonic:  
 
Embryonic Stem Cells (ESC) are derived from the epiblast of the blastocyst and can be 
expanded indefinitely under proper culture conditions in vitro (Evans et al., 1981; 
Thomson et al., 1998). In embryos in vivo, pluripotent cells are transiently present 
before differentiating into somatic cells. ESC can give rise to all cell types of the three 
germ layers of the foetus: ectoderm, mesoderm and endoderm. When ESCs are injected 
into adult mice they produce teratomas, which contain tissues comprising the three germ 
layers. When taken from the blastocyst and cultured in vitro, cells keep their pluripotent 
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potential even after prolonged culture. It was first shown with mouse Embryonic Stem 
Cells (mESC) after being reintroduced into a blastocyst by their complete integration 
into the developing embryo (Beddington et al., 1989). Unlike mESC, human Embryonic 
Stem Cells (hESC) cannot contribute to the germ line after introduction into a host 
blastocyst (Yu et al., 2008). 
 
 
Germinal:  
 
Germinal stem cells or embryonic germ cells (EGC) are the cells that give rise to the 
gametes (sperm and eggs) in adults. They can be derived from primordial germ cells in 
vitro. Mouse EGS are also pluripotent and are undistinguishable from mESC 
morphologically, also expressing typical mESC markers. Furthermore, they can 
contribute to chimaeric mice upon blastocyst injection (Yu et al., 2008).  
 
Somatic:  
 
Somatic stem cells are undifferentiated cells found in adult or fetal somatic 
differentiated tissues. They have limited self-renewal capability and generally can 
differentiate only into cell types associated with the organ system in which they reside. 
Many tissues have niches of somatic stem cells, like: pancreas, brain, bone marrow, 
mammary gland, liver, skeletal muscle, the gastrointestinal tract, skin, dental pulp, 
blood and the eye. 
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2. EMBRYONIC STEM CELLS (ESC) 
 
Mouse embryonic stem cells (mESC) were the first embryonic stem cells to be isolated 
from the inner cell mass (ICM) of mouse blastocysts and successfully cultured in vitro 
(Evans et al., 1981; Martin et al., 1981). They were initially cultured on top of a feeder 
layer of mitotically inactivated mouse embryonic fibroblasts (MEFs). Posterior analysis 
with filtered feeder layer produced conditioned medium led to the identification of 
leukaemia inhibitory factor (LIF). However, in serum-free medium, LIF alone was not 
able to prevent mESC differentiation, although with bone morphogenetic protein (BMP) 
pluripotency was sustained (Yu et al., 2008). 
 
Later in 1998, human Embryonic Stem Cells (hESC) were also isolated from embryos 
(Thomson et al., 1998). Initially it was achieved with a suboptimal culture media 
conditions using a feeder layer and serum-containing medium. This time however, LIF 
and other related cytokines failed to support human and non-human primate ESC. 
Instead, Basic fibroblast growth factor (bFGF) and transforming growth factor β 
(TGFβ)/Activin/Nodal signalling were reported to be of high importance for the culture 
of undifferentiated hESC (Yu et al., 2008). Because of the critical requirement of hESC 
on bFGF, they are thought to be derived from a later stage of the inner cell mass 
development than mESC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction figure 1.  Embryonic stem cells (ESC). ESC are isolated from the inner cell mass of the 
blastocyst. In vitro they can self-renew indefinitely and differentiate into cell types from the three germ 
layers: mesoderm, endoderm and ectoderm. Therefore ESC can be expanded in high numbers in vitro, 
differentiated into specific cell lineages such as: liver, pancreatic islet cells, intestinal cells, neurons, blood 
cells or muscle cells, and then transplanted to patients with damaged target tissues. 
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3. INDUCED PLURIPOTENT STEM CELLS (IPSC) 
 
Due to the difficulty of finding a stable source of hESCs and the ethical issues 
associated to work with human embryos to isolate them, there was an urgency to find an 
alternative method to isolate pluripotent cells for the regenerative medicine field. 
Hence, in 2006 the discovery of induced pluripotent stem cells (iPSCs) signified a great 
leap in the field, which was awarded with the Nobel Prize later in 2012. IPSC avoid the 
ethical concerns of ESC, since they come from somatic cells of an adult organism. 
 
Induced pluripotent stem cells (iPSCs) are originated from adult somatic cells that have 
been reprogrammed, through ectopic expression of four defined factors: Oct4, Sox2, 
Klf4 and c-Myc (OSKM) (Takahashi et al., 2007) to cells with similar characteristics to 
embryonic stem cells (ESCs), meaning they can self-renew and differentiate to tissues 
of the three germ layers: mesoderm, endoderm and ectoderm. It was first discovered in 
2006 by Dr. Shinya Yamanaka with mouse cells (Takahashi et al., 2006), and was 
confirmed later in human cells (Takahashi et al., 2007). Previously, reprogramming 
only had been possible by transfer of nuclear contents into oocytes (Gourdon et al, 
1962, Wilmut et al, 1997) or by cell fusion with ES cells (Cowan et al, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human iPSC can be established from various tissues: adult and embryonic fibroblasts 
(Takahashi et al., 2007; Yu et al., 2007), keratinocytes (Aasen et al., 2008), adipose 
tissue (Sun et al., 2009), peripheral blood (Loh et al., 2009), cord blood (Giorgetti et al., 
2009), amniotic fluid-derived cells (Ye et al., 2009), neural precursor cells (Kim et al., 
2009), among others. 
 
Human iPSCs express marker genes, growth properties and morphology similar to 
human ESCs, however, they are not identical. Thus, it has been of interest the 
investigation to optimize the reprogramming method to yield iPSCs fully equivalent to 
Introduction figure 2.  Induced pluripotent stem cells (iPSC) are reprogrammed from adult cells 
using defined factors: OCT4, SOX2, KLF4 and C-MYC (Takahashi et al., 2006). They can self-renew 
indefinitely and can differentiate into cell types from the three germ layers: mesoderm, endoderm and 
ectoderm. 
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ES cells. The assays used for establishing pluripotency equivalence between ESC and 
iPSC are four criteria (Lujan et al., 2010): 
 
1) By subcutaneously injecting iPSC into mice it results in teratoma formation, 
containing tissues from the three germ layers: ectoderm, mesoderm and 
endoderm. 
2) Injecting iPSC into blastocysts develops into contribution to chimera animal 
formation. 
 
3) Germline transmission: progeny is able to display transgene expression. 
 
4) Full embryo contribution (ability to generate more live-births “all-iPS cell 
embryos”) by tetraploid (4N) embryo complementation. 
 
Human ESC and iPSC present differences in important aspects like global gene 
expression, epigenetic landscape and genomic imprinting. However, iPSC acquire ESC 
cell cycle properties during reprogramming (Ghule et al., 2010). But, although extended 
culture of iPSC makes them transcriptionally closer to ESC (Chin et al., 2009), it as 
well triggers chromosomal aberrations (Mayshar et al., 2010). It has also to be taken 
into account that iPSC derived from adult cells harbor residual DNA methylation 
signatures from their tissue of origin, retaining a specific epigenetic memory that 
influence differentiation propensity. Thus the forming potential of iPSCs depends on the 
differentiation status of the donor cell. For instance, blood-derived iPSC yielded more 
hematopoietic colonies than fibroblast-derived iPSC (Kim et al., 2010).  
 
 
3.1 REPROGRAMMING METHODS: 
 
Several methods have been established for reprogramming cells to a pluripotent state. 
The first method to make human iPSCs used a retroviral vector delivery system, 
carrying the risk of transgene reactivation and insertional mutagenesis (Takahashi et al., 
2006; Takahashi et al., 2007). Since then many other groups have used the same 
methods to reprogram cells to pluripotency (Aasen et al., 2008; Stadtfeld et al., 2008; 
Okita et al., 2007; Yu et al., 2007; Woltjen et al., 2009Edel et al., 2010; McLenachan et 
al., 2012). Research efforts thus focused on searching different ways to induce 
pluripotency with non-viral methods to prevent transgene reactivation and avoid the risk 
of genomic recombination or insertional mutagenesis (Fusaki et al., 2009; Zhou et al., 
2009; Warren et al., 2010; Masuda et al., 2013; Yoshioka et al., 2013). Hence, currently 
only three non-integrative methods appear to be appropriate for reprogramming patient 
cells for clinically safe cellular therapy: Sendai virus, mRNA transfections and episomal 
vectors (Introduction Fig. 3).  
 
3.1.1 Transfection of synthetic modified mRNA:  
 
Consists on the administration of messenger RNA (mRNA) modified to overcome 
innate antiviral immune responses. Although a daily transfection regime is required to 
maintain a sustained expression, mRNA reprogramming allows a higher reprogramming 
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efficiency (Warren et al., 2010). It offers the best option for future clinical applications 
as expression is transient over 48 hours and you can control the dose. In this thesis we 
have focused on reprogramming to iPSC by mRNA transfections as a substitute to 
retroviral transduction. 
3.1.2 Sendai virus:  
 
Non-integrative Sendai virus have the advantages of wide host specificity and low 
pathogenicity, and the disadvantage of strong immunogenic response (Fusaki et al., 
2009), triggering the applicability of this method to firstly require the development of 
less antigenic vectors.  
3.1.3 Episomal vectors:  
 
Consist on introducing episomal genes that are ectopically expressed in the cells. 
Afterwards, the episome is naturally withdrawn by dilution while the iPSC divide (Yu 
et al., 2009). Furthermore, in the case of episomal vectors and Sendai virus, final clones 
have to be shown to be free of the original vector or virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, regardless the method used, cell reprogramming always led to chromosome 
abnormalities and genomic instability (Gore et al., 2011), which is one of the main 
barriers to clinical application. Indeed, about half of the human adult derived iPSC 
clones exhibit genetic and epigenetic variations, thought to result from incomplete 
reprogramming, mutation in somatic cells and cellular stress during reprogramming 
(Koyanagi-Aoi et al., 2013).  
 
Futhermore, an extensive comparison of all the non-integrating reprogramming methods 
has reported that, although having a lower successful rate and having a higher workload, 
mRNA transfections is more efficient, colonies emerge earlier and has a lower rate of 
aneurploidy than Sendai virus and episomal vectors (Schlaeger et al., 2015). 
 
 
 
 
Introduction figure 3.  Three main non-integrative methods for reprogramming adult cells to iPSCs 
in a clinical grade way in order to avoid insertional mutagenesis or transgene reactivation: a) Direct 
transfection of synthetic modified mRNA (Warren et al., 2010), b) Sendai virus (Fusaki et al., 2009) 
and c) Episomal vectors: (Yu et al., 2009). Diagram has been made by the author. 
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3.2 REPROGRAMMING FACTORS 
 
In order to discover the cocktail combination of reprogramming factors, Dr. Yamanaka 
screened 24 candidate factors: Ecat1, Dppa5, Fbxo15, Nanog, ERas, Dnmt3l, Ecat8, 
Gdf3, Sox15, Dppa4, Dppa2, Fthl17, Sall4, Oct3/4, Sox2, Rex1, Utf1, Tcl1, Dppa3, 
Klf4, β-catenin, c-Myc, Stat3 and Grb2 (Takahashi et al., 2006). Finding the most 
suitable reprogramming factors cocktail combination is important to obtain high quality 
iPSCs carrying few or no genetic aberrations to become less tumorigenic. Accordingly, 
other transcription factors alternative to classic Oct4, Sox2, Klf4 and c-Myc (OSKM) 
have been evaluated as potential reprogramming factors, such as the orphan nuclear 
receptor Esrrb, which was used as a substitute of Klf4 together with Oct4 and Sox2 
(Feng et al., 2009), or Glis1 that was able to substitute c-Myc reducing the number of 
partially reprogramed cells (Maekawa et al., 2011). Similarly, it was observed 
reprogramming by removing c-Myc and only using Oct4, Sox2 and Klf4 (Yamanaka et 
al., 2006), although it was highly inefficient and most clones had issues to get 
expanded. Even, it has been explored cell lines that can be reprogrammed with just Oct4 
and Sox2 (Giorgetti et al., 2009; Giorgetti et al., 2010; Montserrat et al., 2013) and even 
only with Oct4 in adult neural stem cells (Kim et al., 2009). However, they were only 
successful starting from specific cell origins like cord blood (CB) cells or neural stem 
cells, which are not easily available, and using lentiviral vectors instead of clinical grade 
methods. Yet, the main transcription factors used for reprogramming are Oct4, Sox2, 
Klf4 and c-Myc, described below: 
 
OCT4:  
 
The main transcription factors to maintain pluripotency are Oct4, Sox2 and Nanog. 
Octamer-binding transcription factor 3/4, also known as Oct4 or Pou5f1, is a POU 
domain containing core transcription factor that binds specific target loci for 
maintaining pluripotency (Boyer et al., 2005). Oct4 expression is necessary to develop 
the inner cell mass in vivo. It is therefore highly expressed in ESC and iPSC and when 
its expression diminishes cells differentiate and lose pluripotency. Actually, the main 
classical four reprogramming transcriptional factors: Oct4, Sox2, Klf4 and c-Myc must 
have a specific stoichiometry: OSKM in a proportion of 3:1:1:1 (Kawamura et al, 
2009). Hence, a critical amount of Oct4 is required to sustain pluripotency since only a 
50% increase or decrease of Oct4 can lead to ESC differentiation (Yamanaka, 2008; 
Niwa et al., 2000).  
 
SOX2:  
 
Sex-determining region Y (SRY)-related HMG-box 2 (Sox2) transcription factor is part 
of a large family of 20 proteins sharing the DNA-binding motif HMG box. Sox2 is 
expressed in ESC, iPSC, extra-embryonic ectoderm, trophoblast stem cells and neural 
stem cells (Avilion et al., 2003). Similarly to Oct4, Sox2 dysregulation results in rapid 
differentiation (Fong et al., 2008; Yamanaka et al., 2008). Sox2 dimerizes with Oct4 
(Yuan et al., 1995) being involved in the self-renewal of ESC and iPSC. Indeed, half of 
Oct4 bound genes are also bound by Sox2 and 87% of these are also co-occupied with 
Nanog (Boyer et al., 2005) 
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KLF4:  
 
Kruppel-like factor 4 (Klf4) was first considered a candidate in the Reprogramming 
factors cocktail since it had been shown to contribute to the long-term maintenance of 
the ES cell phenotype and the rapid proliferation of ES cells in culture (Li et al., 2005a). 
Later, it has been shown that Klf4 induces epithelial properties by up-regulating E-
cadherin directly (Li et al., 2010). Therefore, Klf4 mainly acts at the initial phase of 
reprogramming to initiate mesenchymal-to-epithelial transition (Chen et al., 2011). On 
the other hand, Klf4 had previously been reported to suppres proliferation as well 
through activating p21 (Zhang et al., 2000), to inhibit apoptosis induced by c-Myc 
(Zindy et al., 1998) and to repress p53 (Rowland et al., 2005). 
 
C-MYC:   
 
Myc genes are key regulators of cell proliferation, and their deregulation contributes to 
the origin of most tumours in humans. Specifically, c-Myc is a proto-oncogene that can 
give raise to tumor formation (Okita et al., 2007). It has many targets that enhance 
proliferation and transformation (Adhikary et al., 2005), many of which may have roles 
in the generation of iPSC. In ESC, c-Myc has been shown to maintain pluripotency and 
self-renewal (Varlakhanova et al., 2010). On the other hand, c-Myc role in iPSC 
reprogramming is not only in cell proliferation increase but also through the control of 
histone acetylation (Fernandez et al., 2003; Araki et al., 2011), since it associates with 
histone acetyltransferase (HAT) complexes and induces global histone acetylation 
allowing Oct3/4 and Sox2 to bind to their specific target loci. Therefore, in the absence 
of c-Myc, the overall efficiency of reprogramming is drastically reduced and the 
reprogramming time is increased (Habib et al., 2013). 
 
The first part of the thesis is based on a previous observation that c-Myc oncogene, one 
of the four reprogramming factors, can be replaced by cell cycle gene Cyclin D1 in the 
reprogramming cocktail (Edel et al., 2010). With this replacement we pursue to reduce 
iPSCs cancer threat and genetic instability.  
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3.3 REPROGRAMMING EFFICIENCY  
 
The issue of low efficiency in reprogramming still remains one of the main challenges 
to solve in the iPSC field. Reprogramming efficiency is determined by counting the 
number of iPSC colonies formed after reprogramming and dividing it by the total 
number of infected cells seeded. However, efficiency can be increased by modulating 
key components, like hypoxic condition (5% O2) (Yoshida et al., 2009) during 
reprogramming or by activation of enhancers or inhibition of barriers.  
 
For example, a manner to increase efficiency is to modulate certain genes such as: 
downregulation of p53-p21 pathway (Kawamura et al., 2009), overexpression of Lin28 
that inhibits Let7 induced differentiation (Heo et al., 2009), overexpression of Nanog 
(Han et al., 2010) or depletion of the structural component Mbd3, which promoted near 
100% induction of somatic cells reprogrammed to pluripotency through suppressing the 
formation of the Nucleosome Remodelling and deacetylases (NuRD) complex (Rais et 
al., 2013), among others. 
 
Other approaches to increase efficiency are based on chemicals that are added during 
the reprogramming process. For instance the addition of vitamin C (Esteban et al., 
2009); cytokines like tamoxifen (Yang et al., 2010b); the histone deacetylase inhibitor 
Valproic acid (VPA1) (Huangfu D. et al., 2008); the inhibitor of DNA 
methyltransferases 5-azacytidine (5-AZA) (Shi et al., 2008); inhibitor of MAPK (Yang. 
et al., 2010) or the inhibitor of GSK3 to suppress differentiation (Ying et al., 2008).  
 
Also, depending on the reprogramming method used efficiency is going to be different. 
It has been reported that viral reprogramming efficiency (0.04%) is lower than modified 
mRNA efficiency (1.4%) (Warren et al, 2010). This is another reason why in this thesis 
we wanted to reprogram cells using mRNA transfections.  
 
  
                                                        
1 The lack of chromatin silencing caused by VPA demethylation also renders the activation of the Dlk1-Dio3 gene 
cluster, involved in the development of the wholly reprogramming process (Stadtfeld et al., 2010). 
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3.4 THERAPEUTIC POTENTIAL OF IPSC 
 
Human iPSC technology holds great promise in the regenerative medicine field because 
of their capability to differentiate into any cell type of the three germ layers. Even 
elderly patient cells also have the ability to be reprogrammed into iPSCs (Dimos et al., 
2008). Potential clinical applications range from drug screening, disease modelling and 
autologous cell therapies.  
 
Drug screening in iPSC derived cells is advantageous because of the possibility to do 
the screening on specific cell types that without iPSC differentiation are difficult to find 
a source to obtain. Furthermore iPSC can be easily expanded to produce higher number 
of differentiated cells to work with.  
 
Disease modelling using iPSC derived cells is advantageous to unveil the mechanism of 
specific diseases since scientists can work with iPSC containing the specific mutation 
that confers the illness. For example, iPSC technology has been used for setting cellular 
models for studding human diseases and performing drug screening tests. For instance, 
in 2010, Rett syndrome (RTT) patient-iPSC-derived neurons were produced as a model 
to study the disease. These cells were reported to exhibit fewer glutaminergic synapses 
formation, reduced neuritis spines density, smaller soma size, electrophysiological 
defects and altered calcium signalling; showing thus a neural network maturity 
deficiency (Marchetto et al., 2010). Thus, there is still a need to improve the 
differentiation methods employed not only for being more suitable for transplants but to 
reach an acceptable cellular platform for clinical drug screening research as well.  
 
3.4.1 IPSC Cell Therapy  
 
Regarding cell therapy, the potential application of iPSCs-derived cells offers a source 
for therapeutic treatment, either autologous or allogeneic, of a wide range of diseases, 
like neurodegenerative disorders, spinal cord injury, anaemia or diabetes among others. 
Correspondingly, numerous studies have been conducted since iPSC discovery to prove 
iPSCs derived cells therapeutic potential in animal models, aiming engraftment 
potential and illness recovery. 
 
The first graft trial of iPSC-derived tissue in animal models was done in 2007 to treat 
sickle cell anaemic mice (Hanna et al., 2007). Hematopoietic progenitors (HP) were 
derived from iPSCs reprogrammed from mouse fibroblasts. In those iPSCs, genetic 
defects responsible for the anaemia were repaired through homologous recombination. 
The transplantation of those HPs reconstituted the haematopoietic system of sickle mice 
correcting the disease phenotype (Hanna et al., 2007).  
 
Afterwards, in 2008 it was reported that loss of motor neurons from spinal cord and the 
motor cortex could be replaced with patient specific iPSCS-derived motor neurons in 
mice with amyotrophic lateral sclerosis (ALS) (Dimos et al., 2008). Even elderly 
patients cells were able to be reprogrammed into iPSCs.  
 
Later on, engraftment of iPSC-derived myocites was successfully viable in dystrophic 
mice suffering from Duchenne muscular dystrophy (MD), in which regeneration and 
functional improvement was observed by transplanting satellite cells into dystrophin-
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deficient mice (Darabi et al., 2012). Moreover, the amount of stem or progenitor cells 
needed to be appropriate to succeed in graft transplantation (Darabi et al., 2012). 
 
IPSC-transplantation therapy research has also focus on ischemic stroke of infarcted 
brains. Formerly sensorimotor function in rat brain was significantly improved after 
transplanted iPSCs migrated to injured areas, and differentiated into neuron-like cells 
successfully (Jiang et al., 2011). And most recently iPSC-derived neurons and 
astrocytes were transplanted into brain damaged areas after ischemic stroke injury in a 
rat model in which function recovery was significantly improved in comparison with 
control groups (Yuan et al., 2013).  
 
In another disease model, human iPSC derived from fibroblasts of patient with spinal 
muscle atrophy, were genetically corrected. Afterwards, iPSC were derived into motor 
neurons and were transplanted into a spinal muscle atrophy mouse model. A significant 
recovery was shown in the cells injected group compared with the control sham group 
(Corti et al., 2012). 
 
These previously described approaches in neurodegenerative disorders demonstrate the 
potential viability of transplantation therapy of human iPSCs-derived neuron. This new 
biomedical tool also offers the promises of potential treatment for Parkinson and 
Diabetes for example, as it has been reported the generation of functional human 
pancreatic β cells in vitro (Pagliuca et al., 2014), among other diseases. 
 
Early this year, it has been published the first human clinical trial for iPSC 
transplantation therapies has been finished in the RIKEN institute, Japan (Mandai et al., 
2017). It has consisted on iPSC derived retinal pigmented epithelial (RPE) cells 
transplantation in two age-related macular degeneration (AMD) patients. In the second 
patient however, the experiment was suspended since it were found genetic instabilities 
in that patient iPSC. The trial has demonstrated the viability and safety of the procedure 
and that although there has not been reported any improvement in patients sight, at least 
the degeneration did not worsen but was maintained. Authors insisted though, in the fact 
that only one patient was not enough to claim any conclusion. However, the first 
clinical trial of iPSC in human has been overall satisfactory. 
 
In this thesis, we have assessed iPSC derived Neural Stem Cells (NSC) survival, 
engraftment and differentiation potential in a spinal cord injury (SCI) rat model and 
iPSC derived Motor Neurons (MN) in a Spinal Muscle Atrophy (SMA) mouse model.  
 
 
3.4.1.1 Spinal Cord Injury (SCI) 
 
According to the world Health Organization, every year between 250.000 and 500.000 
people worldwide suffer a spinal cord injury (SCI) (WHO webpage, 2017). In the last 
decades, progress had been made in surgical and rehabilitation treatments for SCI, 
however these approaches are only palliative. Transection of the spinal cord typically 
creates limited repair and poor functional recovery after the loss in motor and sensory 
function below the injury site. The accumulative death of neurons, astroglia, and 
oligodendroglia in and around the lesion site leads to neural circuitry disruption and 
dysfunction (Beattie et al., 2000). After the lesion, because of the scar formation, 
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injured axons are unable to grow, regenerate or reconnect, triggering a permanent 
interruption of the injured nervous route (Beattie et al., 2000; Blight et al., 1992; 
Grossman et al., 2001). Over the following hours after the traumatic insult, by-products 
of cell necrosis (DNA, ATP, glutamate) are released into the microenvironment leading 
to a rapid and progressive secondary injury cascade which generates further cell death 
and activation of pro-inflammatory microglia (Choo et al., 2007; LaPlaca et al., 2007). 
Macrophages and microglia infiltrate and generate ROS while phagocyting debris. 
Neutrophils and later lymphocytes also infiltrate the immune-privileged blood-spinal 
cord barrier and contribute to inflammatory response (Waxman, 1989; Ulndreaj et al., 
2016). 
 
During the following days, neurons are hampered to regenerate by an interlaced 
network of hyperproliferative astrocytes forming the glial scar around the lesion. The 
extracellular matrix also contains chondroitin sulfate proteoglycan (CSPGs) deposits 
which form a formidable barrier to neuronal growth. Therefore, inability to remyelinate 
spared axons and failure of axons to build again the signal conduction because of the 
astrocyte scar contribute to the incurability of SCI (Deumens et al., 2006; Dietz et al., 
2006; Harel et al., 2006). 
 
A number of interventions transplanting cell types derived from the adult Central 
Nervous System (CNS), have shown therapeutic efficacy in various animal models of 
SCI (Ogawa et al., 2002).  However, there were still some barriers to clinical translation 
like the issues of isolation and expansion of large numbers of cells in a uniform manner 
and patient immunosuppression after transplant. In this sense, numerous pluripotent and 
multipotent cell types have been investigated for treating SCI (Tobias et al., 2003; Erceg 
et al., 2010; Tetzlaff et al., 2011; Vawda et al., 2012; Lopez-Serrano et al., 2016). 
Therefore, since the discovery of induced pluripotent stem cells (Takahashi et al., 2006), 
iPSC derived cells have held great promise for the regenerative medicine field. IPSC 
provide an autologous cell source and avoid the ethical and moral concerns of other 
stem cell sources. These pluripotent cells can be expanded indefinitely in vitro and can 
provide a large quantity of differentiated cells for transplantation, including specific 
cells of neuronal or glial fates (Benzing et al., 2006; Gerrard et al., 2005; Itsykson et al., 
2005; Keirstead et al., 2005; Lee et al, 2007; Li et al., 2005b; Ludwig et al., 2006; Erceg 
et al., 2008).  
 
IPSC technology tool offers the promises of potential treatment for a wide range of 
diseases described above. However, autologous iPSC-derived cellular transplantations 
still bargain the hurdle of tumorigenic threat. 
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3.5 TUMORIGENIC THREAT OF IPSC 
 
One of the main concerns of iPSC is the potential tumorigenic threat of iPSC-derived 
cells after transplantation into patients, since stem cells and cancer cells share some 
characteristics. Some shared features are: rapid proliferation rate, lack of contact 
inhibition, propensity for genomic instability, high activity of telomerase, high 
expression of oncogenes, miRNA signatures and epigenetic status (Ben-David et al., 
2011b). Self-renewal capacity and pluripotency are double-edged swords that prompt 
ESC and iPSC tumorigenic as well as cancer cells. Spontaneous transformation of ESC 
in culture increases the risk of formation of teratocarcinomas (Werbowetski-Ogilvi et 
al., 2009) on transplantation of differentiated cells derived from ESC. However, iPSC-
derived teratomas develop faster, more efficiently and more aggressively than ESC-
derived teratomas (Moriguchi et al., 2010). Even the formation of benign teratomas is 
also unacceptable regarding transplantation therapy. There is a need to understand the 
carcinogenic aspects of iPSC. Therefore, ESCs and iPSC tumorigenicity is a big hurdle 
hindering clinical application nowadays.  
 
IPSC cancer risk has been studied widely in mouse models (Alvarez et al., 2013; Mc 
Lenachan et al., 2012; Kiuru et al., 2009; Miura et al., 2009; Okita et al., 2007). 
Interestingly, the tumorigenicity of virally derived iPSC and transgene-free iPSC 
showed no significant differences (Moriguchi et al., 2010). Thus, regardless the method 
used in reprogramming there is a genotoxic stress response that can lead to aneuploidy 
with aberrant iPSC karyotypes (Mayshar et al., 2010). Also iPSC derived from mature 
somatic cells that have lived longer enough to acquire mutation that randomly confer 
anti-apoptotic advantages, are more prone to be selected during culture (Mayshar et al., 
2010). Regarding reprogramming factors, c-Myc is a well-established oncogene 
involved in tumor development (Albihn et al., 2010); however, Oct4, Sox2 and Klf4 are 
also known to be associated with cancer progression in specific tumours (Wang et al., 
2010; Ji et al., 2010; Tian et al., 2010).  
 
Tumorigenesis in ESC and iPSC has been proposed to be Nanog-related, because 
regardless of the reprogramming genes used, its pre-transduction treatment activated the 
carcinogenic program (Grad et al 2011). Also, during reprogramming, inactivation of 
p53-p21 antitumor system either yields iPSC generation or renders cancer (Hussein et 
al., 2011). Hence, downregulation of p53 pathway during reprogramming can lead to 
high levels of DNA damage, therefore compromising genomic integrity. Damage can be 
noted as a rise in the CNV levels, found higher in early-passaged iPSCs. However, most 
of these changes are lost by the selection pressure of the culture (Hussein et al., 2011). 
 
Several strategies have been proposed to cope with tumorigenicity and improve safety. 
As only few several hundreds of pluripotent cells are enough to generate tumours, it is 
required a 100% pure population of differentiated cells to safely apply ESC and iPSC 
derived treatments. Eliminating the remaining pluripotent cells by cytotoxic antibodies 
(Choo et al., 2008) or even separating ESC using MACS or FACS (Fong et al., 2009) 
don’t result in 100% pure cultures of only differentiated cells. Or even introduction of 
suicide genes to attack the tumour (Schuldiner et al., 2003). 
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3.5.1 Ki67 
 
Once iPSC pluripotency capabilities are assessed in vivo with teratoma formation 
assays2 to corroborate differentiation into the three germ layer tissues in vivo, 
assessment of proliferation rate of teratomas can be measured with Ki67 staining.  
 
Ki67 (or MIB1) is a nuclear protein that is a cellular marker for proliferation (Scholzen 
et al., 2000). Furthermore, it is associated with ribosomal RNA transcription 
(Bullwinkel et al., 2006). Through interphase, Ki67 antigen can be solely detected in the 
cell nucleus. However, in mitosis most of the protein is relocated to the surface of the 
chromosomes. During all active phases of cell cycle (G1, S, G2, and mitosis) Ki67 is 
present, but is lacking in resting cells (G0) (Bruno et al., 1992).  
 
Ki67 is an excellent marker to define the growth portion of a population of cells. 
Interestingly, the fraction of Ki67 positive tumour cells, also called Ki67 labelling 
index, is very often correlated with the clinical course of cancer. The main examples for 
this marker are carcinomas of the prostate, brain, breast and nephroblastoma. Prognostic 
values for survival and tumour reappearance has repeatedly been proven in uni- and 
multivariate analysis for these types of tumours. 
 
                                                        
2 By injecting iPSC subcutaneously into nude mice. 
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4. C-MYC AND CYCLIN D1   
 
Since the aim of this first part of the thesis is to remove the oncogenic threat of c-Myc 
from the reprogramming cocktail and replace it with Cyclin D1, here these two genes 
are introduced and an overview is given.   
 
 
4.1 C-MYC 
 
Identified three decades ago, c-Myc is a well-established oncogene, associated with 
many human cancers, involved in tumour development (Dang, 2010; Wasylishen and 
Penn, 2010; Albihn et al., 2010). All Myc family proteins (C-Myc, N-Myc and L-Myc) 
regulate processes involved in many if not all aspects of cell fate. Indeed, in vitro and 
in vivo DNA-binding studies, have designated an increasing number of genes as Myc 
targets (Ji et al., 2011; Margolin et al., 2009; Shaffer et al., 2006; Wasylishen and Penn, 
2010). Likewise, numerous transcription factors and chromatin regulating factors 
interact with Myc (Cheng et al., 1999; Cowling and Cole, 2006; Eilers and Eisenma, 
2008; Rahl et al., 2010; Wasylishen and Penn, 2010). 
 
Regarding genetic aberrations, Myc dysregulation is directly linked with gene 
amplification. Myc overexpression elevated DHFR gene copy number within 3 weeks 
by 10 fold (Denis et al., 1991) or even just within 72h after overexpression (Mai et al., 
1994; Mai et al., 1996). Indeed, every single cell expressing the conditional Myc gene 
showed DHFR3 amplification (Mai et al., 1994). Other genes found amplified after 72h 
of c-myc overexpression are: ribonucleotide reductase R2 (R2) (Kuschak et al., 1999), 
the carbamyl-P synthetase, aspartate transcarbamylase, dihydro-orotase (CAD) enzyme 
conding gene (Miltenberger et al., 1995; Fukasawa et al., 1997; Chernova et al., 1998; 
Eberhardy and Farnham 2001), ornithine decarboxylase (George et al., 1996; 
Rounbehler et al., 2009), Cyclin B1 and Cyclin D2 (Mai et al., 1999, 2005).  
 
 
 
4.1.1 C-Myc pleiotropic effects 
 
Myc carry out important cellular functions by targeting regulator genes involved in 
proliferation, differentiation, metabolism, apoptosis, translation, stromal remodelling, 
inflammation, angiogenesis and invasion (reviewed in Sodir et al., 2009). Accordingly, 
Myc acts as a master regulator of tumor development by activating or repressing genes 
related with all this pathways. Therefore, Myc dysregulation initiates a dynamic process 
of genomic instability that is linked to tumor initiation.  
 
 
 
 
                                                        
3 DHFR gene encodes a protein that provides methotrexate (MTX) drug resistance. 
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4.1.2 C-Myc in cancer 
 
MYC genes are dysregulated in numerous human neoplasias. Indeed, more than 70% of 
all tumours have some form of c-Myc gene dysregulation (Nesbit et al., 1999). 
Therefore, Myc pathology has been studied in neoplasms including Burkitt lymphoma 
(Lombardi et al., 1987), B and T cell lymphoma (Slack et al., 2011), multiple myeloma 
(Anguiano et al., 2009; Chng et al., 2011), plasmacytoma (Shen-Ong et al., 1982), 
hepatocarcinoma (Kawate et al., 1995), lung carcinoma (Little et al., 1983), breast 
carcinoma (Lavialle et al., 1989), pancreatic cancer (Hessmann et al., 2016) , among 
others. 
 
Myc genes are induced as response upon almost every signal transduction pathways 
known to be altered in cancer, comprising, for instance, those ruled by tyrosine kinase 
growth factor receptors, NF-κB and β-catenin (Kelly et al., 1983; Renan, 1989; Duyao 
et al., 1990; Marcu et al., 1997; Zou et al., 1997; He et al., 1998). In turn, Myc proteins 
have a role as master transcriptional regulators of a wide range of target genes that 
execute a cellular response. As a matter of fact, 11% of all cellular loci are candidates to 
be bound by Myc (Fernandez et al., 2003; Orian et al.,2003; Hulf et al., 2005). Actually, 
MYC/MAX heterodimer are estimated to occupy more than 45% of all replication 
origins in human cells carrying Myc-binding E-box motifs (Swarnalatha et al., 2012). 
At the karyotype level, Myc overexpression cause chromosomal changes such as 
formation of extrachromosomal elements, centromere and telomere fusions, 
chromosome and chromatid breaks, ring chromosomes, translocations, deletions and 
inversions, aneuploidy, and the formation of Robertsonian chromosomes (Mai et al., 
1996; Felsher and Bishop 1999; Rockwood et al., 2002; Guffei et al., 2007; Goncalves 
Dos Santos Silva et al., 2008; Silva et al., 2010; Chen et al., 2011).  
 
Dysregulated Myc also modifies the nuclear architecture of cells, affecting therefore the 
positional organization of telomeres and chromosomes, which initiate a dynamic 
process of ongoing genomic instability (Chuang et al., 2004; Louis et al., 2005; Mai and 
Garini 2005; 2006; Vermolen et al., 2005). Myc dysregulation, even for as short as 2-
12h, resulted in nuclear remodelling of the 3D organization and position of telomeres 
and chromosomes (Louis et al., 2005; Mai and Garini 2005). Therefore, by affecting 
nuclear organization, Myc drives dynamic remodelling of chromosomes, genes and 
their structural order. This is particularly relevant as gene activation, function and 
Introduction figure 4.  C-Myc pleiotropic effects. C-Myc target genes involved in a great diversity of 
pathways, such as enhancement of proliferation, inflammation, angiogenesis, metabolism and invasion 
and inhibition of differentiation. Image from Sodir et al., 2009. 
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nuclear space are functionally linked (Solovei et al., 2009). Furthermore, nuclear 
remodelling occurs during early malignancy and set the stage for neoplastic 
transformation (Mai and Garini 2005, 2006; Gadji et al., 2011, 2012). 
 
 
 
 
 
4.2 CYCLIN D1 
 
Cyclin D1 is a well-known cell cycle gene responsible for enabling the progress of the 
cell cycle from G2 to S phase. Its classical role is to interact with CDK4 and form a 
complex that phosphorylates the retinoblastoma (Rb) (Connell-Crowley et al., 1997). 
Then, phosphorylated retinoblastoma derepresses E2F, which internalizes to the nucleus 
and acts as a transcription factor to activate the synthesis of genes involved in cell cycle 
progression. 
On the other hand, Cyclin D1 also carries out important non-canonical roles apart from 
cell cycle progression, in other cellular processes recently reviewed (Hydbring et al., 
2016), such as: DNA damage repair, control of cell death, differentiation, migration, 
immune response and metabolism. 
 
Here we want to seize both the capability of Cyclin D1 to facilitate the cell cycle 
progression, bypassing the limiting step of speeding the cell cycle during early 
reprogramming stages, and its advantageous role in DNA damage repair to propose 
Cyclin D1 as a safer candidate to replace c-Myc in the reprogramming cocktail. 
  
4.2.1 CELL CYCLE 
 
Cell cycle is a sequence of events that eventually leads to division and duplication of a 
cell. Multiple checkpoints are present within the cell cycle to regulate progression 
through various stages. These mechanisms are controlled by a family of cyclins and 
cyclin-dependent kinases (CDKs), where CDK functionality is dependent on their 
association with an active cyclin. Eukaryotic cells have some CDK-cyclin complexes 
that play defined roles at different phases of the cell cycle. These complexes comprise 
ten cyclins belonging to four different types (A, B, D, and E type), three interphase 
CDKs (CDK2, CDK4, and CDK6) and a mitotic CDK1 (Schwartz et al., 2009) 
(introduction figure 5). 
 
Somatic cells are generally dependent on receiving specific mitogen signals, such as 
growth factors, to divide and proliferate (Evan et al., 2001). Once cells have received 
enough mitogen exposure, DNA damage has been checked and cells have confirmed 
they have all required machinery proteins needed for successful division, then they enter 
the cell cycle. On the contrary, ESC and iPSC do not require mitogenic factors since 
they express Oct4, Sox2 and Nanog and are cultured in medium with FGF2 and TGFβ1 
that maintain pluripotency and continuous self-renewal of the cells (reviewed in Huang 
et al., 2015).  
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These cyclins activate CDKs by binding to them depending on their presence and 
levels. For example, Cyclin D complexes with CDK4 and CDK6 to stimulate the 
initiation of G1 phase and the start of the cell cycle, when the cell prepares for DNA 
synthesis (Schwartz et al., 2009). In normal cells, CDK activity is regulated by two 
types of inhibitors: INK4 proteins (A-D) and Cip/Kip family proteins (p21, p27, and 
p57) (Schwartz et al., 2009).  
 
In cancer, cell cycle defects are frequently generated by changes in CDK activity as a 
result of accumulated mutations (Evan et al., 2001; Schwartz et al., 2009). These 
mutations lead to hyperactive CDKs that trigger unscheduled proliferation, such as 
CDK4 in melanoma (Schwartz et al., 2009), CDK6 in pro-B acute lymphocytic 
leukemia (Kuo et al., 2011), CDK5 in pancreatic adenocarcinomas (Eggers et al., 2011) 
or CDK1 and CDK2 in colon adenomas (Vermeulen et al., 2003). 
 
 
4.2.2 Cyclin D1 in cancer 
 
Cyclin D is involved in various types of cancers, however, it is not the only cyclin 
dysregulated. Cyclin E has also been reported to be overexpressed in breast and colon 
cancer (Vermeulen et al., 2003) and cyclin A and E are amplified in certain lung 
carcinomas. D type Cyclins function as growth sensors, which connect mitogen stimuli 
with the cell cycle progression (Choi et al., 2014a). Therefore, Cyclin D translocations, 
amplifications, missense mutations, and elevated protein levels are potential causes of 
cancer. Mutations and abnormities may increase cyclin D activity, resulting in enhanced 
cell cycle progression to S-phase and cell proliferation (Ashgar et al., 2015). Elevated 
levels of cyclin D proteins in cancer have been attributed to defective mechanisms of 
Introduction figure 5.  Cell Cycle phases and Cyclins. Overview of the cell cycle phases: G1, S, G2 
and M (mitosis). Cell-cycle progress is controlled by cyclins and their CDKs. In the G1 phase, Cyclin D-
CDK4 complex phosphorylates Rb protein, which derepresses E2F inducing Cyclin E transcription. On 
the other hand, p21 and p27 oppose these effects and can result in the exit of the cell-cycle finishing in 
G0. To ensure the integrity of the DNA there are several checkpoints in S phase after DNA replication. 
For example, chromosome abnormalities and DNA damage are reported to cyclin B/CDK1 complex via 
diverse pathways to delay or stop progression into mitosis. Image from Niehrs et al., 2012. 
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degradation as well (Lahne et al., 2006). For example, overexpression of cyclin D1 
linked to gene amplification has been studied in breast, esophageal, bladder, lung, and 
squamous cell carcinomas (Vermeulen et al., 2003). In B-cell lymphoma, 
overexpression of cyclin D1 has been observed due to gene translocation (Vermeulen et 
al., 2003). In prostate cancer however, low levels of cyclin D1 and D3 have been 
observed (Olshavsky et al., 2008).  
 
In a ChiP promoter array assay, Cyclin D1 associated with approximately 900 genes in 
close proximity to the transcriptional start site (Fu et al., 2005). A large number of gene 
sets were associated with cell division (most involved in G2/M phase and cellular 
mitosis); other genes were found to regulate chromosomal stability. Hence, Cyclin D1 
overexpression contributes to chromosomal instability by directly regulating a 
transcriptional program that governs it (Casimiro et al., 2012). Indeed, transient 
expression of Cyclin D1 over 7 days in the mammary gland induced chromosomal 
instability (Casimiro et al., 2012). Its overexpression also correlated with aneuploidy, 
supernumerary centrosomes, and spindle defects in mouse hepatocytes (Nelsen et al., 
2005), and with aneuploidy and polyploidy in lymphoid tumors (Aggarwal et al., 2007). 
Still the number of genes targeted by Cyclin D1 is lower than c-Myc. 
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5. IPSC GENETIC STABILITY 
 
Genetic instability refers to a series of chromosomal changes that enables cells to 
develop new and aggressive phenotypes to adapt to the changing selection pressures 
(Bayani et al., 2007). It is generally classified into two major types: DNA base changes 
that occur due to defects in the DNA repair processes including base excision repair, 
mismatch repair and nucleotide excision repair (Kolodner et al., 1995; Modrich et al., 
1997; Rajagopalan et al., 2003) and abnormal karyotypes with structural and numerical 
chromosome alterations (Lengauer et al., 1997). 
Human Pluripotent Stem Cells genomic instability was first documented in 2004 
reporting karyotype abnormalities in ESCs, such as trisomy of chromosome 12 (Cowan 
et al., 2004; Draper et al., 2004). Since then and up to date, an emerging number of 
publications have aimed this issue, focusing on ESCs and iPSCs genetic and epigenetic 
instability (reviewed in Martins-Taylor et al., 2012; Peterson et al., 2013; Steinemann et 
al., 2013). Aberrant cell reprogramming lead to genetic and epigenetic modifications 
(Gore et al., 2011), which are one of the most significant barriers to personalized 
clinical applications of patient iPSC derivatives. Such genetic aberrations are an 
important factor for assessing the quality of iPSC and can result from the cellular stress 
that accompanies reprogramming (Lee et al., 2012b). Therefore, it is crucial to define 
ways to reduce replicative stress induced by reprogramming (Ruiz et al., 2015). In 
Introduction Figure 6 it is schematized how during reprogramming process some but 
not all iPSCs acquire aberrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oct4 + Sox2 + 
Klf4 + c-Myc 
Introduction figure 6.  Reprogramming of patient fibroblast using a clinical therapy viable method 
introducing the four Yamanaka genes: Oct4, Sox2, Klf4 and c-Myc. After reprogramming the resulting 
mosaic cell population contain a mixture of not reprogrammed cells (patient fibroblasts), cells 
reprogrammed carrying no genetic or epigenetic aberrations (green cells with blue nucleus) and cells 
reprogrammed carrying genetic and epigenetic defects (green cells with red nucleus). The proportion of 
cells carrying genetic and epigenetic aberrations is not actually known, but depends on reprogramming 
factors used and cell culture conditions. Diagram has been made by the author. 
 
Introduction 
 
- 52 - 
 
5.1 CELL STRESS 
 
Oxidative and replicative cell stresses are the main causing agents of genetic 
instabilities. In normal situations DNA damage cause an immediate and p53-
independent G1 arrest, caused by rapid proteolysis of Cyclin D1. This degradation is an 
essential component of cellular response to genotoxic stress (Agami et al., 2000). 
Accordingly, lowering replication stress during reprogramming by eliminating Myc, 
provides a simple strategy to reduce genomic instability on mouse and human iPSCs 
(Ruiz et al., 2015). Indeed, replication stress may result from metabolic starvation of 
nucleotides or from RNA polymerase transcription and DNA replication machinery 
clash causing replication fork collapse. Additionally, Myc expression also causes an 
accumulation of reactive oxygen species (ROS), which generates DNA breaks by 
oxidative stress (Khanna and Jackson 2001). ROS increases as a result of a biochemical 
imbalance caused by the sudden increase in gene products via Myc transcriptional 
activation (Vafa et al., 2002). Myc also alteres a mitochondrial gene, TFAM, which 
encodes a protein essential for mitochondrial function and biogenesis, and may lead to 
increased ROS (Dang et al., 2005). 
 
 
5.1.1 Sirtuin 1 
 
Sirtuins are an enzymatic type of NAD-dependent histone deacetylases found in 
prokaryotes and eukaryotes that regulate the expression of certain genes to help 
organisms to respond to metabolic and genotoxic stress through diverse pathways, such 
as metabolic homeostasis, cell survival pathways and cell-cycle control. Descriptions of 
knockout models for each of the seven mammalian Sirtuins suggest that during stress 
response Sirtuins protect genomic stability, triggering integrity through a variety of 
mechanisms, the main involved in chromatin-related functions (reviewed in Bosch-
Presegué et al., 2014). 
 
Sirtuin 1 (Silent mating-type information regulation 2 homologue 1 or Sirt1), a member 
of the class III histone deacetylase (HDAC) famility, plays key roles in a variety of 
physiological processes such as genomic stability, metabolism, neurogenesis and cell 
survival.  
 
It has also been reported to be necessary for proficient telomere elongation and genomic 
stability of iPSC (De Bonis et al., 2014). Also, Sirtuin 1 contributes to telomere 
maintenance and increases global homologous recombination. Sirtuin 1 null mouse 
embryonic fibroblasts (Sirt1-/-MEFs) were shown to express a higher number of 
multitelomeric signals per chromosome (Palacios et al., 2010). In addition, in human 
embryonic stem cells (hESC) Oct4 maintain the pluripotency through inactivation of 
p53 by Sirtuin 1 mediated deacetylation (Zhang et al., 2014). Furthermore, sirt1 has 
been reported to be necessary for proficient telomere elongation and genomic stability 
of induced pluripotent stem cells (De Bonis et al., 2014). 
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5.1.2 Apoptosis 
 
In response of mammalian cells to stress, the tumour suppressor p53, often cited as the 
guardian of the genome, is a key mediator of cell-cycle arrest and/or apoptosis. At all 
times p53 protein is expressed in cells at low levels and is raised in response to stress. 
The regulatory loop ARF–Mdm2–p53 controls the protein level of p53. Mdm2 
negatively regulates p53, causing its degradation by the proteasome, similarly ARF 
inhibits Mdm2 function (reviewed in Nag et al., 2013). 
 
C-MYC has been shown to participate in the apoptotic response, either by inducing or 
sensitizing cells to apoptosis. Apoptosis generated or sensitized by c-MYC can be either 
p53-dependent or independent, determined by the cell type and apoptotic trigger 
(Askew et al., 1991; Evan et al., 1992; Shi et al., 1992). For instance, dysregulated c-
Myc induced apoptosis in Rat-1 fibroblast and in primary rat fibroblasts deprived of 
serum (Evan et al., 1992). Mechanistically, Myc activation leads to increased ARF 
expression (Zindy et al., 1998), causing increased p53 protein, which triggers apoptosis. 
FoxO transcription factors have also been shown to facilitate Myc-induced ARF 
expression, binding to the Ink4a/Arf locus and activating its expression (Bouchard et al., 
2007). 
 
On the other hand, many researches have also linked Cyclin D1 with anti-apoptotic 
properties. For example, Cyclin D1 has been reported to bind and sequester pro-
apoptotic protein BAX, inhibiting therefore apoptosis (Beltran et al., 2011). Also, D-
type cyclins have been shown to have overlapping roles in controlling Fas mediated 
apoptosis by repressing the expression of death receptors FAS and its ligand FASL 
(Choi et al., 2014b). Likewise, in prostate cancer cell lines, cyclin D1 was claimed to 
inhibit anoikis by binding to FOXO1 and FOXO3A in a CDK-independent manner 
(Gan et al., 2009). 
 
 
5.2 EPIGENETIC STABILITY 
 
Reprogramming to iPSC from somatic cells can be incomplete or can induce epigenetic 
anomalies which may alter the developmental potential of cells and may predispose to 
malignancies or rejection potential. Regarding ESC, during early development a 
massive epigenetic reprogramming of ESC chromatin is required, comprising changes 
in both DNA methylation and histone modifications (Ferguson, 2011; Meissner, 2010). 
Is in this delicate phase when alterations in cells epigenome are induced. Essentially, the 
main epigenetic alterations of pluripotent stem cells are: pattern alterations in 
imprinting, DNA methylations and histone modification.  
Imprinting is the epigenetic silencing of some alleles of specific genes depending on a 
parent-of-origin specific manner. Alterations in imprinting provide growth advantages 
for pluripotent cells maintained in culture, since many imprinted genes are known to 
regulate growth during embryonic development (Piedrahita et al., 2011). A large-scale 
comparison of hESCs, hiPSCs, somatic tissues and primary cell lines showed that 
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pluripotent cells are characterized by a high level of variation in the methylation status 
of a subset of imprinted genes (Nazor et al., 2012). 
Alterations in DNA methylation patterns can be either losses or gains of methylations 
that have been reported to be unchanging at different passages (Allegrucci et al., 2007), 
and can affect as well the developmental potential of PSCs lines (Bock et al., 2011). 
These alterations in methylation patterns can be inherited by differentiated cells. Among 
pluripotent cells DNA methylation is particularly typical for a subset of imprinted 
developmental genes, for instance the alteration in methylation of the tumour suppressor 
RAS association domain family member 1 (RASSF1) gene has been observed several 
times suggesting a positive selection pressure. Human iPSC have been reported to have 
increased levels of DNA methylations, which are aberrant and different from ESCs 
during early passages. However, during prolonged culturing they gradually become 
even (Nishino et al., 2011).  
Some studies revising histone trimethylation modifications reported iPSC to have 
increased levels of H3K27me3 (Doi et al., 2009; Guenther et al., 2010; Deng et al., 
2009). However, in other studies lysine 9 (H3K9me3) rather than lysine 27 
(H3K27me3) has been reported to be highly modified (Hawkins et al., 2010).   
 
5.3 GENETIC STABILITY 
 
Possible genetic alterations range from single nucleotide polymorphism, deficient 
mismatch repair, whole chromosome aneuploidies and subchromosomal aberrations, 
including gene duplications and deletions (Copy number variation or CNV) (Amps et 
al., 2011; Lauren et al., 2011; Peterson et al., 2011; Taapken et al., 2011). Aberrations 
can occur during reprogramming and long term culture of iPSCs or during 
differentiation.  
Reprogramming can cause or select for alterations in iPSC as well. However, genetic 
alterations occur mostly during long-term culture of PSC, as late passage PSC are twice 
as likely to have genomic changes than early passage cells (33% compared with 14%), 
as reported in a large-scale study of more than 100 PSC lines (Amps et al., 2011). These 
results point to the fact that selective pressure may play an important role not in the 
acquisition but in a favoured accumulation of genomic alterations.  
 
5.3.1 Aneuploidy  
 
Karyotype abnormalities frequently accumulate in PSC during in vitro culture 
maintenance. Culture-induced genomic aberrations in PSC are unpredictable, variable 
between lines and can occur at any stage (Taapken et al., 2011; Martins-Taylor et al., 
2011; Hussein et al., 2011; Amps et al., 2011; Laurent et al., 2011). Therefore, it is 
difficult to develop specific culture conditions to maintain homogeneous genomically 
stable populations and a save passage number threshold cannot be determined. 
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Most frequent aneuploidy chromosome duplications in pluripotent cells have been 
observed on chromosomes 1, 12, 17 and X and amplifications of 20q have been 
detected in a 34% of PSC lines examined (Amps et al., 2011; Taapken et al., 2011; 
Mayshar et al., 2010). Specifically, trisomy of chromosome 12 is the most recurrent 
abnormality in both ESC (42.6%) and iPSC (32.9%) (Mayshar et al., 2010; Taapken et 
al., 2011). Genetic and epigenetic instability in pluripotent stem cells is associated with 
tumorigenic concerns (Peterson et al., 2013) as the most common genetic alterations in 
PSC, such as the gains in chromosomes 1, 12, 17 and X, are also found in embryonal 
carcinomas (Atkin et al., 1982; Rodriguez et al., 1993; Skotheim et al., 2002; Wang et 
al., 1980).  
 
Many chromosomal abnormalities found in ESC are also found in hiPSCs. While 
chromosome 8 gains are more likely to be found in iPSC, chromosome 17 gains are 
more likely in ESC (Taapken et al., 2011; Ben-David et al., 2011b; Martins-Taylor et 
al., 2011). 
 
5.3.2 Single Nucleotide Polymorphism (SNP) 
 
A single-nucleotide polymorphism is a variation in a single nucleotide that occurs at a 
specific position in the genome. Regarding pluripotent stem cells point mutations, 74% 
of mutations detected in iPSC are generated during reprogramming, 19% pre-existed in 
parental fibroblasts, and only 7% are caused by in vitro maintenance (Ji et al., 2012).  
 
Recently it has been described that by using a high-density DNA methylation array with 
the same sensitivity of SNP platforms, it can also be profiled copy number variation 
(CNV). This new method provided a robust and economic platform for detecting CNV 
and SNP in a single experiment (Feber et al., 2014). 
 
5.3.3 DNA double strand breaks (DSBs) 
 
One of the most dangerous sources of cell instability is the formation of DNA double 
strand breaks (DSB). DSB are generated when both strands of DNA’s phosphor-sugar 
backbones are broken at the same position or in sufficient closeness to enable physical 
separation of the double helix into two separate molecules. It is estimated that up to 105 
spontaneous DNA lesions occur to a cell per day (Hoeijmakers et al., 2009), among 
which, around 10 are thought to be DSBs (Lieber et al., 2010). 
 
DSB can be produced by endogenous and exogenous causes. Endogenous origins are 
reactive oxygen species (ROS) generated by the cellular metabolism and also replicative 
errors generated by replicative stress. Exogenous reasons are ionizing radiation (IR) and 
chemotherapeutic agents. Replication of DNA is believed to be the main cause of DSBs 
in proliferating cells as the DNA intermediates at replication forks are delicate and 
vulnerable to breakage. 
 
DSBs are repaired by three different pathways: homologous recombination (HR), non-
homologous end joining (NHEJ) and alternative non-homologous end joining or also 
called microhomology-mediated end joining (MMEJ). These pathways are schematized 
at the molecular level in introduction figure 7. DSB elimination is crucial for cell 
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survival. While homologous recombination gives rise to a precise recombination, non-
homologous end joining triggers a low fidelity recombination that can lead to 1-4 nt 
deletions. Furthermore, alternative NHEJ leads to a highly error prone recombination 
that can lead to chromosomal translocations, insertions, deletions (CNV) and telomere 
fusions. Therefore, unsuccessful DSB repair potentially induces genetic instability, 
oncogenic chromosome translocations and therefore cancer.  
 
 
5.3.3.1 Histone H2AX 
 
In eukaryotes, DNA is organized into chromatin, a structure necessary for solving the 
problem of spatial accommodation and for restricting the functional transcription of 
DNA (Groth et al., 2007; Li et al., 2007). Nucleosomes are the monomeric blocks that 
build chromatin (Andrews et al., 2011; Zlatanova et al., 2009). They contain around 
150bp of DNA enveloped around a histone octamer that consists of the core histones 
H2A, H2B, H3 and H4 in duplicate each (Luger et al., 1997). These histones can be 
replaced by variants as a mechanism of chromatin regulation (Talbert et al., 2010). 
Indeed, the H2A family contains plenty of variants, some of which are universally 
found in human and other eukaryotes, such as H2AX, H2AZ, H2A.F/Z, H2ABbd, 
macroH2A1 and macroH2A2. C-terminal usually contains the highest grade of 
divergence among H2A (Millar et al., 2013). Specifically, H2AX histone variant was 
first described in 1980 (West et al., 1980) and constitutes about 2.5-25% of the total 
H2A histone in the mammalian genome (Rogakou et al., 1998) and contains a 
hydrophobic Φ motif (SQ) in the C-terminus. H2AX serine 139 is phosphorylated 
(γH2AX) by ATM4 (Burma et al., 2001), which forms a docking site for the 
accumulation of DNA repair proteins that triggers genome integrity preservation 
through HR, NHEJ and MMEJ repairing mechanisms.  
 
5.3.3.2 DSBs repair molecular pathways 
 
After DNA double strand break damage, histone variant H2AX binds to the broken 
strand ends. ATM then phosphorylates it at Ser139 (γH2AX) (Burma et al., 2001), 
which recruits damage-response factors in order to initiate the repair response to DSBs. 
The three main DSB repair mechanisms are schematized in introduction figure 3 and are 
explained in detail in the following paragraphs. 
 
 
 
 
 
 
 
 
 
 
 
                                                        
4 Ataxia telangiectasia mutated (ATM) is a PIKK (phosphatidylinositol 3-kinase related kinase).  
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There is a dynamic interplay between several molecules that fluctuate depending on the 
cell cycle phase the cell is in that determines the repair pathway the cell is going to 
choose (reviewed in Frit et al., 2014 and Aparicio et al., 2014; Ceccaldi et al., 2016). 
Thus, depending on the cell cycle phase the cell is in, one pathway or another is going 
to be preferentially chosen to repair the DSB. Therefore, DSBs can be repaired in a 
Ku70/80 dependent manner through NHEJ or in an end resection mediated repair 
manner that can be conducted through homologous recombination or alternative NHEJ 
(Truong et al., 2013). NHEJ takes place during G1 and G2 phases. HR occurs during G2 
and S phases, as Cyclin D1 is required to bind to BRCA2 to prevent Cyclin A/CDK2 
phosphorylation. Alternative homologous recombination however, can occur at any 
phase of the cell cycle (G1, G2, S and M) (Aparicio et al., 2014). 
 
If the cell enters the classical non-homologous end joining (NHEJ), Ku70-Ku80 
heterodimer recognizes and binds the DSB site. To be able to form the heterodimer, 
Ku70 has to be deacetylated by Sirtuin 1 (Jeong et al., 2007). Ku70/80 proteins have 3 
domains, 2 involved in the dimerization and one in DNA binding. Once Ku70-Ku80 has 
bound to the damaged DNA ends with high affinity, it acts as a scaffold to other factors 
to render the NHEJ repair (reviewed in Davis et al., 2013). Afterwards, Ser/Thr kinase 
Introduction figure 7. Schematic diagram drawn by the PhD student about all different molecules 
involved in the main three repair pathways for DNA double strand breaks (DSB). It is represented 
how DSB caused by cell reprogramming induced stress can be repaired by homologous recombination 
(HR), non-homologous end joining (NHEJ) and alternative non-homologous end joining of 
microhomology-mediated end joining (MMEJ). Diagram authors: JRO: Jordi Requena Osete and CGB: 
Carme Grau Bové. 
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DNA-PKc5 binds to Ku70/80, self-phosphorylates and phosphorylates Artemis nuclease 
protein, which is important for the stabilization of the DSB site. Artemis then cleaves 
the DNA blunt ends to allow the binding of X polymerases (Pol μ, Pol λ) (Franco et al., 
2008; Davis et al., 2013). Then, although Polymerase μ has template-dependent activity 
(Moon et al., 2015), it also polymerizes along a discontinuous template in the presence 
of Ku, XRCC4 and Ligase 4 (Mahajan et al., 2002). Polymerase λ also polymerizes in a 
template-independent manner (García-Díaz et al., 2002). NHEJ finishes when Ligase 4 
(LIG4) and the scaffold protein XRCC4 directly bind Ku70-Ku80 and catalyses the 
ligation and repair of the DNA ends. 
 
If cells enter an end resection dependent repair mechanism, MRN complex, CtIP and 
RPA proteins are going to be recruited to the damaged site. The MRN complex is 
formed of: Meiotic recombination 11 (MRE11), RAD50 and Nijmegen breakage 
syndrome 1 (NBS1) proteins. Beforehand, sirtuin1 is responsible for NBS1 
deacetylation (Yuan et al., 2007), which enables ATM to phosphorylate it (Lim et al., 
2000; Wu et al., 2000; Zhao et al., 2000) to facilitate the assembly of the MRN complex 
at the DSB. Then, MRN nuclease with CtIP exonuclease together resect the double 
strand into a single strand ssDNA ends, where Replication protein A (RPA) is rapidly 
bound to protect them and facilitate the recruitment of Rad51 (Ruff et al., 2016). 
 
After the strands have been resected, if the cell is in G2 or S phases the cell is 
preferentially going to enter homologous recombination (HR). In order to enter this 
mechanism, BRCA2 (breast cancer 2) has to bind ssDNA and is essential to mediate 
Rad51 monomer filaments binding to the strands (Davies et al., 2001; Davies et al., 
2007). Rad51 recombinase monomers replace RPA and polymerize around the ssDNA 
ends forming a helical nucleoprotein (Holloman, 2011) that is essential to catalyse the 
exchange of strands with the homologous sister chromatid. Correspondingly, mutations 
in BRCA2 gene cause a loss of tumor suppressive function which correlates with an 
increased risk of breast cancer (O’Donovan et al., 2010). However, when BRCA2 is 
phosphorylated at the C-terminal domain at Serine 3291 by Cyclin A-CDK2, Rad51 
cannot bind and homologous recombination is repressed (Chalermrujinanant et al., 
2016; Esashi et al., 2005).  
 
It has recently been reported a non-canonical function of the cell cycle gene Cyclin D1 
in the homologous recombination pathway mechanism.  Cyclin D1 directly interacts 
with the C-terminal domain of BRCA2 and with Rad51 and enhances Rad51 
recruitment to BRCA2-bound DSB sites by blocking Cyclin A-CDK2 phosphorylation 
and inactivation of BRCA2 (Chalermrujinanant et al., 2016; Jirawatnotai et al., 2016). 
 
If BRCA2 is phosphorylated at the Serine 3291, Rad51 is not recruited and HR is 
inhibited. Then, the cell engages the alternative non-homologous end joining (Alt-
NHEJ) or micro-homology mediated end joining (MMEJ) mechanism to repair the 
damage. Alt-NHEJ, which is most active in the S and G2 phases of the cell cycle, is 
dependent on PARP16 signalling and relies on resection of the DNA by MRN and CtIP. 
First, PARP1 enzyme promotes poly(ADPribosyl)ation of the c- and n-terminus tail 
residues of the histones H1 and H2B, which induces relaxation of the chromatin and 
                                                        
5 DNA-PKcs is a member of the phosphatidylinositol-3 (PI-3) kinase-like kinase family (PIKK). 
 
6 Poly (ADP-ribose) polymerase-1 (PARP1). 
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also acts as a signal for alternative NHEJ scaffold proteins to join and recruit the 
molecular machinery (Schreiber et al., 2006). Then, microhomologous base pairs at the 
resected ends drives the annealing of opposite ends of a DSB. Finally, annealed ends are 
subject to fill-in synthesis by the low-fidelity DNA polymerase θ (Pol θ), a specific 
polymerase of the alternative NHEJ pathway, which stabilizes the annealed 
intermediates and promotes end joining, primarily by LIG37.  
 
Due to the high risk of mispairing during the microhomology base pairing, this process 
is highly promiscuous and leads to low-fidelity DNA synthesis. Therefore, alt-NHEJ 
introduces deletions and insertions that mark the break sites following repair. The 
deletions are produced by extended nucleolytic processing, whereas insertions are 
caused by Pol θ activity (Ceccaldi et al., 2015; Kent et al., 2015). Furthermore, Pol θ 
blocks HR by impeding the formation of the Rad51 nucleoproteins filaments (Mateos-
Gomez et al, 2015). 
 
As a consequence of DSB repair malfunction or the usage of the alternative NHEJ, cells 
can accumulate genetic instabilities such as chromosomal rearrangements (insertions, 
deletions or translocations) that can trigger CNV.  
 
5.3.3.3 Myc and Cyclin D1 in DSB pathways  
 
During reprogramming to iPSC using the classical cocktail of factors (Oct4, Sox2, Klf4 
and c-Myc), c-Myc forced overexpression in the cells is going to produce a direct effect 
on the cell’s choice of repairing mechanism. Correspondingly, it has been reported that 
c-Myc overexpression disrupts c-NHEJ because it directly interacts with Ku70 through 
its Myc box II (MBII) domain and inhibits therefore the DNA-PKcs activity (Li et al., 
2012). It is also well established that c-Myc overexpression stimulates CDK2 activity 
(Rudolph et al., 1996; Pusch et al., 1997). Since CDK2, together with Cyclin A1, are 
responsible for phosphorylating BRCA2 impeding Rad51 binding, this might imply that 
Myc does not benefit HR. Likewise, in leukaemia cells, it has been reported that c-Myc 
overexpression downregulates microRNAs miR-150 and miR-22, two microRNA that 
inhibit ligase 3 and PARP1 transcription (Muvarak et al., 2015); thus, c-Myc tend to 
lead to an increase of LIG3 and PARP1 transcription. Furthermore, in cancer cells, c-
Myc overexpression restores PARP1 expression by suppressing PAPR1 inhibitor BIN1 
(Ganesan et al., 2011; Pyndiah et al., 2011). C-Myc overexpression therefore, has been 
reported through several lines to lead the repairing machinery towards the error-prone 
MMEJ repairing mechanism, promoting it rather than the other two more precise 
methods; contrarily to Cyclin D1 that is essential for conducting homologous 
recombination, rather than promoting the other two low fidelity repairing methods.  
 
5.3.4 Copy Number Variation (CNV) 
 
Copy Number Variation (CNV) occur when sections of the genome are repeated and the 
number of repeats in the genome varies between individuals in the human population 
(McCarroll et al., 2007). Long-term culture positively selects for amplifications but 
negatively select for deletions (Laurent et al., 2011). This phenomenon can be explained 
by the strong culture dish selective pressure favouring best adapted cells (Hussein et al., 
                                                        
7 Ligase 3 (LIG3) acts in Alt-NHEJ and recognises single-stranded blunt ends with homology.  
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2011), resulting in enrichment of chromosomal trisomies and copy number gains, 
contributing to genomic variation detected in iPSC (Gore et al., 2011; Ji et al., 2012). 
 
There are three technological platforms for copy number variation detections: array-
based technology (including array comparative genomic hybridization (aCGH), as well 
as many other variants such as oligonucleotide array), SNP genotyping technology 
(Carter et al., 2007), and next-generation sequencing technology (Chiang et al., 2009). 
Various algorithms have been proposed for different data in recent years. The primary 
goal of all such studies is to identify and localize the copy number changes. One 
important commonality in data from different platforms is the spatial correlation among 
clones/probes/sequences.  
 
The most recurrent Copy Number Variation (CNV) hotspot is the culture-induced 
amplification of the gene-rich locus at the long arm 20q11.21, has been estimated to be 
present in approximately 14.5% of PSC lines in independent experiments (Matins-
Taylor et al., 2011; Maitra et al., 2005; Lefort et al., 2008; Spits et al., 2008; Wu et al., 
2008; Werbowetski-Ogilvie et al., 2009; Narva et al., 2010; Amps et al., 2011, Laurent 
et al., 2011; Elliott et al., 2010; Lund et al., 2012). Common subchromosomal 
duplications in chromosome 20q were found in genes conferring cell growth or survival 
advantage, such as BCL2L1 (20Q11.21), which enhances ESC survival (Bai et al., 
2012) giving a selective advantage by attenuation of apoptosis; or also mir1825, which 
has over 400 predicted targets, rendering suppression of apoptosis as well or cell growth 
enhancement. 
 
In order to promote transformation and tumour progression, amplified and rearranged 
loci must provide a selective survival advantage. For example, amplification of genes 
involved in DNA synthesis and cell-cycle progression provide a proliferative advantage 
to cells that harbor it (Kuschak et al., 2002). Therefore, CNV have been reported to be 
implicated in the growth and progress of many human malignancies, including cancers 
in breast, prostate and bladder (Feber et al., 2004; Holcomb et al., 2009; Hammerman et 
al., 2012). It has been noted that iPSC may have higher numbers of subchromosomal 
CNV than ESC (Laurent et al., 2011;  Martins-Taylor et al., 2011; Hussein et al., 2011), 
therefore making iPSC more prone to become tumorigenic than ESC. Early-passage 
iPSC are characterized by a huge incidence of CNV compared with parental fibroblasts. 
These alterations, especially copy number losses, are usually negatively selected in 
culture (Hussein et al., 2011). 
 
CNV are not randomly distributed in the human genome, but tend to be clustered in 
regions of complex genomic architecture, consisting of complex patterns of direct and 
inverted LCRs (low copy repeats). For instance, CNVs preferentially occur in regions of 
heterochromatin near telomeres (Shao et al., 2008; Yatsenko et al., 2009) and 
centromeres (She et al., 2004; Nguyen et al., 2006).  
 
5.3.5 TELOMERE LENGTH IN IPSC 
 
Another source of instability in cells comes from the malfunction of cell chromosomes 
telomere maintenance. Telomeres consist of (TTAGGG)n palindromic repeats and 
associated proteins at the end of chromosomes. Mammalian telomeres contain a specific 
protein complex, shelterin, that functions to protect chromosome ends from all aspects 
of DNA damage to maintain genomic stability by protecting the chromosomes from 
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degradation and end-to-end fusion (Blackburn, 2001; Palm et al., 2008). It has been 
proposed that telomeres are fragile sites and shelterins are essential for preventing 
telomere breakage associated with replication fork stalling at telomeres (Martínez et al., 
2009; Sfeir et al., 2009). Specifically, TRF1 shelterin is required for proper telomere 
replication preventing fork stalling. TRF1 deletion activates ATR signalling pathway 
causing fragile phenotype at telomeres and leading to end-to-end fusions and to a high 
incidence of telomere breakage causing multitelomeric signals (Sfeir et al., 2009).  
5.3.5.1 Multitelomeric Signal (MTS) 
 
Multitelomeric signals (MTS) consists on a telomere doublet signal in the chromosome 
arm (introduction figure 8, B). MTS have been proposed to reflect increased breakage at 
chromosome termini and subsequent repair by homologous recombination mechanisms 
(Lydeard et al., 2007). Therefore multitelomeric signals are regarded as a type of 
genetic instability (Meeker et al., 2004; Muñoz et al., 2005; Blanco et al., 2007; 
Martinez et al., 2009; Sfeir et al., 2009; Tejera et al., 2010). Cell tumorigenicity is 
fuelled by the accumulation of cellular damages, however, it remains to be established 
whether or not MTS are associated to cancer in humans. Furthermore, Sirtuin 1 also 
contributes to telomere maintenance. Sirtuin 1 null mouse embryonic fibroblasts (Sirt1-
/-MEFs) were shown to express a higher number of multitelomeric signals per 
chromosome (Palacios et al., 2010).  
 
5.3.5.2 Signal-free ends 
 
Signal-free ends are short telomeres that cannot be detected with the specific telomere 
QFISH staining (introduction figure 8, C). Signal-free ends has been reported to lead to 
chromosome fusions, constitute telomere dysfunction and limit cellular survival in the 
absence of telomerase (Hemann et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction figure 8. Chromosome telomeres Q-FISH staining. A) Chromosome with normal 
signal of telomeres. B) Chromosome with an arm with multitelomeric signal (white arrow). C) 
Chromosome with an arm with signal free ends (white arrow). Images are examples extracted from the 
thesis data. 
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6. IMMUNE SYSTEM 
The immune system consists of all the different biological structures and procedures 
that a host organism has as defense system to protect against disease. The system has to 
be able to distinguish all sort of different external pathogens, ranging from small viruses 
to big parasites and differentiate them from the organism’s own tissues to function 
properly. Actually, immune system disorders can result in autoimmune and 
inflammatory diseases and cancer (O’Byrne et al., 2001). Conversely, pathogens can 
rapidly evolve to avoid detection and neutralization by the immune system; however, 
host defense mechanisms have also evolved to recognize and neutralize evolving 
pathogens.  
Simple unicellular organisms like bacteria possess rudimentary immune systems in the 
form of enzymes to protect against bacteriophage virus infections. Other basic immune 
mechanisms, including phagocytosis, antimicrobial defensins and the complement 
system, evolved in ancient eukaryotes and remains nowadays in their descendants, such 
as in plants and in invertebrates. Jawed vertebrates, comprising humans, have developed 
even more sophisticated defense mechanisms (Beck et al., 1996), like the ability to 
adapt over time to recognize pathogens more efficiently and specifically.  
This adaptive or acquired immunity generates immunological memory8 after an initial 
response to a pathogen, leading to an enhanced response in subsequent encounters with 
that same pathogen. Therefore, in numerous species, the immune system can be 
classified into innate and the adaptive immune system (or humoral and cell-mediated 
immunity).  
 
 
 
 
 
 
 
 
 
 
  
                                                        
8 This process of acquired immunity memory is the basis of vaccination. 
Introduction figure 9. Innate and adaptive immune response. Diagram showing the two types of 
immune response that the host has against pathogens. Innate immunity is the first barrier that the organism 
has against pathogens to resist the infection during the first hours. Afterwards, immune cells involved in 
the adaptive immunity generate a long-term response with antibodies specific for the antigens presented to 
the B cells. Image from Abbas et al., 2011. 
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 6.2 INNATE IMMUNE RESPONSE 
 
During the initial phase of an infection, a rapid inflammatory response is generated by 
the innate immune system that blocks the spreading of the infectious agents. The innate 
immune system, also known as the non-specific immune system (Grasso et al., 2002), is 
a generic response that provides immediate defense against infections by other 
organisms and is an evolutionarily old defense strategy found in all classes of plant and 
animal life. Indeed, it is the dominant immune system of plants, fungi, insects, and 
primitive multicellular organisms (Janeway et al., 2001). However, unlike adaptive 
immune system, the system does not provide to the host long-lasting immunity (Alberts 
et al. 2002).  
 
The innate immune system receptors are germline-encoded and have been evolutionally 
selected to recognize pathogen-derived compounds essential for pathogen survival or 
endogenous cellular molecules released in response to infection (Matzinger, 1994; Yang 
et al., 2010a; Erridge, 2010).  
 
6.2.1 Toll like receptors (TLRs) 
 
Also known as pattern recognition receptors (PRRs), innate immune receptors are found 
in the serum, on the cell surface, in endosomes, and in the cytoplasm (Medzhitov, 
2007). The Toll-like receptors (TLRs) represent a particularly important group of PRRs 
(Gay et al., 2007), which trigger innate immune responses after recognition of a wide 
variety of pathogen-derived compounds. TLRs are expressed on the membranes of 
dendritic cells, macrophages, natural killer cells, T and B lymphocytes and also in non-
immune cells such as epithelial cells, endothelial cells, fibroblasts and neurons 
(Delneste et al., 2007; Lafon et al., 2006). 
 
In human cells, ten TLRs respond to a range of Pathogen-Associated Molecular Patterns 
(PAMPs), including lipopolysaccharide (TLR4), lipopeptides (TLR2 associated with 
TLR1 or TLR6), bacterial flagellin (TLR5), viral dsRNA (TLR3), viral or bacterial 
ssRNA (TLRs 7 and 8) and CpG-rich unmethylated DNA (TLR9), among others 
(Kumar et al., 2009). All these TLRs, recently reviewed (Botos et al., 2011), are located 
on cell surfaces or within endosomes and have important roles in the protection against 
pathogenic organisms all over the animal kingdom.  
 
Despite the wide variety of ligands recognized by TLRs, a common structural 
framework is shared in their ligand-binding extracellular receptor domains (or 
ectodomains, ECD). All these ECDs adopt horseshoe-shaped structures and are built 
from tandem copies of leucine-rich repeat (LRR) motifs, which are the building blocks 
of TLRs. ECDs are typically 22–29 residues in length and contain hydrophobic residues 
spaced at distinctive intervals. Interestingly, LRR motifs are found in many proteins in 
animals, plants and microorganisms (Palsson-McDermott et al., 2007). 
 
Classically, after ligand binding, two extracellular domains dimerize forming an "m"-
shaped structure, docking the ligand molecule in the middle of two TLR molecules. 
This ligand-induced dimerization brings the transmembrane and cytoplasmic domains in 
close proximity and triggers a downstream signalling cascade.  
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Specifically TLR3 has been studied in this thesis, since it was found differently 
expressed between iPSC derived cells and their original cell type. 
 
 
6.2.1.1 Toll-like receptor 3 (TLR3) 
 
TLR3 recognizes dsRNA, produced by most viruses at some stage in their lifecycles, 
being a potent indicator of viral infection. TLR3 is located inside endosomes, contrarily 
to other cytoplasmic dsRNA receptors. Cells normally have short chains of dsRNA (25 
bp or less), such as in miRNA and tRNA hairpins. This is the reason why TLR3 dimers 
cannot bind dsRNA of less than 40 bp, providing an essential mechanism for preventing 
self-reactive responses against the cell’s own dsRNA.  
 
Homodimerization of TLR3 is essentially required for ligand binding (wang et al., 
2010), and an intact binding site is required for dsRNA binding and stable dimerization 
to activate the downstream signalling cascade. TLR3 ectodomains, which are made by 
23 LRR, bind as dimers to 45 bp segments of dsRNA, the minimum length required for 
TLR3 binding and activation (Wang et al., 2010). Furthermore, binding is independent 
of base sequence and occurs only at pH 6.5 and below (Leonard et al., 2008). It has 
been identified the essential interacting residues in the complex. The dsRNA interacts at 
two sites on each TLR3-ECD, one near the N-terminus (comprising LRR-NT and LRRs 
1–3), and one near the C-terminus (comprising LRRs 19–23) (Liu et al., 2008). 
Mutational analyses (Wang et al., 2010) have established that these three sites 
individually interact weakly with their binding partners but together form a high affinity 
receptor-ligand complex. Simultaneous interaction of all three sites at the same time is 
therefore required for stable and functional binging of TLR3/dsRNA. In addition, the 
two ECDs interact with each other at their LRR-CT motifs.  
 
In the cell, two TLR3 ECDs interacting on the luminal side of an endosome bring the 
two TIR domains together on the cytoplasmic side, forming a dimeric scaffold on which 
adaptor molecules could bind and initiate a signalling cascade. When TLR3 dimerizes, 
it is recruited TICAM1 for the production of pro-inflammatory cytokines (Brikos et al., 
2008). TICAM recruits poly-ubiquitinated RIP1, which interacts with TRAF6/TAK1 
complex and leads to activation of NF-κB and induction of pro-inflammatory cytokines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction figure 10. Structure of the TLR3 dimer/dsRNA complex. A) Molecular surface of 
TLR3 dimer (green) with bound dsRNA. The interaction of the C-terminal capping motifs stabilizes the 
TLR3 dimer. B) Top view. Figure from Botos et al., 2011. 
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6.2 ADAPTIVE IMMUNE RESPONSE 
 
In vertebrates, the initial innate immune response is followed by an adaptive immune 
response, in which highly specific B and T cell receptors recognize the pathogen 
antigens and generate antibodies against them leading to pathogen elimination 
(Janeway, Jr. et al., 2002). The adaptive immune system, also known as acquired 
immune system, is composed of highly specialized, systemic cells and processes that 
eliminate pathogens or prevent their growth.  
Adaptive immunity provides long-lasting protection, since it creates immunological 
memory after an initial response to a specific pathogen, and leads to an enhanced 
response to subsequent encounters with that particular pathogen in a highly specific 
manner to destroy attacking pathogens and toxic molecules produced by them. If the 
system is unable to discriminate harmful from harmless foreign molecules; the effects 
of this may be fever, asthma or allergy.  
The cells that carry out the adaptive immune response are white blood cells known as 
lymphocytes, classified in two different classes: B cells and T cells, for antibody 
responses and cell mediated immune response. B cells are activated to secrete 
antibodies, immunoglobulin proteins that travel through the bloodstream and bind to the 
foreign antigen to inactivate it, preventing the antigen to bind to the host (Alberts et al., 
2002). T cells are distinguished from B cells and NK cells by the presence of a T cell 
receptor on the cell surface and can be classified into helper and cytotoxic T cells 
(Alberts et al., 2002). While in innate immunity pathogen recognition receptors are 
already encoded in the germline, in adaptive immunity antigen receptors consist of 
many structurally similar molecules with millions of different specific binding 
combinations created by rearrangements and mutations within the binding site regions 
of the variable domains of the B and T cell receptor (Jung et al., 2004; Schatz et al., 
2005). Therefore, adaptive immune receptors are acquired during the lifetime of the 
organism.  
 
6.2.1 Cytotoxic T lymphocytes (CTL) 
 
Cytotoxic T lymphocytes (CTLs), also known as killer T cells, CD8+ T cells or 
cytolytic cells, are a type of white cells that kill infected cells, cancer cells or cells 
damaged in other ways. Most CTLs express T cell receptors (TCR) that recognize 
specific antigens, often from virus or cancer cells.  
 
Pathogen antigens bind to class I major histocompatibility complex (MHC-I) molecules 
and are brought to the surface of the cell, where they can be recognized by the T cells. 
When the TCR is specific for an antigen, it binds to the complex of the class I MHC 
molecule and the antigen, the CD8+ CTL becomes activated and destroys it. CD8 and 
the MHC molecules high affinity binding keeps the CTL and the target cell bound 
closely together during antigen-specific activation.  
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6.3 IPSC IMMUNE RESPONSE 
 
One of the main advantages of iPSC technology for clinical application has been 
thought to be the potential of autologous cell therapies to remove immune rejection 
eliminating the need for immune suppression drugs and their associated side effects. 
Then, iPSC derived from patient cells that are differentiated into a specific cell type are 
unlikely to provoke an immune response in the same individual, making 
immunosuppression therapy dispensable. However, taking into account the prevalence 
of naturally happening autoimmune diseases such as diabetes type I, multiple sclerosis 
or systemic lupus erythematosus, the idea of an immune alteration or reactivity of 
patient’s own cells is not rare to contemplate, signifying that immunogenic privilege of 
autologous cells could have been underestimated. 
 
6.3.1 Allogeneic iPSC immune alterations 
 
Regarding rejection of transplanted allogeneic cells and organs, the main immune 
response involves the major histocompatibility complex-I (MHC-I), expressed on every 
nucleated cell in the body, whose function is to display foreign antigens to T cells. 
Humans have three main MHC class I genes, known as HLA-A, HLA-B and HLA-C. 
Proteins encoded from these genes are present on the surface of nearly all cells. On the 
surface, these proteins are bound and present protein fragments (peptides) exported 
from within the cell. Then, these peptides are displayed to the immune system by the 
MHC1 proteins. If the immune system recognizes the peptides as foreign, like viral or 
bacterial peptides, it responds by prompting the infected cell to self-destruct. Pick et al. 
already showed that during reprogramming, iPSC downregulated expression of human 
leukocyte antigen (HLA)-A/B/C and β2 microglobulin (β2M) (Pick et al., 2012), the 
two components of MHC-I. Their results showed very low expression levels of MHC 
class I (MHC-I) proteins on the surface of hESC. During differentiation of ESC, MHC-I 
levels increased back, resulting in an increase in immunogenicity, through increasing 
expression of HLA (Boyd et al., 2010; Bonde et al., 2008; Robertson et al., 2007; 
Drukker et al., 2002). 
 
6.3.2 Syngeneic Models 
 
Professor Fairchild was one of the former scientists who expressed concerns about 
potential immunogenicity of iPSCs derivatives in syngeneic models (Fairchild et al., 
2010). Indeed, work by Zhao et al. in 2011 demonstrated that when injecting 
retrovirally reprogrammed iPSCs in syngeneic recipients, it was induced a T-cell-
dependent immune response potent enough to almost completely prevent the formation 
of teratomas in mice (Zhao et al., 2011). This rejection was not observed after injection 
of syngeneic mouse embryonic stem cells (ESC). Interestingly, Episomal vectors 
reprogrammed iPSCs were capable of forming teratomas. However, authors also 
showed CD4+ T cell infiltration in those teratomas produced with the non-integrative 
reprogramming method, with apparent necrosis within parts of the tumour, suggesting 
that the reprogramming process itself may impact on the potential immunogenicity of 
reprogrammed cells. Authors revealed as well that Zg16 and Hormad1 genes 
overexpression in iPSCs was directly contributing to the immunogenicity of iPSC 
derivatives (Zhao et al., 2011).  
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In 2013 it was found that the injection of mouse iPSCs into syngeneic C57BL/6 mice 
produced teratomas and was not rejected (Thanasegaran et al., 2013). Likewise, iPSC 
derived cells were not rejected after syngeneic transplantation (Ghua et al., 2013). Also 
Araki R. et al. compared the immunogenicity of differentiated skin and bone marrow 
tissue derived from integration-free mouse iPSC generated by episomal vectors and 
ESC-derived tissue, and did not observe any differences between the two groups (Araki 
et al., 2013). However, cardiomyocytes derived from these same iPSCs were highly 
immunogenic. 
 
In the same line, in another research using non-human primates, Morizane et al. found 
that autologous transplantation of the iPSC-derived cells generated a minimal immune 
response compared with allografts both in the nonhuman primate brains in the absence 
of immunosuppression (Morizane et al., 2013). They suggested thus that 
immunosuppression is not necessary for autologous transplantation of iPSC-derived 
neural cells into brain. 
 
Liu et al. made a new turn on the topic when reported that human iPSCs derived neural 
progenitor cells (NPC) were more immunogenic when iPSCs came from skin fibroblasts 
(SF) than when iPSCs came from umbilical cord mesenchymal stem cells (UMCs) (Liu 
et al., 2013), suggesting that low immunogenicity due to the lower cell commitment of 
UMCs could be retained after cell reprogramming and further differentiation. NPCs 
differentiated from UMC-iPSC retained low immunogenicity as the parental UMCs, 
because SFs as a more committed cell, generally carry a higher number of instabilities 
than UCMs and thus are more likely to become more immunogenic as reported. 
 
Taken together all these publications seem to suggest that some but not all iPSCs 
derived cells could become immunogenic at different extents. Thus, estimating 
immunogenicity of iPSCs derived cells appears to be of great relevance in the field. 
Furthermore, it is possible that genetic and epigenetic alterations during reprogramming 
can somehow contribute to the immunogenicity of iPSCs derivatives. It is still an open 
question to know which kind of tissues differentiated from iPSC can be immunogenic, 
idea firstly proposed by Dr. Xu (Zhao et al., 2011), and reviewed recently (Cao et al., 
2014).  
 
Whether genetic alterations in pluripotent cells are meant to be immunogenic or not for 
transplantation potential is to be determined yet. It is likely that most iPSCs genomic 
aberrations acquired during reprogramming are going to be harmless and only a few 
types of abnormalities are actually hazardous. Thus it appears to be of great relevance to 
estimate the immunogenicity of clinical valuable cells, as well as the tissue specific 
propensity to become immunogenic in relationship with the number and type of 
cumulated defects. 
 
In this thesis we wanted to compare an F1 population of original patient cells with their 
corresponding iPSC derived cells (F2), comprising iPSC derived fibroblasts, neural 
stem cells, cardiomyocytes and endoderm cells. We aim to compare F2 derived from 
iPSCs reprogrammed with 3 different methods: retroviral transduction, Episomal 
vectors and mRNA transfections.  
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Even though cell reprogramming is an established technique for production of induced 
pluripotent stem cells (iPSC), several challenges still need to be addressed before 
clinical application.  
 
 
 
 
 
 The first objective is the replacement of the oncogene c-Myc by the cell cycle gene 
Cyclin D1 in the reprogramming cocktail, as a way to promote DNA repair through 
homologous recombination during the reprogramming process in order to reduce 
genetic instability and avoid the threat of cancer in iPSC.  
 
 We hypothesise that 3F+Cyclin D1 made iPSC will have reduced genetic instability due 
to Cyclin D1 involvement in DNA repair mechanisms and the fact that it is not involved 
in as much pleiotropic and tumorigenic effects as c-Myc. 
 
 
 
 
 
 
 The second objective is to characterise and identify alterations in the immune response 
of iPSC derived cells, by comparing with the original non-reprogrammed cells. 
 
 We hypothesise that iPSC derived from patient cells that are differentiated into a 
specific cell type are unlikely to provoke an immune response in the same individual. 
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Cell culture  
Mouse C2C12 cells were obtained from ATCC (CRL-1772). Mouse Embryonic 
Fibroblasts were obtained from embryos of pregnant mice Wild Black6, C57 strain, at 
day 12.5 post coitum (extraction protocol approved by the university of Barcelona 
ethics committee). Human foreskin fibroblasts were obtained from ATCC (SCRC-
1041). All three lines were cultured in DMEM (Gibco # 21969-035) supplemented with 
glutamate 1% (GlutaMAX 200mM, Gibco # 35050-038), penicillin-streptomycin 1% 
(10.000 U/ml) and Fetal Bovine Serum 10% (Gibco # 10270-106). In order to arrest 
MEFs to prepare feeder layer, cells were treated with Mytomicin C during 4h or 
irradiated with gamma irradiation. Mouse iPSC mESC (W4 and G4 mESC clones) were 
maintained on irradiated mouse embryonic fibroblasts (irMEFs) in G4 medium: 
knockout (KO)-DMEM (Gibco # 10829-018) supplemented with glutamate 1%, 
penicillin-streptomycin 1%, Fetal Bovine Serum 15%, non-essential aminoacids 1% 
(NEM-NEAA 100x Gibco), sodium pyruvate 1% (Gibco # 11360), 2-mercaptoethanol 
0.2%, the cytokine leukemia inhibitori factor (LIF) 0,02% (Chemicon # ES61107, 1.000 
U/ml) and 2mM valproic acid (Sigma-aldrich, 1069-66-5). Retrovirally made hiPSC 
were maintained on irradiated human foreskin fibroblasts (irHFFs) in hES medium 
consisting of knockout (KO)-DMEM, 1mM pen/strep, 1 mM Gluta-MAX, 1X 
nonessential amino acids (NEAA), 55 μM β-mercaptoethanol (β-ME) (Gibco, Carlsbad, 
CA), 10% Knockout (KO) serum replacement (Invitrogen, Carlsbad, CA), and 10 ng/ml 
FGF2 (R&D Systems Inc., Minneapolis, MN). For maintenance of undifferentiated 
colonies, differentiated cells were manually removed and undifferentiated cells were 
passaged once a week. Feeder-free clinical grade mRNA iPSC were cultured in Flex E8 
culture medium (Life Technologies, A2858501) on Vitronectin (Life Technologies, 
A14700) coated plates. Essential 8 medium components: DMEM F-12, L-ascorbic acid, 
Selenium, Transferrin, NaHCO3, Insulin, FGF2 and TGFβ1. 
Six human skin fibroblast cell lines and their iPSC that have been previously published 
were analysed in this study. IPSC were then differentiated to fibroblasts by plating 
embryoid bodies on gelatine coated plates using DMEM/10% FBS for three to six 
weeks. Permissions to use the published iPSC lines were granted under normal 
guidelines from the authors of the relevant publications. Ethics and permission to obtain 
human fibroblasts and iPSC was obtained from the relevant institutes of the published 
articles.  
 
Generation of human and mouse iPSC by viral infection 
For human fibroblasts or mouse C2C12 reprogramming experiments, about 50,000 or 
100,000 cells were seeded per well of a 6-well plate and infected with retroviral 
supernatants of a polycistronic retroviral vector containing Oct4, Sox2, Klf4 and GFP as 
a reporter gene (pPMXS-OSKG). Then, either pMSCV - c-Myc or p-Babe puro Cyclin 
D1 was also used to infect for 3F+c-Myc or 3F+Cyclin D1 respectively. Retroviruses 
for the different factors were produced. Phoenix ecotropic packaging cell line was used 
to produce supernatant with virus to infect mouse cells, and phoenix amphotropic for 
human cells, using Polyethylenimine as transfection reagent according to the 
manufacturer's instructions. After 24 h, DMEM medium was replaced, cells were 
incubated at 32°C, and viral supernatant was harvested after 24 and 48 h. Infection 
consisted of a 45-min supernatant spinfection at 750 g in the presence of 1 mg/mL 
polybrene. Three rounds of infections on consecutive days were performed. Two days 
after beginning the last round of infection, cells were trypsinized and seeded onto feeder 
layers of irradiated MEFs or HFFs depending on whether cells were mouse or human. 
The medium was changed upon platting to G4 with LIF for mouse iPSC or hES with 
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FGF2 for human iPSC. Cultures were maintained at 37°C, 5% CO2, changing medium 
every other day.  
 
Synthetic mRNA reprogramming to iPSC 
Clinical grade reprogramming method was done using Stemgent’s microRNA-enhanced 
mRNA reprogramming kit (STEMGENT, #00-0071) protocol. Messenger RNA used 
for transfections are included in Stemgent kit, minus Cyclin D1 mRNA, that was used 
to replace c-Myc and was synthetized by in vitro transcription (IVT) using the 
MEGAscript Kit (Ambion, Ref#AM1334). DNA template for the mRNA IVT for 
Cyclin D1 was made by cloning Cyclin D1 ORF between the 3’ and 5’ untranslated 
regions (UTRs) of alpha-globin by splint ligation to increase the stability and translation 
efficiency of the transcript. Using Cyclin D1 template proceed to synthesize the 
messenger RNA by IVT. Cyclin D1 mRNA was functionally tested by counting the % 
EdU positive cells after 24h in low serum and transfecting HFFs with different amounts 
of mRNA (Supplementary figure 2, E). RNase and DNase free tubes and tips were used, 
and it was eliminated RNases in gloves and working surface with RNaseZap (Sigma, 
#R2020). For the cells transfection, briefly, HFFs were seeded on vitronectin-coated 
24MW plate wells at six different densities: 7.5k, 10k, 12.5k, 15k, 17.5k and 20k. The 
next day, three densities with 50-70% confluency were selected. Transfections were 
done in cells cultured in Pluriton medium (Stemgent Ref#00-0070), adding 300ng 
B18R/ml to inhibit immune response to transfected material. Pluriton medium was 
conditioned 24h before on irHFFs the day before adding it to the target HFFs to be 
transfected. MicroRNA and mRNAs were transfected as indicated by the 
manufacturer’s protocol (STEMGENT, #00-0071) using stemgent’s transfection 
reagent. Messenger RNA cocktail is transfected at a proportion of 3:1:1:1 of the 
reprogramming genes: Oct4, Sox2, Klf4, Lin28 and c-Myc or Cyclin D1 (OSKLM or 
OSKLD). It was transfected 200ng of mRNA per well of a 24MW plate. MicroRNA to 
enhance reprogramming efficiency is transfected at day 0 and 4, and mRNA from day 1 
to 12. At day 14-15 colonies were picked by mechanically scrapping them and were 
transferred to Vitronectin coated plates in Conditioned Pluriton mixed 1:1 with E8 
medium. Rho kinase inhibitor (ROCKi, Y-27632, STEMCELL #72302) was added at 
10µM final concentration during the first 24h after colony picking to prevent cell 
apoptosis. Medium was change to E8 (not feeder conditioned and with no Pluriton) 24h 
later and refreshed daily. Colonies were passaged by gentle dissociation with 0.5mM 
EDTA when they are 75-80% confluence. 
 
In vitro differentiation 
To differentiate mouse iPSC to cardiomyocytes, EBs were seed on gelatin and cultured 
in DMEM medium with 10% FCS and 100mM of Ascorbic Acid changed every second 
day for 2 weeks, until beating started. To differentiate mouse iPSC to fibroblast-like 
cells, EBs on gelatin and DMEM medium with 10% FCS changed every second day for 
3-6 weeks. 
Mouse and human iPSC general differentiation was carried out by plating embryoid 
body (EBs) on gelatin and the DMEM medium, with 20% FCS changed every second 
day for 2–3 weeks. Human iPSC in vitro guided differentiation toward endoderm, 
mesoderm, and ectoderm was done using PSC Neural Induction Medium kit 
(A1647801) for Neural Stem Cells coating the plates with Geltrex (Life Technologies, 
A1413201). Cardiomyocytes (CM) differentiation was done using PSC Cardiomyocyte 
Differentiation kit (A2921201) and CM were kept in culture until beating was stable. 
Definitive endoderm was differentiated from iPSC using PSC Definitive Endoderm 
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(DE) Induction kit (A27654SA). Motor Neurons were differentiated from Neural Stem 
Cells using the motor neuron induction medium: hES media supplemented with Sonic 
hedgehog 200ng/ml, 50 μM Retinoic Acid, 8ng/ml FGF2, 10ng/ml Activin A during 50 
days. As an internal control for all the differentiation protocols, we differentiated in 
parallel a commercial Episomal made iPSC (Life Technologies, A18945). 
 
Teratoma formation 
Animal experiments were approved by the University of Barcelona ethics committee. 
Two million cells were subcutaneously injected at the flank of athymic FoxN1 nu/nu 
mice (ENVIGO). After 3-4 months teratomas were extirpated and fixed in 
paraformaldehyde 4% O/N. Next day teratomas were embedded in paraffin and sections 
were analyzed for Hematoxilin-Eosin staining to recognize germ layer structures and for 
KI-67 to assess the in vio tumorigenic potential of injected iPSC. 
 
Immunofluorescence, immunocytochemistry and flow cytometry 
Cells were grown on plastic cover slide chambers and fixed with 4% paraformaldehyde 
(PFA). After fixation and washing, cells were blocked with PBS containing 6% donkey 
serum, and 0.5% Triton X-100 for 30 min. Cells were then stained for appropriate 
markers described in the figures. Pluripotency markers: anti-Oct4 (Santa Cruz, sc-5279, 
1:60), anti-Sox2 (CalBiochem, sc1002, 1:100) anti-SSEA3 (Abcam MC631, ab16286, 
1:10), anti-SSEA4 (Biolegend, MC-813-70, 1:50) and anti-Tra-1-81 (Merck, 
MAB4381, 1:200). For generally differentiated cells cells it was performed an IF for 
endoderm marker anti-AFP (Dako, A0008, 1:400), mesoderm marker anti-αSMA 
(Sigma, A5228-100) and ectoderm marker anti-Tuj1 (Biolegend, MMS-435P-100, 
1:500). Primary antibodies for guided differentiation into Cardiomyocyte markers: anti-
Cardiac troponin T (Abcam, ab10214, 1:400) and anti-Gata4 (Santa Cruz, sc-9053, 
1:200);  Neuronal markers: anti-Nestin (Biolegend, 841801, 1:200), anti-MAP2 (R&D 
systems, MAB8304, 1:250); Motor Neurons markers: anti-OLIG2 (R&D systems, 
AF2418), HB9 (Hybridoma bank, 81.5c10-s, 1:100); endoderm cells were analyzed 
with anti-hCXCR4 PE conjugated (FAB173P); astrocyte markers: anti-S-100 (Dako, 
Z0311, 1:100), anti GFAP (Dako, Z0334, 1:200). Secondary antibodies used were all 
the Alexa Fluor Series from Invitrogen (diluted 1:200). Images were taken using a Leica 
SP5 confocal microscope. During confocal microscopic observation, all the images 
were taken using the same settings. It was performed a tile scan image gathering with an 
AF6000 Epifluorescence microscope for SCI spinal cord IF. TLR3, anti-human CD283 
(TLR3)-PE conjugated, (eBioscience, 12-9039-80) at a 1:100 dilution. All flow 
cytometry analysis was performed on a FACS Canto II machine. 
 
H2AX Double strand breaks (DSB) and Rad51immunofluorescence staining 
Methanol:acetic fixed cells were stained for anti-gamma H2AX (Ser139) antibody 
(Novus, NB100-78356-0.025, 1:500) to determine the % of DNA double strand breaks 
(DSBs) and Rad51, NB100-148, Bionova, 1:300. Cells were blocked in PBS, 2% Donkey 
serum, 0.05%Triton-X100. Primary antibody was incubated o/n at 4ºC. Secondary 
antibody, goat anti-mouse A568 (A11031), was incubated 1:1000 for 2h at 37ºC. 
Quantification was performed using ImageJ by counting yH2AX and Rad51 positive foci 
in 200 nuclei per experiment. To stain the cell membrane, cells were incubated with 
WGA (wheat germ agglutinin A594, Thermo Fisher #W11262), 1:500 in PBS during 
10min at 37ºC after fixation with PFA 4% before permeabilizing. 
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Alkaline phosphatase staining  
Pluripotent stem cells present high levels of alkaline phosphatase enzyme. Alkaline 
Phosphatase Blue Membrane Substrate Solution (AB0300-1KT) was used to detect 
iPSC AP expression levels as a standard assay. 
 
Western Blot 
Protein extracts of cells collected by centrifugation, washed twice in PBS, lysed in 1x 
lysis buffer (50 nM Tris-HCl, 70 mM 2 mercaptoethanol, and 1% sodium 
dodecylsulfate (SDS) and the concentration of total protein was measured.. Lysates 
were then boiled for 5 min, and subjected to 12% polyacrylamide SDS gels or 4-12% 
SDS resolving gels (Invitogen). After electrophoresis, proteins were transferred to a 
nitrocellulose membrane using a submerged transfer apparatus (BioRad), filled with 
25mM Tris Base, 200 mM glycine, and 20% methanol. After blocking with 5% non-fat 
dried milk in TBS-T (50 mM Tris- HCl (pH 8.0), 150mM NaCl, and 0,1% Tween 20) 
the membrane was incubated with the primary antibodies diluted in TBS-T and washed 
extensively. The membrane was washed 3 times with TBS-T and then incubated with 
the appropriate horseradish peroxidase linked secondary antibody (Amersham). The 
detection was performed with the Western Breeze Immunodetection Kit (Invitrogen). 
Membranes were blotted overnight at 4°C with anti-Oct4 (Santa Cruz Biotechnology, 
Inc, sc-5279, 1:100) and anti-Cyclin D1 (Santa Cruz, sc753, 1:500). 
 
Kariotype analysis 
In order to see chromosome G bands, methanol:acetic acid (3:1) fixed cells were stained 
with Wright: Sorensen buffer (1:3). Chromosomes were analysed and classified using 
Ikaros software. 
 
Electrophysiology 
It was determined the electrophysiology of sodium and potassium currents of iPSC 
derived Motor Neurons using the patch-clamp voltage recording method. In several 
cells, Na currents could be inhibited by tetrodotoxin (TTX). Motor neuron firing action 
potentials were also recorded. 
 
Telomere length and cytogenetic analysis using telomere Q-FISH on metaphases 
Cells were incubated with 0.1 μg/mL colcemide (Gibco) for 4 h at 37°C, , swollen in 
hypotonic buffer (Sodium citrate 0.03M) for 25-45min and then fixed in 
methanol:acetic acid (3:1). Cells were concentrated and 30ul were dropped onto slides 
falling from 10cm high. After washing, metaphase spreads were fixed in 4% 
formaldehyde in PBS, and FISH was performed as described previously (Samper et al., 
2000; Tarsounas et al., 2003), using a telomere probe (Panagene, Cy3-TEL). For 
analysis of chromosomal aberrations, metaphases were analyzed by superimposing the 
telomere image on the DAPI image using TFL-telo software. 
 
Single Nucleotide Polymorphism (SNP), Copy number variation (CNV) and 
Methylome array 
Single nucleotide polymorphism and copy number variation was analyzed with Infinium 
Omni5.0-8 v1.3 Kit (20001112). Total 1ug DNA was hybridized to the bead chips o/n 
following manufacturer’s instructions. Methylome analysis was performed using 
Infinium MethylationEPIC kit (WG-317-1001), which targets >830k methylated CpGs 
in promoter, gene body, and enhancer regions for genome wide methylation studies.  
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Real Time PCR 
Total mRNA was isolated using Ambion RNA purification columns kit (#12183018), 
and 500ng was used to synthesize cDNA using the SensiFAST cDNA synthesis kit 
(Bioline, BIO65053). One μL of the reaction was used to quantify gene expression by 
quantitative PCR as previously described (Aasen et al., 2008). Primers sequences are 
listed in supplementary table 1. Relative quantification was determined according to the 
ΔΔCT method. 
 
NSC injection into rat spinal cord 
Neural Stem Cells (NSC), 2·10^6, suspended in 10µl, were injected in between 
segments T8-9, using a stereotaxic arm with an attached Hamilton, at two levels: rostral 
(5µl) and caudal (5µl) separated by 2-3 mm, at a speed of 2µl/min. Right after injecting 
the cells, a complete transection was practiced in the middle of the two injection sites. 
After transection, rats were maintained alive until two months. After this time, rats were 
perfused and spinal cords were extirpated and embedded in sucrose for 6 days. In order 
to cut the tissue with a cryostat microtome, spinal cords were embedded in OCT and 
froze at -80ºC. Cords were entirely cut longitudinally in 10µm thick slices. Longitudinal 
cuts were stained by immunofluorescence for Tuj1 and GFAP to detect neurons and 
astrocytes respectively. All experiments performed were approved by the ethics 
committee responsible of the animal house facility. 
 
MN injection into spinal cord in an SMA mouse model 
Neural Stem Cells were differentiated into Motor Neurons (MN) to test engraftment and 
survival in a Spinal Muscle Atrophy (SMA) mouse model (Smn(2B/-)). MNs were 
injected in 15-17 days old SMA mice (n=7). Isoflurane was used to anesthetize. 40.000 
MN Vybrant CFDA-tagged (green tracker) resuspended in 2ul of MN medium were 
injected with a Hamilton into the spinal cord at segment L1 to innervate L4-L5. Sham 
control SMA mice (n=6) were injected with MN medium. 
 
Proteomic analysis for Global analysis 
Protein solubilisation was performed with 1% sodium dodecyl sulfate (SDS) lysis 
buffer, and samples were quantified using BCA Reagent (Thermo Scientific) following 
the manufacturer’s instructions.  For global analysis, 50mg of proteins from each 
sample were digested and labelled with tandem mass tag (TMT 10-plex) isotopic label 
reagent set (Thermo Scientific, Rockford, IL, USA) following the manufacturer’s 
instructions. Labelled peptides were separated by means of nanoliquid chromatography 
using a nanoLC ULTRA AS2 (Eksigent). For identification of TMT labelled peptides, 
higher energy collisional dissociation (HCD) with 40% fixed collision energy (CE) was 
the fragmentation method used. Data was processed using Proteome Discoverer 1.4.1.14 
(Thermo Fisher Scientific). For database searching, raw mass spectrometry files were 
submitted to the in-house Homo sapiens UniProtKB/Swiss-Prot database using 
SEQUEST (Thermo FisherScientific). The method used for HLA typing was PCR-
sequence specific oligonucleotide reverse (PCR-SSO) using bead arrays on a Luminex 
platform.  
 
LPS and Poly(I:C) stimulation and IL6 detection 
F2 cells were seeded in 24-w plate and once 80% confluent they were stimulated o/n 
with 100ng/ml lipopolysaccharides (LPS) and 1ug/ml Poly(I:C) to stimulate an innate 
immune response. The next day, supernatants were collected and analysed with an 
ilumina cytokine kit for IL6.  
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Illuminex cytokine detection array 
Cytokine production determination was assessed by Luminex (Millipore, Billerica, MA, 
USA) at 48h culture point following the manufacturer’s instructions. Briefly, 
supernatants were incubated for 2h with corresponding anticytokine magnetic beads, 
and then washed with 1x washing buffer and stained with detection antibodies 
(provided) for 1h. Strepatividin-PE was then added for 30 more minutes. During all 
incubation steps the plate was agitated at 650rpm. After washing, plate was agitated for 
15 minutes at 650rpm and read in the xMAP Luminex reader (Waltham, MA, USA). 
 
Lentiviral production 
TLR3 Lentiviral Vector (human) (pLenti-GIII-UbC) (Abcam, LV335740) was used to 
overexpress TLR3 full length. Viral particles were produced with a 293T packaging cell 
line. NSC were infected once with viral supernatants. At day 3 after transduction with 
viral particles, infected NSC were selected with puromycin during 7 days to isolate 
transduced cells. Then overexpression of the transgene was checked by RT-PCR and 
FACS.  
 
Apoptosis assay and CTL degranulation detection 
All animal experiments were approved by the University of Barcelona ethics committee. 
Cells were in vivo injected isogenically into C3H mice. Four iPSC clones and four iPSC 
derived cardiomyocytes clones were injected in duplicate into the testis of mice. One 
week after injection, cells were reinjected again for boosting the priming of the 
Cytotoxic T lymphocytes (CTLs) against injected cells. One week after reinjection 
(final priming period of 14 days), CTLs were collected with an isolation by FICOLL 
gradient from mice smashed spleens. For T cell kill assay, CTLs were added on top of 
the cardiomyocyte line that was injected in the mouse from where the CTLs were 
isolated. Co-culture assay lasted 4h. CTLs degranulation in response to cytotoxic 
activation was determined by CD107a staining (Biolegend, FITC anti-mouse CD107a, 
#121605) and apoptosis of target cardiomyocytes was assessed by an Annexin V-FITC 
staining (Apoptosis detection kit, Biotools, Cat #B32115). CD107a antibody must be in 
the medium during the coculture because CD107a protein is rapidly endocyted 
following externalization. After coculture, CTLs were collected by pipetting up and 
down in the well. Rinse the dish with cold buffer. Check microscopically for any 
remaining cell, if necessary, rinse the dish again. Once CTLs have been removed, target 
cells were trypsinized and stained for annexin V. Staining percentage was analyzed by 
flow cytometry. 
 
Differential Protein Annotation and Bioinformatics Analyses 
Proteins identified in different amounts in each of the two experiments were analysed 
using the bioinformatics tool DAVID v6.7 (Database for Annotation, Visualization and 
Integrated Discovery; http://david.abcc.ncifcrf.gov/) in order to identify overrepresented 
biological pathways (21, 22). Similarly, differential proteins were analysed for protein-
protein interaction networks using the online tool STRING v10 (23). 
Statistical Analyses 
All experiments were repited three times and unpaired two-tailed Student’s t-test was 
calculated to determine significance. To determine differentially expressed quantified 
proteins between the groups (F1 versus F2) statistical analysis was carried out using 
SPSS for Windows (version 21.0, Chicago, IL, USA). Comparison between groups (F1 
vs F2) was performed using Student’s t-test. p≤ 0.05 was considered to be significant. 
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DETAILED PROTOCOLS 
 
Transduction protocol using Phoenix cells 
 
 
1. Defrost 1 vial (5x106 cells) of Phoenix (amphotropic or ecotropic to infect 
human or mouse cells respectively) in a 10cm plate. 
 
2. After 48-72h,wash x2 PBS, tripsinize cells with trypsin 0.5%, count cell number 
and seed 4,5x106cells/plate. 
 
3. After 24h transfect 10 µg of retroviral vector with 30 µl of Lipofectamine 2000 
in a volume of 3ml of Opti-MEM: 
               1.5ml OptiM + 30 µl Lipo   +   1.5ml OptiM + 10 µg plasmid.  
Mix gently and let 20min at R/T in dark. 
4. Add the transfection complex to the Phoenix cells resuspended in 3ml DMEM 
10% (no P/S), o/n (16h maximum). 
 
5. 24h later refresh the medium (add 6ml of DMEM) and let plates and incubate @ 
32ºC. The same day seed 200.000 target cells/well (6-w) for infecting. 
 
6. Collect supernatant 24h later with a 10ml pipette and filter the virus using a 
0.45µm filter on the tip of the pipette. Add another 6ml of DMEM 10% to the 
Phoenix. Add 1ml polybrene/µl virus. 
 
7. 1st infection (morning): Add 2ml of filtered virus to each well of a 6-w plate. 
Centrifuge: 45min 700G @ 32ºC. Leave it for 1h in the incubator @ 32ºC then 
remove the virus containing supernatant and replace it with fresh DMEM 10%. 
 
8. 2nd infection (night): After the day collect virus again and add 7ml of DMEM 
10% to the Phoenix (because during the night it evaporates) and infect again 
with 0.5 µl polybrene/ml virus. Add 2ml of filtered virus to each well of a 6-w 
plate. Centrifuge: 45min 700G @ 32ºC. Leave it for 1h in the incubator @ 32ºC 
then remove the virus containing supernatant and replace it with fresh DMEM 
10%. 
 
9. 3rd infection (morning): the next day, collect virus and infect cells during the day 
with 1 µl polybrene/ml virus. Add 2ml of filtered virus to each well of a 6-w 
plate. Centrifuge: 45min 700G @ 32ºC. Leave it for 1h in the incubator @ 32ºC 
then remove the virus containing supernatant and replace it with fresh DMEM 
10%. 
 
10. 48-72h later, seed cells onto feeder layer (650.000 cells/well) with the 
corresponding medium (G4 for mouse cells, hES medium for human cells) 
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Immunofluorescence Protocol 
 
 
 
1. Grow cells on coverslips or on chamber slides to about 40-50% confluence. 
Remove medium and wash with PBS. 
 
2. Carefully aspirate PBS, and fully cover the cells in PFA (paraformaldehyde) 4% 
during 30’ at RT. Aspirate fixative, and wash 3x with PBS for 5min each. Do 
not let cells dry out. 
 
3. Block samples in blocking buffer (PBS + 6% donkey serum, 1% BSA, and 0,5% 
triton 100x if the antigen is intracellular). Block for 1h at RT. 
 
4. Wash with PBS, and add primary antibody (1:1000 dilution in blocking buffer 
with 0,1% triton 100x if the antigen is intracellular). Cover the sample with the 
required amount (100-200µl). Place the samples in a container with moist paper 
towels covered in aluminum foil. Place a piece of parafilm over the slide to 
ensure even coverage, and prevent cells from drying out. Incubate overnight at 
4C. 
 
5. Wash 5’ 3x with PBS at RT. Add 200ul secondary antibody and incubate 2h at 
37C.  
 
6. Wash 5’ 3x with PBS at RT. Cover the coverslip with DAPI and incubate for 3’. 
Mount with anti-fade and let dry for 5’. Seal with nail polish, let dry, and store at 
4C. 
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Flow cytometry immunostaining (FACS) protocol 
 
 
 
1. Spin tripsinizated cells in eppendorfs at 1500rpm 5’. Discard St. 
 
2. Wash x1 DPBS. Spin 1500rpm 5’. Discard St. 
 
 
3. PFA 4% fixation of cells at 4ºC 30’ in the dark (200ul/tube). 
 
4. Wash x1 DPBS. Spin 1500rpm 5’. Discard St.  
 
5. Add 250ul/tube of permeabilization buffer (TBS + 1%BSA + 0.5% Triton 100x 
+ 6%Horse serum). Incubate 15’ at 4ºC. Spin 1500rpm 5’. Discard St. 
 
6. Add 200ul/tube of dilution buffer (PBS + 6% Horse serum + 1%BSA + 0.1% 
Triton 100x) + 1ary Ab (1:200). Incubate at 4ºC 30’. Spin 1500rpm 5’. Discard 
St. 
 
7. Wash x3 with washing buffer (TBS+1%BSA + 0.1% Triton 100x). Spin 
1500rpm 5’. Discard St. 
 
8. Add 200ul/tube of dilution buffer + 2ary Ab (1:400). Incubate at 4ºC 30’ in the 
dark. Spin 1500rpm 5’. Discard St. 
 
9. Wash x3 with washing buffer. Spin 1500rpm 5’. Discard St. 
 
10. Resuspend stained cells in 250ul of DPBS. 
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Quantitative real time PCR (qPCR) protocol 
 
 
 
1. Tripsinizate cells. Wash with PBS. Pellets can be stored at -80ºC for as long as 6 
months before extracting RNA. 
 
2. Extract RNA with Life Technologies an RNA  extraction kit (#12183018A). 
 
3. Quantificate RNA with Nanodrop. 
 
4. Prepare cDNA (Bioline, BIO-65053). Calculate final concentration of 1µg-500 
ng of RNA. Dilute sample with water up to 15µl, then add 4µl buffer + 1µl RT. 
 
5. To do the planning of the Real time PCR consider every sample in duplicate or 
triplicate. 
 
6. Total volume: 15µl: 6µl (1 µl cDNA+5 µl water) + 9µl (7.5 µl SybrGreen 
(Ecogen, BIO-94005) + 0.75 µl Forward primer 10 µM + 0.75 Reverse primer 
10µM). 
 
7. It was used a 7500 Applied Biosystems machine. Lo Rox settings: 
10’ 95ºC    
X 40 cycles:     10’’ 95ºC     
 34’’ 60ºC        
8. Evaluate results by double delta Ct analysis (2^(-delta delta Ct)). 
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Western blot protein detection 
 
 
 
1. Lysate extraction: Trypsinize the cells and wash them with PBS. Add lysis 
buffer (50ul/sample) + protease inh (x200) + phosphatase inh (x200). 
 
2. Quantify using Qubit prot. (dilute 1:5 first to take 1ul to quantify). Boil at 100ºC 
during 10min. Centrifugue at 2000rpm 5min. Work out the ul necessary to load 
between 40-60ug. Add loading buffer (x4). First add 2-M 10% to the loading 
buffer. 
 
3. Prepare the precast gel. Remove it from the box, remove the long White stick of 
the bottom and remove the plastic covering the wells. Put it in the running cage 
and add MES (x20) diluted in distillated water. Total 400ml (20ml+380ml). 
Load the samples in the gel. 
 
4. Run the gel at 30mA during the first 10min (corresponding to 42V). Then you 
can increase up to 100V to finish to run it. Keep an eye on the loading buffer 
while the samples run. Open the precast gel separating the two plastic walls and 
sink four sponges, two filter papers and one nitrocellulose membrane in transfer 
buffer. 
 
5. Stick one filter paper to the gel to transport it to bind the nitrocellulose 
membrane. Wrap the gel-membrane with the filter papers. On every side put two 
sponges. The side of the gel goes in the negative side (catode). Run the 
transference at 20V during 1h (1h to transfer small proteins and 2h for big 
proteins). 
 
6. Wash the membrane with TBS-Tween and block for 1h in TBS-T 5%milk. 
Wash x3 TBS-T. Add 1ary ab at the manufacturer’s recommended dilution o/n 
4ºC rocking. Wash x3 TBS-Tween. Add 2ary ab at the manufacturer’s 
recommended dilution 1h RT rocking. Wash x3 TBS-Tween. 
 
7. Add ECL (1ml A + 1ml B) during 3-5min. Remove the leftover and put the 
membrane in the revealing cassete. 
 
8. Open the revealing cassete in a dark room and put on top the nitrocellulose 
revealing radiography. Close the cassete to expose the signal during 2’, 5’, 10’, 
20’ or 30’ depending on the amount of signal visible. After the exposure 
submerge the radiography in the revelation liquid for 2’. Then wash it in the 
water container and submerge it in the fixation liquid for 7’. Let the radiography 
dry and label on top the protein ladder, the date, ab and dilution. 
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Alkaline Phosphatase staining 
 
 
 
1. Remove cell culture media from cells. 
 
2. Wash with cold PBS x1 (3ml per well of a 6-w).  
 
3. Fix with PFA 4% 1’30’’ on ice (1ml per well of a 6-w plate), rocking or moving 
around the plate to ensure good coverage and fixing. 
 
4. Wash with cold PBS x1. 
 
5. AP stain: 1ml reactive A +1ml reactive B (per well of a 6-w). Reagents from 
Sigma, AB0300-1KT, Alkaline Phosphatase Blue Membrane Substrate Solution. 
 
6. Keep it away from light covering the plate with tin foil. 
 
7. Leave it rocking at RT for 20’-40’. Check every 5’. Do not leave it for more than 
1 or 2h maximum.  
 
8. Wash with cold PBS x1. Fix cells again with PFA 4% for 2’ at RT after 
developing the blue color. 
 
9. Wash with cold PBS x1. 
 
10. Count blue positive colonies. 90% blue colonies are considered fully 
reprogrammed iPSC. 
 
11. Plates can be stored at 4ºC during 4 weeks adding PBS. 
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Immunohistochemistry (IHC) staining of frozen sections 
 
1. To preserve tissue morphology and retain the antigenicity of the target 
molecules, fix the tissue by vascular perfusion with 50-70ml of formaldehyde. If 
it is not possible to fix by perfusion, dissected tissue may be fixed by immersion 
in a 10% formalin solution for 4 to 8 hours at room temperature. It is commonly 
accepted that the volume of fixative should be 50 times greater than the size of 
the immersed tissue. Avoid fixing the tissue for greater than 24 hours since 
tissue antigens may either be masked or destroyed. All rodent tissues are usually 
perfused-fixed with the exception of lung, spleen, and embryonic tissue, which 
are immersion fixed. For cryopreservation of tissues prior to fixation, snap 
freeze fresh tissue immediately in isopentane mixed with dry ice, and keep at -
70°C. Do not allow frozen tissue to thaw before cutting. 
 
2. After tissue has been properly fixed, embed the tissue in sucrose solution over 
48h. Embed the tissue completely in OCT compound prior to cryostat sectioning 
and freeze at -20 to -80 °C.  
 
3. Cut 5-15 µm thick tissue sections using a cryostat (temperature is between -15 
and -23 °C). The section will curl if the specimen is too cold. If it is too warm, it 
will stick to the knife. 
 
4. Thaw-mount the sections onto gelatin-coated histological slides. Slides are pre-
coated with gelatin to enhance adhesion of the tissue. Dry the slides for 30 
minutes on a slide warmer at 37 °C. Slides containing cryostat sections can be 
stored at -20 to -70 °C for up to 12 months. 
 
5. Air dry the sections for 30 minutes at room temperature to prevent sections from 
falling off the slides during antibody incubations. Slides can be stored unfixed 
for several months at -70 °C. Frozen tissue samples saved for later analysis 
should be stored intact. 
 
6. When staining cryostat sections stored in a freezer, thaw the slides at room 
temperature for 10-20 minutes. Then fix for 8 minutes at 2-8 °C for 20 minutes. 
 
7. Rehydrate the slides in wash buffer for 10 minutes. Drain the excess wash 
buffer. Block non-specific staining between the primary antibodies and the 
tissue, by incubating in blocking buffer (PBS + 6% donkey serum and 0,5% 
triton if the antigen is intracellular) for 1h at RT.  
 
8. Add primary antibodies diluted in Incubation Buffer according to 
manufacturer’s instructions. Incubate overnight at 4°C to allow optimal specific 
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binding of antibodies to tissue targets and reduce non-specific background 
staining.  
 
9. Wash slides 3 times for fifteen minutes each in wash buffer. Incubate with the 
secondary antibody diluted in Incubation Buffer according to the manufacturer’s 
instructions for 60 minutes at room temperature. From this step forward samples 
should be protected from light. 
 
10. Wash slides 3 times for 15’. Add DAPI solution to stain the nucleous, and 
incubate 2-5 minutes at room temperature. Wash with PBS. Mount with 
mounting media and visualize using a fluorescence microscope. 
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Mouse perfusion and fixation (PFA 4%) 
 
 
1. Fill with 50ml PBS and PFA 4% two syringe pumps and place them in the 
perfusion pumper machine. Run the liquid first a little bit in case there are air 
bubbles. 
 
2. Anesthetize the mice with ketamine/xilacine following manufacturer’s advices.  
 
3. Fix the mice face-up by pinning hands and feet with thick needles to a foam 
platform (with holes for dripping down the fluid to a recipient container). 
 
4. Excise the skin on the belly area and open to find the heart, cutting the 
diaphragm. Cut out the ribs and breastbone to access comfortably the heart 
(work quickly at this stage since the heart has to be pumping when starting the 
perfusion). 
 
5. Introduce the needle with the butterfly catheter through the left ventricle. Secure 
the butterfly catheter with a pin to the foam. 
 
 
 
 
 
 
 
 
 
 
 
 
6. Start running PBS a few seconds and observe the heart filling up. Immediately 
make a cut in the right atrium (a gush of blood should pour out). 
 
7. If PBS is running properly the mice will lift the head and the tail will get erect 
for a few seconds and drop again. Run the 50 ml of PBS through the mouse 
(liver should look yellowish and the heart pinkish). 
 
8. Change to perfuse PFA 4% and let run at least 30 ml (tissues should become 
stiff). Stop the flow and un-pin the mouse. Excise the organs to be studied and 
immerse in 4% PFA for 48h.  
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Neural Stem Cells (NSC) induction from iPSC 
 
 
 
(protocol based on PSC Neural Induction Kit, #A1647801, Life Technologies). 
 
1. Pre-warm complete PSC Neural Induction Medium (#A1647801) to RT. 
 
2. On day 0 of neural induction (about 24 hours after PSC splitting), PSCs should 
be at 15–25% confluency. Refresh the media adding 2,5 ml of pre-warmed 
complete PSC Neural Induction Medium into each well of 6-well plate. Return 
plates to the 37°C incubator with a humidified atmosphere of 5% CO2. 
 
3. On day 2 of neural induction, morphology of cell colonies should be uniform. 
Mark all non-neural differentiated colonies, if any, and remove such unwanted 
colonies with a Pasteur glass pipette or pipette tip. Aspirate the spent medium 
and add 2,5 ml pre-warmed complete PSC Neural Induction Medium into each 
well of the 6-well plate. Return the plates into the incubator. 
 
4. On day 4 of neural induction, cells will be reaching confluency. Any non-neural 
differentiated colonies should be marked and removed. Aspirate the spent 
medium from each well and replace it with 5 mL of pre-warmed complete PSC 
Neural Induction Medium per well. Return the plates into the incubator.  
 
5. On day 6 of neural induction, cells should be at near maximal confluence. 
Remove any non-neural differentiated colonies and add 5 mL of pre-warmed 
complete PSC Neural Induction Medium into each well. Return the plates into 
the incubator. If the color of cells turns brownish with many floating cells during 
day 4 to 7 of neural induction, it indicates that the starting density of PSCs was 
too high. In this case, change the medium every day with 5 mL of PSC Neural 
Induction Medium per well. 
 
6. On day 7 of neural induction, NSC (P0) are ready to be harvested and expanded. 
Cells must be passaged with Rock inhibitor in Geltrex coated plates 
(A1413201). Then induction medium can be diluted with Advanced DMEM/F12 
as a NSC expansion medium.  
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Pluripotent Stem Cells (PSCs) differentiation into cardiomyocytes  
 
 
(protocol based on PSC Cardiomyocyte Differentiation Kit, # A25042SA, Life 
Technologies). 
 
1. Coat a 12-w plate with Geltrex at RT during 1h. 
 
2. On day 0 (day of splitting), PSC should be at 70–85% confluence. Trypsinize 
iPSC with EDTA 0,5mM. Incubate 2’ at 37ºC.  
 
3. Aspirate the EDTA solution and resuspend the cells in an appropriate amount of 
Essential 8 Medium to obtain a split ratio (typically 1:8 to 1:12) in order to 
achieve 30–70% confluence within four days.  
 
4. Move the plate in several quick back-and-forth and side-to-side motions to 
disperse the cells across the surface and place them gently in a 37°C incubator 
with a humidified atmosphere of 5% CO2. To promote cell survival add ROCK 
inhibitor (10 μM Y27632) at the time of splitting.  
 
5. On day 1 (about 24 hours after PSC splitting), iPSC should be at 10–30% 
confluence. Refresh medium and return the plate to incubator. On days 2 and 3, 
as well refresh cells with Essential 8 Medium.  
 
6. On day 4, the PSC culture should exhibit 30–70% confluence (ideal is 35–60%). 
Aspirate the spent medium and add 1ml of pre-warmed Cardiomyocyte 
Differentiation Medium A to each well of the 12-well plate.  
 
7. On day 6, the cells will start to become opaque. Shedding of dead cells is 
normal. Aspirate the spent medium from each well and replace it with 1 ml of 
pre-warmed Cardiomyocyte Differentiation Medium B.  
 
8. On day 8, the cells will continue to become more opaque. Aspirate the spent 
medium from each well and replace it with 1 ml of pre-warmed Cardiomyocyte 
Maintenance Medium per well.  
 
9. On days 10 and 12, refresh cells with Cardiomyocyte Maintenance Medium. 
Contracting cardiomyocytes can appear as early as day 10. 
 
10. On day 14, spontaneously contracting syncytium of troponin T cardiac type 2 
(cTnT2) positive cardiomyocytes will be present and ready for use in various 
research applications. Differentiated cells can be further cultured to day 20 for 
harvesting. 
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PSC Definitive Endoderm (DE) Induction protocol 
 
 
(protocol based on PSC Definitive Endoderm Induction Kit, # A3062601, Life 
Technologies). 
 
1. Day 0: Plate iPSC. Trypsinize with EDTA 0.5mM 2’ at 37ºC, previously washed 
with PBS. 
 
2. Aspirate the EDTA solution and collect the cell clumps in an appropriate 
amount of Essential 8 Medium to obtain a split ratio clumps at ~1:10 split ratio 
(from 70% confluent culture) into Vitronectin coated plates. For extremely 
confluent hPSC cultures (i.e., >90%confluent), it will be necessary to seed 
clumps at a 1:15–1:30 split ratio as the optimum range for seeding density is 
0.01× 106–0.04 × 106cells/cm2. Otherwise, the culture will be over-confluent 
post-plating and the cells will detach during induction.  
 
3. Move the plates in several quick back-and-forth and side-to-side motions to 
disperse the cells across the surface and place them in a37°C incubator with a 
humidified atmosphere of 5% CO2. Add ROCK inhibitor (Y27632, 10 μM) at 
the time of splitting. 
 
4. Day 1: Begin DE induction: Warm the DE Induction Medium A from life 
technologies kit (A27654SA) to RT. Shake the bottle several times to ensure 
even distribution of the components in the medium.  
 
5. Assess the iPSC; if the cells are 15–30% confluent, proceed with induction. If 
the culture is at a higher confluency, the cells will start detaching.  
 
6. Aspirate spent Essential 8 medium completely from the wells and add pre-
warmed DE Induction Medium A. Incubate cells at 37°C for 24 hours.  
 
7. Day 2: Warm the DE Induction Medium B to RT. Shake the bottle several times 
to ensure even distribution of the components in the medium.  
 
8. Aspirate spent DE Induction Medium A completely from the well and add pre-
warmed DE Induction Medium B. Incubate cells at 37°C for 24 hours. 
 
9. Day 3: Characterize induced cells. After 24 hour incubation of cells in DE 
Induction Medium B, cells will be ready to be assessed for Definitive Endoderm 
characteristics or be further differentiated to downstream lineages. 
  
Materials and methods 
 
- 95 - 
 
Motor neuron (MN) induction 
 
Based on:  Jha BS, Rao M, Malik N. Motor neuron differentiation from pluripotent stem 
cells and other  intermediate proliferative precursors that can be discriminated by 
lineage specific reporters. Stem Cell Rev. 2015 Feb; 11 (1): 194-204. Doi: 
10.1007/s12015-014-9541-0.  
 
NSC to MN progenitors: 
1. Plate cells on Geltrex coated 6-w plates (1ml/w 1h at 37ºC or o/n at 4ºC). 
Passage 1:4 a fully confluent well of NSC. 
 
2. When cells are 80% confluent transfer to hES media + SHH 200ng/ml, RA 
50µM, FGF2 8ng/ml, Activin A 10ng/ml. Incubate for 2 days. 
 
3. Coat a plate with ornithine-laminine: thaw laminin o/n at 4ºC and always keep it 
on ice. Dilute ornithine 1:5 in sterile water. Coat 1ml O/w 1h at 37ºC or o/n at 
4º. Wash 2x with sterile water. Coat with 20µg/ml laminin 2h at 37ºC or o/n at 
4ºC. Wash with PBS x1. 
 
4. Cells should be 100% confluent, then plate 100,000 cells/cm2 (950,000 
cells/well of a 6-w) onto Ornithine-laminin coated wells in hES + SHH 
200ng/ml, RA 50µM, FGF2 8ng/ml. 
 
5. Change medium every 48h. Every day add fresh RA (1µl of 100nM to 2ml 
medium). Cells can be frozen from day 10. Keep culturing cells until day 16. 
Cells at this stage should be OLIG2 positive. 
 
6. Maturation of Motorneuron precursors (MNP): Transfer cells to hES medium + 
10ng/ml BDNF and 10ng/ml GDNF. Culture cells for 3 weeks changing 
medium every 2-3 days. Cells should be HB9 positive. 
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Q-FISH measurement of telomere length. 
 
 
Protocol extracted from Dra. María Blasco’s laboratory in Centro Nacional de 
Investigaciones Oncológicas (CNIO). 
1. Day 1: Metaphase obtention. 
 
2. Add colcemid (KARYOMAX COLCEMID SOLUTION LIQUID 19ML, 
#15210-040, Life Technologies, S.A., 35,22 EUR) to the cells in culture (10ul 
for each ml of medium from stock 10ug/ml). Prepare one P10 plate if cells are 
not dividing fast (MEFs, HFFs…) and only one well of a 6-w plate if cells are 
dividing at a high rate (for example iPSC). 
 
3. Leave cells in medium with colcemid between 2-4 hours. Exceptionally you can 
leave O/N to increase the number of metaphases in cells with low division rate. 
 
4. After incubation, tripsinize cells. Centrifuge 8’ at 800rpm. Aspirate medium, 
leaving 1ml of supernatant. Resuspend cells in that 1ml. 
 
5. Add slowly and softly, while vortexing tubes at 1000rpm, 9ml of hypotonic 
solution (0,03M sodium citrate, Sigma S4641-500G, 44,8 EUR) pre-warmed at 
37ºC. Leave tubes in the warm bath at 37ºC for 25’. 
 
6. Add 3 drops of fresh fixer (methanol/acetic acid 3:1). Methanol quality for 
analysis, ACS and ISO. Put tape onto the tubes labeling. 
 
7. Centrifuge 8’ at 800rpm. Aspirate supernatant, leaving 1ml. 
 
8. Add 2ml of fresh fixer drop by drop while vortexing tubes. Then add 7ml more 
slowly (faster than first 2ml). If there are many tubes, add first the 2ml to all 
tubes and then the rest. 
 
9. Repite (Centrifuge, aspirate leaving 1ml and add fixer the same way). Store at -
20ºC until metaphases preparation. 
 
10. Centrifuge 8’ at 800rpm. Aspirate supernatant leaving a specific amount of fixer 
depending on the size of the cells pellet (700ul – 200ul for big – little pellets). 
Resuspend cells. 
 
11. Prepare slides, labeling them with pencil. Rinse the slide with 45% acetic (acetic 
diluted in H2O) by pouring 500ul on top of it. As an alternative, distillated H2O 
can also be used instead of acetic. 
 
12. Drain acetic and drop 30ul of the cell suspension onto the slide (2-3 dropplets). 
Drops must fall from a distance of around 20-30cm on top of the slide. The more 
distance the better. By doing this, some cells are going to break when crushing 
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against the slide as they are fixed with a bigger cytoplasmic volume due to the 
hypotonic solution incubation. 
 
13. Dry slides O/N at RT. 
 
14. Day 2: Metaphase hybridations: Prepare acidified pepsin and incubate at 37ºC 
for 15’ (for every glass box prepare: 200mg pepsin + 200ml H2O + 168ul of 
concentrate HCl).  
 
15. Place slides in washing chambers to make easier all washing steps. Glass box: 
200ml of PBS are required to cover slides.  
 
16. Wash slides in PBS (with no Ca/Mg), rocking during 15’ (60-70rpm).  
 
17. Fix cells in PFA 4% for 2’. Rocking 60-70rpm. Wash 5’ in PBS x3. Rocking 60-
70rpm. 
 
18. Digest with pepsin pre-warmed 10’ at 37ºC. Wash 5’ in PBS x2. Rocking 60-
70rpm. 
 
19. Fix cells in PFA 4% for 2’. Rocking 60-70rpm. Wash 5’ in PBS x3. Rocking 60-
70rpm. 
 
20. Dehydrate putting slides in ethanol 70% -- 90% -- 100%, 5’ each. Rocking 60-
70rpm. Dry slides from 5’ to 20’. 
 
21. Prepare prove solution Cy3-TEL (Panagene, Cy3-OO-
CCCTAACCCTAACCCTAA-Lys, 50nmole, 900 EUR). 
 
 
 
 
 
 
 
 
 
Buffer MgCl2: 25mM MgCl2, 9mM citric acid, 82mM Na2HPO4, adjust pH7. 
 
22. Add a line of 25ul of the prove solution on top of every coverslide (one per each 
slide). Revert the slides on top of the coverslide and smash the slide against the 
coverslide. Push firmly to make the prove solution distribute all through the 
slide and the leftover fall out the edges. 
 
23. Denaturalize at 80ºC in a heating plate for exactly 3’. 
 
Stock 250ul (10 slides) Final concentration 
1M Tris pH7.2 2,5ul 10mM Tris 
Buffer MgCl2 21,4ul   
Formamide desionized 175ul 70% 
Probe (25ug/ml) 5ul 0,5ug/ml 
10% Blocking reagent 12,5ul 0,25% 
H2O 33,6ul   
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24. Incubate in a wet chamber 2h in the dark at RT. 
 
25. Wash 15’ x2 strongly rocking (use the vortex with a rectangular adapter at a 
speed of 150rpm). Place the glass box on top of the vortex. After 5’ check that 
coverslides have fallen. The last 10’ set the vortex at 100rpm.  
 
26. Washing solution: 
 
 
 
 
 
 
 
27. Wash 5’ x3 with TBS-Tween (0,08%). Rocking 90rpm. 
 
28. Dehidrate putting slides in etanol 70% -- 90% -- 100%, 5’ each. Rocking 60-
70rpm. Dry slides. 
 
29. Cover with Vectashield (Mounting medium/DAPI, 3:1). Add a line of 25ul of 
the mounting/DAPI solution on top of every coverslide (one per each slide). 
Revert the slides on top of the coverslide and smash the slide against the 
coverslide. Push firmly to make the solution distribute all through the slide and 
the leftover fall out the edges.  
 
30. Dry for 5’ and seal the edges. Store at 4ºC in the dark. 
 
31. Take images of the metaphases and analyze them with TFL-TELO software to 
identify telomere length intensity. 
  
Stock For 400ml Final concentration 
Formamide (standard) 280ml 70% 
1M Tris Ph7.2 4ml 10mM Tris 
BSA 10% in H2O 4ml 0,10% 
H2O 112ml   
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Lentivirus infection 
 
 
1. Trypsinize target cells (Neural Stem Cells) gently with TryplE (#12563-029). 
 
2. Resuspend the cells in fresh pre-warmed culture medium at concentration of 2·105 cell 
in a final volume of 200 µl into sterile conical tubes.  
 
3. Add concentrated viral supernatants to the cells at a MOI of 5. A part from the 
TLR3 FL overexpression plasmid, include a transduction well with a negative control 
virus with an appropriate blank control viral construct. In this case, the negative control 
is an empty vector that has an Ubiquitin (UbC) promoter. 
 
4. Also leave one well of uninfected cells as an additional standard control. 
Following the infection, incubate the cells at 37°C with 5% CO2. 
 
5. Gently mix and incubate cells for 50 minutes in the incubator at 37°C with 5% 
CO2. Leave the lid of the tube loosen. 
 
6. Seed infected cells in a Geltrex pre-coated (2h at 37ºC) 6-well plate. Incubate 
the cells at 37°C with 5% CO2. 
 
7. The next day remove virus containing medium and resuspend cell pellet with 2 
ml of fresh complete culture media.  
 
8. The following day, split the cells 1:3 or 1:5 (depending on the growth rate of 
your target cells) and continue incubating for 48 hours in complete media.  
 
9. Infected cells can then be selected for stable expression using appropriate 
antibiotic selection at a minimum concentration, in this case with puromycin 
selection at a final concentration of 2,5µg/ml.  
 
10. TLR3 expression can then be assayed by Western blot, FACS or RT-PCR.  
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Phenol:chloroform:isoamil acid DNA extraction 
 
 
1. After an o/n proteinase K digestion at 4ºC, mix (1:1) the digested samples with 
Phenol + Chloroform + Isoamil Acid (IAA) (25:24:1). Example: 500µl + 500µl. 
If digested reaction is less, such as 50µl, add water until reaching 500µl.  
 
2. Mix thoroughly manually during 15min (5min mixing, 5min pause and 5min 
mixing). 
 
3. Centrifuge samples 15min at 14000 rpm at RT. Carefully take the upper layer 
phase, which contains the DNA, to a new eppendorf. Don’t mix with the 
medium layer, which contains protein and would contaminate your samples. 
 
4. Add 250µl Ammonium acetate (7.5M) to the extracted phase. Add cold EtOH 
(1:1). Example: 750µl + 750µl. To help precipitation add glycogen at 0.5µg/ml. 
Mix gently by inverting eppendorf 3-4 times. 
 
5. Precipitate DNA: 1min liqN or 20min -80ºC or o/n -20ºC. 
 
6. Centrifuge 20min at 13000rpm at 4ºC. Remove supernatant. No need to drain 
everything as we are cleaning with 70% EtOH. Add 1ml of 70% EtOH and 
centrifuge again 20min at 13000rpm at 4ºC. 
 
7. Remove supernatant and drain as much as possible. Let the pellet dry at RT until 
no EtOH remains.  
 
8. Resuspend DNA pellet in 30µl of DNase and RNase free water. Quantify 
genomic DNA samples. 
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Spinal Cord induced injury detailed procedures 
 
1. Animals will be induced for deep anesthesia plane with 3% of isofluorane using 
the plexiglass chamber connected to the anesthesia workstation and keep with 
1.5-2% isofluorane when is anesthesically induced (normally 1-2 minutes after 
3% isofluorane induction). To check the anesthesia stage, the muscles should be 
relaxed, with no pedal retraction or palpebral and corneal reflexes. 
 
2. The animals will be pre-medicated with subcutaneous morphine (2.5 mg/kg) and 
Baytril (enrofloxacine, 5 mg/kg, Bayer, Germany). 
 
3. Shave the dorsal area between the neck and hindlimbs extending ~2 cm 
bilaterally from the spine and pulverized with clorhexidine solution covering the 
whole shaved area and paint the surgical area with betadine. It is recommended 
to use a separated surface for shaving the animals in order to avoid 
contamination in the surgical area.  
 
4. Position the animals on heating pad (set up at 37ºC) mounted on Spinal Cord 
Unit with stretched anterior and posterior legs adjusting the mouth and nose in to 
the anesthesic mask keeping enough space for gas interchange   
 
5. Set up the Anesthesia Workstation at 1,5% of isofluorane and maintain this flow 
during all surgery. 
 
6. Introduce an intravenous cannula in the more visible and caudal venous in the 
tale. Compression of the tale and EtOH pulverization dilatants’ the vessels. 
Connect the pre-filled cannula to the continuous 0.9% of NaCl perfusion, 
2ml/hour. Maintain the caudal in during all surgical and transplantation 
procedure. 
 
7. Put the eye drops (Lipolac; 1 drop to each eye) and keep the eyes closed. 
 
8. Perform a longitudinal skin incision of approximately 2.5 cm with scalpel blade. 
Dissect the fat tissue without cutting it, keeping the fat pad under the skin.  
 
9. Make an incision on the middle line of the muscles overlying the vertebral 
column exposing the T7-T10 vertebral segments. 
 
10. Position the alm retractors to keep the incision widely open. It is very important 
to visualized the thoraco-dorsal arteria, located over the T6 segment and avoid to 
touch it for any hemorrage complication. 
 
11. Detach the spinotrapezium muscle from bone on the spinal laminaes using the 
scalpel blades or detacher. Use the headband magnifier visor for fine 
visualization of the operation procedure.  
 
12. Identify the T7 and T8 vertebral apophysis by anatomical criteria (both keeps 
transversal and parallel between each other). 
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13. Under the headband magnifier carefully lift the T9 spine backwards while 
introducing slowly a Rongeur of a very fine-pointed side-cutting bone. Cut out 
T9 and T8 vertebral apophysis leaving clean lateral spaces avoiding lateral 
compression of the cord. SCI by complete cross section at T8 will be performed 
by cutting the cord from the boton with an iridectomy scissors helped by a hook.  
 
14. Cell transplantation: Immediately after injury (for acute stage intervention) 10 
µl of cell suspension (containing 2 million cells) will be intrathecal 
administrated caudally to the injured area.  
 
15. Cover the laminectomy areas with a piece of subcutaneous fat pad. Remove 
vertebrae clamps and retractors. 
 
16. Carefully suture the deep and superficial muscle layers with reabsorvible 
Monosyn 4/0 and finally suture the skin. 
 
17. Remove the superficial blood on the incision area with diluted H2O2. 
 
18. Close the anesthesia flow and leave the animal to wake up on a heating pad. 
 
19. Carefully empty the animal´s bladder manually pressing the bladder until is 
completely empty. 
 
20. All animals will be subjected to post-surgery cares, passive and active 
rehabilitation protocols as was previously described (Rodriguez-Jimnez, F.J., A. 
Alastrue-Agudo, S. Erceg, M. Stojkovic, and V. Moreno-Manzano. 2012. 
FM19G11 favors spinal cord injury regeneration and stem cell self-renewal by 
mitochondrial uncoupling and glucose metabolism induction. Stem Cells. 
30:2221-2233).  
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 Trasplante de Motoneuronas derivadas de iPSCs en ratones Smn(2B/-)  
 
 
 
1. Para este procedimiento se emplearán un modelo de ratones con atrofia 
muscular espinal, correspondiente a la cepa Smn(2B/-). En cada experimento 
se utilizará un número total de 6 animales. Estos ratones serán clasificados en 
dos grupos: grupo control (n=3 ratones) tratado con salino y grupo tratado con 
motoneuronas (n=3 ratones). Se realizarán hasta 10 experimentos 
independientes con 6 animales cada uno hasta llegar a un total de 60 animales. 
El procedimiento se aplicará en ratones de entre 10 y 15 días de edad. El 
experimento pretende comprobar si las motoneuronas humanas son capaces de 
extender sus axones para inervar los músculos de las patas traseras de los 
ratones para mejorar la supervivencia o movilidad. 
 
2. Previamente al trasplante celular habrá que anestesiar a los ratones mediante 
ketamina-xilacina a una dosis de 50mg/kg y 5mg/kg respectivamente. Se dará 
analgesia pre-operatoria (Buprenorfina a una dosis de 0.1mg/kg, que tiene un 
efecto más rápido). Se llevará a cabo la monitorización durante la duración de 
la anestesia, puesto que puede ocurrir la muerte por sobredosis anestésico. Los 
ratones se colocarán sobre una manta calefactora durante toda la operación y 
hasta su recuperación.  
 
3. Las motoneuronas a ser trasplantadas serán pretratadas in vitro con cell tracker 
(tinción fluorescente intracelular) para su posterior identificación una vez 
fijados los tejidos. 40.000 células resuspendidas en un volumen de 2ul se 
inyectarán en la médula espinal a nivel lumbar y/o cervical de cada ratón del 
grupo con tratamiento celular.  
 
4. Para el grupo control se inyectarán 2µl de suero salino utilizando el mismo 
procedimiento que en los ratones del grupo tratado con células. Se emplea un 
volumen de 2µl dado que una alta densidad celular facilita una mayor 
supervivencia y capacidad de asentamiento celular post-inyección. 
 
5. Se realizará la inyección usando una pipeta de precisión Hamilton con una 
punta de cristal modelada a partir de pipetas Pasteur de vidrio. La Hamilton 
será fijada mediante un aparato de estereotaxia sujeto a la mesa de operaciones.  
 
6. Para realizar la inyección se utiliza una técnica que ya dominamos. Primero es 
necesario hacer una única incisión para dejar al descubierto la médula espinal a 
nivel lumbar y/o cervical. Para ello se practicará con un bisturí una pequeña 
incisión de 5 mm en la piel, cortando tejido conectivo y muscular hasta llegar 
al hueso. Entonces se practicará una laminectomía parcial, perforando en la 
vértebra el mínimo espacio necesario para permitir la inyección de las células 
en la médula. Se procederá a inyectar los 2µl de volumen de forma progresiva 
a lo largo de un tiempo de 2 minutos para no aumentar la presión medular de 
forma brusca. 
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7. Se cierra la incisión (2-3 puntos), suturando primero la capa muscular y luego 
la piel con una seda de 6-0 ambas. Nos aseguramos de que el ratón se recupera 
con éxito de la anestesia y comprobamos su estado al día siguiente. 
 
8. Al final de la cirugía se administrará una dosis de meloxicam. Durante las 
primeras 72h después de la operación se supervisará el ratón y se administrará 
analgésicos diariamente (meloxicam a dosis: 2mg/kg). A partir de entonces se 
administrará también a aquellos ratones que presenten signos de dolor. Los 
animales permanecerán junto a la madre para que pueda continuar 
alimentándolos por lactancia materna. Para evitar el rechazo materno se 
rebozarán las crías en las virutas de la jaula antes de devolverlos con la madre. 
 
9. Para evitar el rechazo de las motoneuronas por parte del sistema inmunitario de 
los ratones, estos se inmunosuprimirán mediante la administración de 
ciclosporina A por inyección subcutánea cada 48h en dosis de 20mg/kg. 
 
10. A día 28 de vida de los ratones se sacrificarán 3 animales del grupo de 
inyectados con células y 3 del grupo inyectado con suero salino y se 
perfundirán previa anestesia con ketamina-xilacina a una dosis de 75 mg/kg y 
7,5mg/kg respectivamente, y se procederá a la fijación de tejido neural para 
estudiar si las células se han injertado y sobrevivido.  
 
11. Con el resto de animales se estudiará la mejora de la motilidad y la curva de 
supervivencia. Aunque es cierto que en la medida de lo posible debe evitarse la 
muerte natural como criterio de punto final, en este caso es imprescindible. 
Para determinar el porcentaje de supervivencia de ambos grupos se 
contabilizarán los días en que los ratones hayan perecido de forma natural. La 
esperanza de vida media de los ratones de este modelo de atrofia es de 26-30 
días, por lo tanto entre 15-20 días después de la intervención. En este modelo 
de SMA nunca se ha reportado ningún caso que haya superado los 40 días. 
 
12. Durante los últimos días de vida, si el animal presentara sufrimiento a causa de 
la enfermedad genética se administrará meloxicam a dosis: 2mg/kg. No 
obstante en este modelo de atrofia en ratones, no se observan manifestaciones 
fenotípicas de malestar severo como la caída de pelo, arqueamiento de la 
espalda, agresividad, automutilación o aspecto comatoso. Tampoco se produce 
pérdida de peso sino estancamiento de este. Además los ratones no son 
separados en ningún caso de la madre, que es quien se ocupa de alimentar-los, 
siendo raro el caso en que la madre se niega a alimentar a sus crías. 
 
 
Willmann, R., et al., Developing standard procedures for pre-clinical efficacy studies in 
mouse models of spinal muscular atrophy: report of the expert workshop "Pre-clinical 
testing for SMA", Zurich, March 29-30th 2010. Neuromuscul Disord, 2011. 21(1): p. 
74-7 
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Cyclin D1 template and mRNA production protocol  
 
 
We have extracted protocols from two articles: 
-Loh et al., Curr Protoc Stem Cell Biol 2012, CHAPTER: Unit4A.5 (for ORF forward 
primer phosphorylation)  
Simeonov KP, Uppal H. Direct reprogramming of human fibroblasts to hepatocyte-like 
cells by synthetic modified mRNAs. PLoS One. 2014 Jun 25;9(6):e100134. doi: 
10.1371/journal.pone.0100134. eCollection 2014. (for splint ligation protocol). 
 
Materials list: 
 
-Falcon 15mL Conical Centrifuge Tubes (Falcon, #14-959-53A), x1 box. 
-Falcon 50mL Conical Centrifuge Tubes (Falcon #14-432-22), x1 box. 
-RNase-free 1,5ml eppendorf tubes (Thermo Fisher, #AM12400), x1 bag. 
-RNase-free 0,3ml eppendorf tubes (Thermo Fisher, #AM12300), x1 bag.  
-Six-well plates (Cornig, #CLS3516), x1 box.  
 
-MEGAscript Kit, (Ambion, #AM1334), x1 kit. 
 
-1.2µl ARCA (TriLinkBioTechnologies, #N-7003, stock: 100mM), x1 unit. 
 
-1.5µl 5-Methyl-CTP (TriLinkBioTechnologies, #N-1014, stock: 100mM), x1 unit. 
 
-1.5µl Pseudo-UTP (TriLinkBioTechnologies, #N-1019, stock: 100mM), x1 unit. 
 
-Qiaquick PCR purification kit (Qiagen, #28104), x1 kit. 
-Qiaquick Gel Extraction Kit, (Qiagen #28704), x1 kit. 
-MicroRNA-enhanced mRNA reprogramming kit (STEMGENT, #00-0071), x1 kit. 
 
-Pluriton basal media (Stemgent Ref#00-0070), x1 bottle. 
 
-CTS E8 complete medium (Life Technologies # A26561-01), x6 bottles. 
-Vitronectin (Life Technologies, #A14700), x5 ml 
 
-Knock out serum replacement (LifeTechnologies, #10828028), x1 bottle. 
-Dimetil sulfoxid (Sigma, #472301), x1 bottle. 
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Phosphorylate forward primer. 
 
1. Reaction Mix (50µl total): 300pmol forward primer (3µl 100µM), 1µl 
(10U) PNK, 5µl 10X Buffer, 50nmol ATP (0,5µl 100µM stock), 40,5 µl 
MQ. Incubate 30 min 37ºC. 
 
2. Order the 3’UTR oligo already phosphorylated. 
 
3. ORF PCR. Reaction Mix (25µl total): 2x KAPA Mix: 12.5µl, 10µM 
Forward Primer: 0.75µl, 10µM Reverse Primer: 0.75µl, 3ng/µl Template 
DNA: 1µl, Water: 10µl. Note: Primers are ORF specific. PCR Setup: 
1 cycle: 
95ºC 5min 
20 cycles: 
98ºC 20sec 
65ºC 15sec 
72ºC 60sec 
1 cycle: 
72ºC 5min 
4ºC hold 
 
4. Run a gel (Speed E-Gel protocol on 1.2% gel, load ~100ng in 20µl per 
well) to make sure the amplicons are the correct length, may need to 
extract the correct band using CloneWell Gel. 
 
5. Purify tubes with Qiaquick Purification Kit (if not doing gel band 
purification). Quantify with nanodrop each tube (yield ~55ng/µl in 50µl). 
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Template Splint Ligation protocol 
 
 
1. Reaction Mix (50µl total): 10x Ligation Buffer: 5µl, 5µM 5’UTR: 2µl, 5µM 
3’UTR: 2µl, 2µM 5’Splint: 2.5µl, 2µM 3’Splint: 2.5µl, ORF DNA from above 
(~50ng total maximum, corresponds to ~40nM, 1µl should be enough) and 
water: to 50µl. Note: Splints are ORF specific, but UTRs are not. 
 
2. Add 1 unit of vortexed Ampligase and vortex mix thoroughly. Ligation Setup: 
5 cycles: 
95ºC 10sec 
45ºC 1min 
50ºC 1min 
55ºC 1min 
60ºC 1min 
 
3. Purify with Qiaquick Purification Kit 
 
4. Large Scale Template Tail PCR (we adapted this to the recommendations of our 
own high fidelity enzyme). Reaction Mix for 6 reactions (153µl total): 2x KAPA 
Mix: 76.3µl, 10µM Forward Template Primer: 4.6µl, 5µM Reverse Tail 
Template Primer: 9.2µl, DNA: 31µl from ligation and water: 32µl.  
 
5. Template Tail PCR Setup is same as ORF PCR (except with 30 cycles instead of 
20). Run some of the template PCR product next to the ORF PCR product on a 
1.2% gel with Speed E-Gel protocol to see if there is a discreet band of correct 
length (slightly longer than ORF PCR product). 
 
6. Template PCRs should be purified using traditional gel extraction to avoid loss 
of product. Open gel with a razorblade and excise bands with a new blade for 
each template. Gel purify using the Qiaquick Gel Extraction Kit. Re-purify with 
Qiaquick PCR purification kit (elute with water) since gel purification produces 
consistently bad 260/280 ratio. Adjust concentration to rounded number. 
 
7. Sequence templates. Templates can now be directly used to template IVT. 
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In Vitro Transcription (IVT)  
 
 
This protocol explains in detail how to synthetize by IVT the mRNA for transfections. 
MEGAscript Kit, Ambion, Ref #AM1334. 
1. Using Cyclin D1 gene template, proceed to synthesize the messenger RNA by in 
vitro transcription (IVT). Use RNase and DNase free tubes and tips and 
eliminate RNases in gloves, working surface and with RNaseZap (Sigma, 
#R2020). In case the template is cloned inside a plasmid first it has to be 
digested and amplified by PCR. 
 
2. Plasmid Digestion. Digest 5µg of plasmid each time, no more. Cut 10 µg 
preparing two digestions of 5µg. Prepare a mix with all the other components 
and add DNA in the end so it does not stick to the walls and out of reach for the 
restriction enzyme. Add 20-30U of enzyme (usually: 5-10 U/µl), 10µl 10X 
buffer and RNase-DNase free water to a final volume 100µl. Add 10U more of 
enzyme and digest all night at 37ºC. 
 
3. Next day load 3µl in agarose gel to check digestion on gel. Check on gel again. 
If a 100% is not cut, add 10U more and digest 2h 37ºC. When 100% is cut, pool 
together both digestions and purify with Qiaquick PCR purification kit. Elute in 
70µl: 40µl 1’ sit, 1’ spin and 30 µl 1’sit, 1’spin. The expected concentration is 
100ng/µl. 
 
4. Template preparation, PCR tailing (set reaction as described above in step 5 of 
template splint ligation protocol). Set the reaction on ice. Use 5-10 ng of cut 
plasmid as PCR template per tube. Then, put together all the PCR reaction in 
one tube. Run 1-2 µl on agarose gel to check there is only one band. Purify with 
Qiaquick PCR purification kit; elute in 30µl. Concentration should be around 
200ng/µl  
 
5. To start IVT, work in RNase free dedicated area. Clean surfaces, racks and 
pipettes with RNaseZap. Frequently during the process spray a bit of RNaseZap 
on a tissue and wipe surface, pipettes, etc. It is also recommended to wear 
surgical mask. Use only RNase free filter tips and tubes. 
 
6. Place RNA Polymerase enzyme mix (supplied in Megascript kit) on ice. Vortex 
ribonucleotide solutions until thawed and store them on ice. Aliquot dNTPs mix 
to avoid freeze/thaw cycles. 
 
7. Thaw buffer at 37ºC, vortex, and keep at RT. This is important to avoid 
precipitation. Aliquot enzyme mix to avoid freeze/thaw cycles. 
 
8. Shake and spin down components of the kit before using. 
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9. Start with 0.5-1 µg DNA template. Reaction is set on PCR tubes at RT. Prepare 
mix in this order, mixing well after adding each component:  
 
H2O up to 20µl 
2µl ATP (supplied in Megascript kit) 
0.4µl GTP (supplied in Megascript kit) 
1.2µl ARCA (TriLinkBioTechnologies Ref#N-7003, stock: 100mM) 
1.5µl 5-Methyl-CTP (TriLinkBioTechnologies Ref#N-1014, stock: 100mM) 
1.5µl Pseudo-UTP (TriLinkBioTechnologies Ref#N-1019, stock: 100mM) 
2 µl 10x reaction buffer (supplied in Megascript kit) 
0.5-1µg template DNA 
2µl Enzyme Mix (supplied in Megascript kit) 
Total volume 20 µl 
 
10. Gently flick the tube or mix well with pipette. Quick spin. Incubate for 2-4h 
37ºC in PCR machine (we usually prefer 4h). 
 
11. DNase treatment: Add 1 µl Turbo DNase (supplied in Megascript kit). Mix well 
by pipetting + pulse spin. Incubate for 15’ at 37ºC. 
 
12. Transfer 20 µl of the IVT reaction to RNase free 1.5 ml centrifuge tube. 
 
13. Precipitate RNA by adding 30µl Nuclease-free Water (supplied in Megascript 
kit) to the 20 µl reaction, mix and add 30µl LiCl Precipitation Solution 
(Megascript kit). Mix thoroughly.  
 
14. Chill for at least 30’ at -20ºC. Centrifuge at 4ºC for 15’ at maximum speed to 
pellet the RNA. Carefully remove the supernatant and keep it in case RNA 
didn’t precipitate. 
 
15. Wash pellet with 0.5ml 70% EtOH RNase free. Centrifuge at 4ºC for 15’ at 
maximum speed to pellet RNA. Carefully remove the supernatant (put it aside in 
case RNA did not precipitate). 
 
16. Air-dry pellet at RT (at this stage the pellet might be visible white, or invisible if 
it becomes transparent). 
 
17. mRNA dephosphorylation: add 42µl nuclease-free water + 5µl Alkaline 
Phosphatase Buffer + 3 µl Alkaline Phosphatase (1U/µl) (Promega, #M182A). 
Incubate 30’ at 37ºC. 
 
18. Precipitate with LiCl again (add 30µl LiCl).  
 
19. Wash with 0.5ml EtOH 70%.  Air-dry pellet at RT. 
 
20. Resuspend in 50µl TE (put aside 1µl RNA to quantify and 1µl to run in a 
denaturing agarose gel). Quantify by Nanodrop. 
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21. Dilute it to a final concentration of 100ng/µl with RNase free TE (Ambion Ref# 
AM9861) or RNase free water. 
 
22. Check RNA quality by gel: prepare a 1.2% agarose denaturing gel made of: 
MOPSx10 (final concentration: 20mM), non-contaminated agarose + 
formaldehyde (final concentration 2M). Formaldehyde should be added in a gas 
extracting hood. Electrophoresis equipment should be RNase free: used only for 
RNA gels and cleaned with RNaseZap. 
 
23. Run 1µl (200-300ng) of RNA + 4µl of RNase-free water with 5µl of Gel 
Loading Buffer II (Ambion, Ref#AM8546G) for RNA + 1µl BrEt 0.1 mg/ml 
(dilute 1µl BrEt 10 mg/ml stock solution in 100µl gel loading buffer). Incubate 
RNA 5’ at 70ºC. 
 
24. Load ssRNA ladder (DNA ladder is double strand and runs different. Get 
Invitrogen ssRNA 2kb ladder).  
 
25. Load RNA and run gel in 1XMOPS buffer at 70V for 45’. 
 
26. If RNA is clean of RNases, it should be a single clear band. If it is degraded a 
smear will be observed in the lower part. 
 
27. Storing mRNA and checking functionality: if there are no RNases in the 
samples, RNA can be kept even at 4ºC for a few days; however it is always 
recommended to be stored at -80ºC. If RNA has been frozen and thawed several 
times, run a gel to check integrity. 
 
28. Check by Western Blot that the gene is still expressed 12-24h after transfecting 
your target cells. Depending on the protein turnover of your gene you may need 
to wait no more than 16h.  
 
29. Antibiotics could inhibit transfection complex formation depending on 
transfection reagent used, and therefore it is recommended to exclude antibiotics 
from the complex formation step. Transfection complexes can be added to cells 
grown in complete culture medium containing low levels of antibiotics (0.1-1X 
final concentration of P/S). 
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Micro-RNA enhanced mRNA reprogramming protocol: 
 
Non-integrative reprogramming method based on Stemgent’s microRNA-enhanced 
mRNA reprogramming kit (STEMGENT, #00-0071) protocol, with the replacement of 
c-Myc mRNA by Cyclin D1. This protocol explains in detail the procedure to transfect 
target cells and defines how to pick, passage and freeze iPSC colonies when they appear 
after the transfection period. 
Reprogramming timeline: 
 
1. Aliquot reagents. Aliquot Pluriton basal media (Stemgent Ref#00-0070) and E8 
complete medium (Life Technologies #A1517001) in 50ml tubes and store at -
20ºC. The day before using it, aliquots should be thawed o/n at 4oC. B18R and 
Pluriton supplement must be aliquot in sizes of 2.4µl and 1.6µl (for 6 and 4 ml 
of total medium respectively) to avoid freeze/thaw cycles. Aliquot Vitronectin 
(Life Technologies, #A14700) in sizes of 60-100µl to avoid freeze/thaw cycles. 
Aliquot messenger RNA cocktail at a proportion of 3:1:1:1:1 of the 
reprogramming genes: Oct4, Sox2, Klf4, Lin28 and Cyclin D1 (OSKLD) (all 
100 ng/µl). Prepare aliquot size depending on the number of wells you want to 
transfect: 200ng of total mix (2µl) per well in 24MW plate. Aliquot MicroRNA. 
Prepare aliquot size depending on the number of wells you want to transfect: 
0.7µl/well in 24MW plate. 
 
2. Day -2: Plate a feeder layer of irradiated human foreskin fibroblasts (irHFFs) 
and leave it o/n with Pluriton to condition the medium (1vial of irHFFs into 2 
wells of a 6MW plate in 2ml of medium each). 
 
3. Day -1: Coat 24MW plate with 250µl/well of vitronectin diluted 1:100 in PBS 
for at least 1h at RT. Plate human foreskin fibroblasts (HFF) in FibroGRO™ 
Xeno-Free Human Fibroblast Expansion Medium (Millipore, Ref # SCM044) 
the vitronectin coated wells.   
 
4. Seed cells at 6 different densities (7.5k, 10k, 12.5k, 15k, 17.5k and 20k per well) 
to decide the next day the three best ones to start the transfections with. 
 
5. Transfecting cells (Day 0): If cells are looking healthy, select the three best 
densities, between 50-70% confluency, to start transfections. 
 
6. Thaw one B18R aliquot on ice. Once thawed, keep the vial on ice at all times. 
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7. Collect the 4ml Pluriton conditioned medium and add 2.4µl of the B18R (0.6µl 
B18R/1ml Pluriton equivalent to 300ng B18R/ml). Add 1.6µl of Pluriton 
supplement to the 4ml conditioned Pluriton before adding to the cells. 
 
8. Aspirate the target cells medium from each of the 3 wells to be transfected and 
add 666µl of the conditioned medium with B18R and supplement to each well. 
Keep the remaining 2ml at 4ºC as a backup. Incubate the cells for 2h at 37ºC, at 
5% CO2 and appropriate oxygen tension, then proceed to transfect. 
 
9. MicroRNA transfection (Day 0 and 4): Tube 1: (2.1µl of microRNA, 0.7µl/well) 
+ 12.85µl transfection buffer. Tube 2:  12.55µl buffer + 2.4µl Stemgent 
transfection reagent. 
 
10. Transfer the content of tube 2 into tube 1 and pipet gently 3 to 5 times to 
generate the transfection complex (total 30µl). Incubate the mix for 15’ at RT. 
 
11. Holding the plate at a 45 degrees angle, add 10µl/well into the medium in each 
well to be transfected. After adding the transfection complex to the wells, gently 
rock the plate from side-to-side and front-to-back to distribute the transfection 
complex evenly. 
 
12. Messenger RNA-OSKD1- transfections (Day 1-11): Tube 1: (6µl of mRNA mix, 
2µl/well) + 9µl buffer. Tube 2: 12.65µl buffer + 2.4µl of reagent stemgent. 
 
13. Transfer the content of tube 2 into tube 1 and pipet gently 3 to 5 times to 
generate the transfection complex (total 30µl). Incubate the mix for 15’ at RT. 
 
14. Holding the plate at a 45 degrees angle, add 10µl/well into the medium in each 
well to be transfected. After adding the transfection complex to the wells, gently 
rock the plate from side-to-side and front-to-back to distribute the transfection 
complex evenly. 
 
15. Colony picking: As an indication of reprogramming, cells must show signs of 
mesenchymal to epithelial transition (MET) around days 4-6. Keep transfecting 
until day 12. If cells don’t display MET when reaching 100% confluence or if 
cellularity starts declining, transfections should be considered to stop for that 
particular density.  
 
16. Colonies can start appearing as early as day 10. 
 
17. At day 14-15 pick colonies, when they are big enough, by mechanically 
scrapping them. Transfer picked colonies into vitronectin-coated plates. Add to 
the cells condition Pluriton mixed 1:1 with E8 medium. Add Rho kinase 
inhibitor (ROCKi, Y-27632, STEMCELL #72302) at 10µM final concentration 
(10mM stock) during the first 24h after colony picking to prevent cell apoptosis. 
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18. Change to E8 medium9 24h later and onwards (without feeder layer conditioned 
medium and with no Pluriton). Maintain cells by daily medium exchange. 
Failure to replace medium daily can result in spontaneous differentiation. 
 
Colony passaging 
 
19. When colonies are ready, passage them by gentle dissociation with EDTA. 
Notice that colonies are ready to passage when they are around 75-80% 
confluent. However, if there are few big colonies (not properly disaggregated in 
the previous passage) it should be considered to passage earlier, as this could 
threaten the proper growth of iPSC. 
 
20. Coat a 6-well plate with 1ml/well vitronectin (1:100 in PBS) for 1h at RT. 
 
21. Remove culture medium and wash once with PBS. Add 1ml of 0.5mM EDTA 
and incubate for 2’ at 37ºC in the incubator. Remove EDTA carefully not to 
detach the cells and then immediately resuspend cells in E8 supplemented with 
10µM ROCK inhibitor by pipetting up and down three to four times (no more to 
avoid cell death). Do not centrifuge. 
 
22. Remove vitronectin and wash the plate with PBS. Then distribute resuspended 
cells into the 6-w plate wells depending on the desired split ratio. 
 
Cell freezing 
 
23. Remove culture medium and wash once with PBS. Add 1ml of 0.5mM EDTA 
and incubate for 2’ inside the incubator. 
 
24. Remove EDTA carefully not to detach the cells and resuspend them in E8 
supplemented with 10µM ROCK inhibitor by pipetting up and down three to 
four times.  
 
25. Collect resuspended cells in a 15ml tube and centrifuge at 200g for 5’ at RT. 
Discard supernatant.  
 
26. Resuspend cells in 90% knock out serum replacement (KSR) + 10% DMSO, add 
1ml/ freezing vial. Store first at -80ºC and 24h later transfer vials to liquid 
Nitrogen. 
 
Cell thawing 
                                                        
9 In the case of the failed reprogramming attempts for MEFs, in the conditioned G4 medium we also added VPA 
0.5mM from day 1 to day 11 and siRNAs (Infb1, Stat2 and Eif2ak2) every other day (days 0, 2, 4, 6, 8, 10): Eif2ak2 
siRNA (stock 20µM): add 0.5µl; Infb1 siRNA (stock 10µM): add 1µl; Stat2 siRNA (stock 10µM): add 1µl. These 
amounts were used for each well of a 6-w plate (0.5ul + 1ul + 1ul) for every 2ml.  
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27. Coat several wells (depending on the number of cells to be thaw) of a 6-well 
plate with 1ml/well vitronectin (1:100 in PBS) for 1h at RT. 
 
28. Immerse the cryotube in a 37ºC water bath. Thaw quickly by gently swirling 
until only a small piece of frozen material is left. Spray the tube with 70% EtOH 
before entering it into the safety cabinet hood.  
 
29. Transfer cells to a 15 ml tube and add 10ml of warm E8 medium + 10µM 
ROCKi drop wise and gently mix cells. Centrifuge the tube at 200g for 5’ at RT. 
Discard supernatant. Gently resuspend cells into 6ml of warm E8 + 10µM 
ROCKi and plate cells on the three vitronectin coated wells.   
 
-Loh et al., Curr Protoc Stem Cell Biol 2012, CHAPTER: Unit4A.5 (for ORF fwd 
primer phosphorylation). 
 
-Kamen P. Simeonov, Hirdesh Uppal Regarding – DOI: 10.1371/journal.pone.0100134 
(for the rest of splint ligation protocol). 
 
-http://assets.stemgent.com/files/1369/original/AppNoteMicroRNA_GK_061314.pdf 
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Cytotoxic T lymphocytes CTL coculture with CM 
(All animal experiments were approved by the University of Barcelona ethics 
committee).  
 
1. Cells are in vivo injected isogenically into C3H mice. Four iPSC clones and four 
iPSC derived cardiomyocytes clones are injected subcutaneously in mice in 
duplicate. One week after injection, cells are reinjected again for boosting the 
priming of the Cytotoxic T lymphocytes (CTLs) against injected cells.  
 
2. One week after reinjection (final priming period of 14 days), collect CTLs with 
an isolation by FICOLL (density of 1,077g/ml) gradient from mice smashed 
spleens. Briefly, spleens are smashed with two coverslips and cell lysate was 
resuspended in 5ml of RPMI-10 + 1%Pen/Strep medium and filtered through an 
autoclaved Nylon filter. 
 
3. In a 15ml tube prepare 2,5ml of Ficoll + 1ml of FBS + 5ml of RPMI with cells 
(2,5ml Ficoll: 5ml RPMI with cells, 1:2 ratio). Do not mix phases.  
 
4. Centrifuge at 500xg 30’ at RT. Remove centrifuge brake. Collect the white layer 
interphase to a new tube with PBS. Be careful not to contaminate with the lower 
Ficoll phase. Cells in this interphase are mononuclear cells of which a 20-40% is 
expected to be activated T cells. Wash x3 with PBS, this time centrifuging at 
200xg. Count the number of cells. 
 
5. The day before extracting the CTLs, seed target cells, in our case the same 
cardiomyocyte (CM) lines that were injected into the mice from where the CTLs 
are isolated. Put 30.000 cells in a well of a 96-w plate. 
 
6. For T cell kill assay, add 30.000 isolated CTLs on top of the cardiomyocyte 
seeded the day before. Co-culture assay of CTL: CM lasts 4h. CTLs 
degranulation in response to cytotoxic activation is determined by CD107a 
staining (Biolegend, FITC anti-mouse CD107a, #121605) and apoptosis of 
target cardiomyocytes was assessed by an Annexin V-FITC staining (Apoptosis 
detection kit, Biotools, Cat #B32115).  
 
7. CD107a antibody must be in the medium during the co-culture because CD107a 
protein is rapidly endocyted following externalization. After co-culture, CTLs 
are collected by pipetting up and down in the well. Rinse the dish with cold 
buffer. Check under the microscope for any remaining cell, if necessary, rinse 
the dish again.  
 
8. Once CTLs have been removed, target cells are trypsinized and stained for 
Annexin V for apoptosis assay. Briefly, trypsinize cells and wash in cold PBS. 
Then, add 30µl of binding buffer + (0.5µl/sample) of Annexin V-FITC 
conjugated to tripsinized cells and incubate 5’ on ice in the dark. Then, add on 
top 120µl of binding buffer + PI (0,5µl/sample). Analyze by flow cytometry 
immediately. Cells considered viable are both Annexin V and PI negative, while 
cells that are in early apoptosis are Annexin V positive and PI negative, and cells 
that are in late apoptosis or already dead are both Annexin V and PI positive. 
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C-Myc can be replaced by Cyclin D1 to reprogram mouse C2C12 cells. 
 
To test the pluripotency potential of Cyclin D1 to replace c-Myc oncogene in the 
reprogramming cocktail, we first transduced C2C12 mouse cell line. A retroviral 
delivery system to overexpress the reprogramming factors was used as described in the 
methodology. We infected C2C12 cells with three conditions: 3F (Oct4, Sox2 and 
Klf4), 3F+c-Myc and 3F+Cyclin D1. Oct4 and Cyclin D1 protein levels were checked 
by western blot to corroborate that the retroviral vector was being expressed 
(Supplementary Figure 1, B). Infected cells were seeded onto a feeder layer of MEFs in 
G4 media for a colony formation assay. 
 
We isolated individual clones by mechanically picking emerging colonies with a cell 
scraper from a colony formation assay for 3F+c-Myc and for 3F+Cyclin D1. GFP 
reporter gene was also monitored to be expressed during the first days after the infection 
(Supplementary Figure 1, A) Once picked, clones were cultured adding VPA to the 
medium following Teng et al. protocol, as it was reported to enhance Oct4 promoter 
activity in myogenic cells such as C2C12 (Teng et al., 2010). After 3 weeks of 
expansion, best 3 clones were chosen selecting by Alkaline Phosphatase staining, 
morphology and absence of GFP expression. These clones were expanded to passage 
10. Then, clones were stained by immunofluorescence for pluripotency markers: Oct4, 
Sox2, SSEA3 and SSEA4 (Figure 1, A) to check their pluripotency at protein level; and 
also by real time PCR for pluripotency markers: Oct4, Sox2, Nanog, Rex1 and Utf1 
(Figure 1, B). IPSC were then differentiated in vitro into the three germ layers and cells 
were stained with markers for mesoderm (Alfa Smooth Muscle Actinin, SMA), 
endoderm (alfa-1-Fetoprotein, AFP) and ectoderm (B-III-Tubulin, Tuj1) (Figure 1, C). 
We checked that at this point GFP was not expressed what indicates transgene 
expression is silenced (supplementary figure 1, D).  
 
We also analyzed alkaline phosphatase expression (Supplementary Figure 1, C), as a 
recognized pluripotency marker. Alkaline phosphatase was also analyzed to study the 
reprogramming efficiency. For every condition 1000 cells were seeded on irradiated 
feeder cells to let them grow for two and three weeks before staining them for the stem 
cell marker alkaline phosphatase. Results show that the reprogramming process is being 
accelerated from three weeks required by 3F+c-Myc clones to only two weeks with 
3F+Cyclin D1 (Figure 1, D), as shown by a higher alkaline phosphatase number of 
colonies in 3F+Cyclin D1 after two weeks (p-value = 0.0062). However, efficiency is 
not higher but similar to 3F+c-Myc after 3 weeks (day 21). 
 
Cell stress genes decrease when reprogramming with Cyclin D1.  
 
C-Myc pleiotropic effect activates several pathways simultaneously, originating 
replicative and oxidative stress to cells during the reprogramming process. In order to 
determine whether Cyclin D1 can reprogram cells causing less cell stress, we tested by 
qPCR the expression of several markers related with DNA damage response: ATM and 
53BP1, NFkB related protein MnSOD, apoptosis inhibition related genes IAP2 and 
GADD45b and sirtuins 1, 3 and 6. We analyzed C2C12 RNA as negative control and 
mouse Embryonic Stem Cells RNA as a stem cell internal control. Three clones for 
every condition (3F+c-Myc and 3F+Cyclin D1) were compared at passage 1 and 
passage 5. Differences where mainly found during early passage 1, where iPSC clones 
reprogrammed with 3F+c-Myc expressed higher levels of IAP2 (p-value = 0.0184), 
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Gadd45b (p-value = 0.0342) and sirtuin1 (p-value < 0.0001) than clones reprogrammed 
with 3F+Cyclin D1 (Figure 1, E-G). The induction of GADD45b and IAP2 is associated 
with the inhibition of apoptosis, functioning as a protective mechanism against 
apoptosis, as a protective mechanism, suggesting that 3F+c-Myc iPSC clones might 
require to be assisted or protected from more stress and damage than Cyclin D1 clones. 
Interestingly, Sirt1 is upregulated in 3F+c-Myc clones during early passage 1, and is 
decreased in 3F+Cyclin D1 clones, meaning either Cyclin D1 protein is directly or 
indirectly interacting with Sirtuin 1 protein levels or 3F+Cyclin D1 clones might 
originate less genomic instability, avoiding the requirement of Sirtuin 1 function. The 
rest of the genes analyzed gave no significant differences between conditions 
(Supplementary Figure 1, E-I). 
 
We wondered whether stress genes were also affected in human cell reprogramming, 
that’s why we also retrovirally infected human foreskin fibroblasts (HFFs) for the same 
three conditions as for C2C12 cells previously described. After 2 weeks of being onto 
feeders, 3F reprogramming colony formation assay gave rise to 1 colony, but 3F+Cyclin 
D1 reprogramming gave rise to 28 colonies, a 40% of the number of colonies raised 
with 3F+c-Myc (71 colonies). GFP expression was used as a reporter of polycistronic 
retroviral vector expression (Supplementary figure 2, A). A polyclonal scrape of 
different colonies randomly picked was stained with Tra-1-81 and analyzed by FACS. 
3F+c-Myc iPSC had 1,3% positive cells and 3F+Cyclin D1 had a 5,6% (Supplementary 
Figure 2, C), suggesting again an acceleration of the reprogramming process with 
3F+Cyclin D1 reprogramming compared with 3F+c-Myc. 
 
Three clones per condition were picked and passaged for the human reprogramming. 
After 5 passages hiPSC were stained for pluripotency markers Oct4 and Sox2 
(Supplementary Figure 1, B). Then, the same cell stress markers were tested as in 
mouse at previously in early passage in human reprogramming cells. Sirtuin 1, at day 4 
after infection, was found to be differently expressed between the two conditions 
(p=0.0215) as seen in mouse, but GADD45B and ATM2 levels were not different. 
However, human 3F+c-Myc colonies expressed higher levels of sirtuin 6 (p=0.0042) 
and 53BP1 (p=0.0185) compared to 3F+Cyclin D1 colonies (data not shown). 
 
Sirtuin 1 is not essential when reprogramming MEFs with 3F+Cyclin D1.   
 
It has been reported that Sirt1 has an essential role for proficient telomere elongation 
and for genomic stability in the reprogramming process of induced pluripotent stem 
cells (De Bonis et al., 2014). Correspondingly, we found that Sirtuin 1 is significantly 
upregulated in 3F+c-Myc clones (Figure 1, E). However, in 3F+Cyclin D1 clones, 
Sirtuin 1 is downregulated compared to the control C2C12 (p-value = 0,0096). 
 
Thus, in order to determine whether Sirtuin 1 role can be bypassed by reprogramming 
with 3F+Cyclin D1, we reprogrammed Sirtuin 1 null MEFs with our condition. Wild 
type and Sirtuin 1 null mouse embryonic fibroblasts (wt and Sirt1-/- MEFs) were 
transduced with the conditions 3F, 3F+c-Myc and 3F+Cyclin D1. Afterwards, we 
performed an alkaline phosphatase staining of reprogramming cells seeded in 6 well 
plates: 10.000 cells/well onto feeders. Positive colonies were counted and numbers were 
graphed (Figure 1, H). Transduced wild type MEFs showed that 3F+c-Myc 
reprogramming was producing more number of colonies than 3F+Cyclin D1 
reprogramming. But transduced Sirt1-/- MEFs showed that 3F+c-Myc number of 
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colonies was decreased (p-value = 0,01), suggesting that Sirtuin 1 is essential to rescue 
genetic alterations or instability accumulated on cells due to cell stress induced by c-
Myc. It was previously found that knocking down Sirtuin 1 with siRNA produced a 
threefold reduction in the number of iPSC colonies when reprogramming with c-Myc 
(Lau et al., 2012). Here, after reprogramming sirtuin 1 null MEFs with c-Myc we have 
found a fourfold reduction (p-value = 0,01). On the other hand, in 3F+Cyclin D1 
reprogramming, Sirtuin 1 was not essential at all, as in 3F+c-Myc reprogramming, as 
there was no difference between wild type and Sirtuin 1 null MEFs reprogramming 
(Figure 1, H). Thus, Sirtuin 1 seems to be not essential when reprogramming with 
3F+Cyclin D1, contrarily to 3F+c-Myc reprogramming. 
 
 
 
Cyclin D1 made mouse iPSC show a reduced % of DSB. 
 
DNA double strand breaks (DSB) appear as a consequence of oxidative and replicative 
stress and can be repaired by homologous recombination (HR) or by the classical or 
alternative non-homologous end joining (NHEJ). Both replicative and oxidative stresses 
are induced during the reprogramming process. Furthermore, replication stress has been 
linked with genomic instability on mouse and human iPSC (Ruiz et al., 2015). 
Additionally, Myc expression causes an accumulation of reactive oxygen species 
(ROS), which generates DNA breaks (Khanna and Jackson 2001). Moreover, c-Myc 
expression suppresses the classical NHEJ pathway by binding to ku70 (Li et al., 2012) 
and in various cancer cell lines Myc also inhibits homologous recombination through 
regulation of RAD51 (Luoto et al., 2010). Furthermore all Myc protein family members 
contain the Box II domain that has been reported to interact and inhibit Ku70 (Li et al., 
2012), protein necessary for non-homologous end joining (NHEJ) DSBs repair 
mechanism. On the other hand, it has been reported an unexpected non canonical 
function of Cyclin D1 in facilitating homologous recombination repair process by 
helping BRCA2 to recruit RAD51 to repair DSB in homologous recombination 
(Jirawatnotai et al., 2011; Chalermrujinanant et al., 2016). DSBs can be studied by 
detection of the standardly used biomarker: H2AX expression. 
 
Therefore, we hypothesized that 3F+Cyclin D1 iPSC could present a lower number of 
DSBs than 3F+c-Myc iPSC. Results show that 3F+Cyclin D1 iPSC present a lower 
percentage of H2AX positive cells by immunofluorescence than 3F+c-Myc iPSC at 
passage 4 (Figure 1, I). The fact that c-Myc promotes replicative stress in the cell could 
explain why more DSB are found in 3F+c-Myc iPSC. Furthermore Cyclin D1 helps 
BRCA2 recuitment of Rad51 and therefore promotes the more precise repairing 
machinery of the homologous recombination process.  
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Figure 1. Cyclin D1 replaces c-Myc to reprogram mouse cells with reduced Sirt1 cell stress 
response and increased genetic instability.  
 
A) Mouse iPSCs made with 3F+c-Myc and 3F+Cyclin D1 were characterized for their pluripotency. We 
analyzed alkaline phosphatase staining, Immunofluorescence staining of iPSCs colonies for Oct4 and SSEA3 
and 4',6-diamidino-2-phenylindole (DAPI) for the nucleus and with RT-PCR  (B) for mouse Oct4, Sox2, 
Nanog, Rex1 and Utf1. C) IPSCs were differentiated in vitro into: MESODERM stained with alfa smooth 
muscle actin (SMA); ENDODERM, stained with alfa 1 fetoprotein (AFP) and ECTODERM, stained with 
Tubulin 3 (TUJ1) and 4',6-diamidino-2-phenylindole (DAPI) for the nucleus. D) Alkaline phosphatase 
staining of reprogramming C2C12 cells in a colony formation assay  in a 6-w plates, onto a feeder layer of 
MEFs treated with Mitomycin C. C2C12 were infected with 3F alone (Oct4, Sox2, Klf4), 3F+c-Myc or 
3F+Cyclin D1, seeding 1,000 cells/well. Cells were stained after 14 and 21 days. Colonies were counted and 
graphed, showing how after 14 days 3F+Cyclin D1 infected cells start to form more alkaline phosphatase 
positive colonies than 3F+c-Myc infected cells (p-value=0,0062). After 21 days the number of colonies was 
not significantly different between conditions. The experiment was done in triplicate. E) Relative expression 
of the stress gene Sirtuin 1 at passage1 and 5 for both conditions (3F+c-Myc and 3F+Cyclin D1) comparing 
with C1C12 and mouse Embryonic Stem cells (mES). F) Relative expression of the NFkB target gene 
Gadd45b at passage1 and 5 for both conditions (3F+c-Myc and 3F+Cyclin D1) comparing with C1C12 and 
mES. G) Relative expression of the NFkB target gene IAP2 at passage1 and 5 for both conditions (3F+c-
Myc and 3F+Cyclin D1) comparing with C1C12 and mES. H) Alkaline phosphatase staining of 
reprogramming Mouse Embryonic Fibroblasts (MEFs) in a colony formation assay (CFA). Wt and Sirt1-/- 
MEFs were transduced with the conditions 3F, 3F+c-Myc and 3F+Cyclin D1. Then, 10.000 cells/well were 
seeded onto feeders in a 6-well plate for a CFA. After 21 days, alkaline phosphatase staining was performed. 
Experiment was done in duplicate. H) Sirtuin 1 is not essential when reprogramming MEFs with 3F+Cyclin 
D1. It is compared the relative number of colonies positive for AP found for the three conditions. 3F+Cyclin 
D1 reprogramming has the same reprogramming efficiency in wt and in Sirt1-/- MEFs, sugesting that Cyclin 
D1 is rescuing cells undergoing reprogramming negative effects. On the other hand, 3F+c-Myc 
reprogramming shows a reduction in the number of positive alkaline phosphatase colonies, as if c-Myc was 
not able to rescue reprogramming negative effects or as if c-Myc itself is causing emerging colonies to enter 
apoptosis by the lack of recovery of reprogramming negative effects by sirtuin 1. I) DNA double strand 
breaks (DSB) analysis of mouse iPSCs compared with C2C12 and mouse embryonic stem cells (MES) 
through H2AX immunofluorescence staining showing less yH2AX signal in 3F+Cyclin D1 than in 3F+c-
Myc iPSCs. Two representative images are given. J) Telomere length analysis by quantitative fluorescence 
in situ hybridization (Q-FISH), using a Cy3 labeled prove to detect CCCTAA palindromic repeats. 
Representative images of telomere Q-FISH in mouse cells are shown. 4',6-diamidino-2-phenylindole (DAPI) 
was used to stain the nucleus. Comparison between 3F+Myc and 3F+Cyclin D1 samples, for the % of signal 
free ends of iPSCs telomeres compared to control C2C12. 3F+Cyclin D1 clones show a lower % of signal 
free ends compared with 3F+c-Myc clones. Three clones per condition with 10 metaphases per clone were 
studied. K) Comparison between 3F+Myc and 3F+Cyclin D1 samples for the number of chromosomal free 
fragment found in the nucleus of iPSCs cells, compared to the control C2C12. All cells were arrested in 
metaphase to allow detection. 3F+Cyclin D1 clones decrease the number of fragments from a 70,2% found in 
3F+c-Myc to a 53,4% found in 3F+Cyclin D1. Three clones per condition with 10 metaphases per clone were 
studied. 
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3F+Cyclin D1 mouse iPSC decrease % of signal-free ends and 
fragments/metaphase. 
 
One of the main aims of this study is to discern whether 3F + Cyclin D1 reprogrammed 
iPSC acquire less genomic instability during the reprogramming process as compared to 
3F+c-Myc. Therefore we established a collaboration with Dra María Blasco laboratory 
in Centro National de Investigaciones Oncológicas (CNIO) where I stayed and received 
training to analyse telomere analysis to determine which condition accumulates fewer 
abnormalities. We analyzed chromosome instability in 3F+c-Myc and 3F-Cyclin D1 
clones, at passage 4 and 8. For controls we used non infected C2C12 and infected 
C2C12 cells 2 weeks after the infection with 3F, 3F+c-Myc and 3F+Cyclin D1. 
 
First we decided to analyze the overall telomere length distribution by using the 
quantitative telomere FISH (Q-FISH) assay for the samples collected for the two 
conditions at different passages with controls. We then expressed the same data 
classifying it in % of long telomeres, % of short telomeres and % of signal-free ends. 
We could observe that 3F+Cyclin D1 clones compared to 3F+c-Myc clones presented a 
significant (p=0.00015) 50% reduction of “signal-free” ends (4,18% to 1,83%) (Figure 
1, J). Signal-free ends on iPSC telomeres is associated with the appearance of 
extrachromosomal telomere circles or t-circles (Lustig et al., 2003), which have been 
associated with cancer. Multitelomeric signals (MTS) were analysed as well, in this case 
both conditions showed no difference (data not shown). 
 
Next, we sought to test what was the number of chromosomal free fragments present in 
the nucleus of reprogrammed cells with both conditions. Chromosomal fragments have 
been reported as a sign of instability after irradiation-induced lesions (Pantelias, 1986). 
Interestingly, 3F+c-Myc clones’ average showed a higher tendency (70.19%) of 
chromosomal fragments/metaphase than 3F + Cyclin D1 clones (53.4%). Therefore, 
Cyclin D1 clones showed a trend of lower rate of chromosomal instability (Figure 1, K).  
 
 
 
Messenger RNA mouse reprogramming 
 
We also attempted several times to reprogram mouse embryonic fibroblast (MEFs) with 
mRNA transfections of the reprogramming factors as reported by Warren in human 
cells (Warren et al., 2010). At the beginning, we attempted with mRNA synthetized 
with non-modified nucleotides, and immune response of transfected cells was avoided 
by siRNA transfection of INFb1, Stat2 and Eif2ak2 as previously reported (Angel et al., 
2010). However, we only managed to obtain partially reprogrammed colonies that 
suddently stopped growing (Annexes Figure 1).  
 
Then, we also attempted with modified mRNA (pseudouridine instead of uridine and 5-
methyl cytosine instead of cytosine) as had been reported to prevent the mRNA from 
generating an innate immune response in the transfected cells (Karikó et al., 2008). 
However, we did not succeed either, ending up with the same partially reprogrammed 
colonies. After several attempts changing the amount of mRNA transfected material, the 
type of nucleotides (non-modified and modified), cell densities and different MEF 
sources, we decided to focus on the human mRNA made iPSC rather than mouse. 
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Clinical grade reprogramming of human fibroblasts (HFF) into iPSC using 
synthetic messenger RNA. 
Given that we have shown that Cyclin D1 represents a safer alternative to c-Myc for 
reprogramming, we wanted to develop a clinical grade procedure to reprogram human 
cells into iPSC using Cyclin D1. Therefore, messenger RNA (mRNA) transfection of 
the reprogramming factors (OSKLM or OSKLD, here called MH and DH iPSC) was 
used to eliminate the retroviral risk of insertional mutagenesis or transgene reactivation. 
Messenger RNA transfection reprogramming was first done in 2010 (Warren et al., 
2010), and it was reported to increase reprogramming efficiency.  
 
IPSC were cultured feeder-free to eliminate contamination with irradiated feeder cells; 
instead, reprogrammed cells were cultured in vitronectin coated plates. OSKM mRNA 
was obtained from a commercial reprogramming kit (Stemgent); however, Cyclin D1 
mRNA template was constructed by splint ligation to add the alfa globin 5’UTR and 
3’UTR to the Cyclin D1 coding sequence in order to stabilize it (Annexe Figure 1, C).  
Then, mRNA was synthetized by IVT as described in the methods. The in vitro 
synthesis of the mRNA and the development of this transfection protocol was 
performed by Dra. Ana Belén Álvarez. 
 
HFFs were then reprogrammed by mRNA transfections during 12 days in a row, 
including a microRNA transfection at day 1 and 4 for reprogramming enhancement. At 
day 15 colonies appeared and were mechanically picked. Due to his key experience, Dr. 
Michael Edel picked the colonies and did the passaging of the clones during early 
passages. OSKLM reprogramming gave rise to 22 colonies, OSKLD gave 8 and OSKL 
gave no colonies (Supplementary figure 2, F). Clones were picked monoclonally and 
passaged until passage 10, then three clones per condition were characterized by RT-
PCR and IF (Figure 2, A-B; Supplementary figure 2, D). Alkaline phosphatase (AP) 
staining was also performed to characterize iPSC pluripotency (Figure 2, A). Karyotype 
analysis showed normal chromosomal display with the presence of no aneuploidies or 
detectable deletion or translocation in any of the iPSC clones reprogrammed with 
neither c-Myc nor Cyclin D1 (Figure 2, A).   
 
Human mRNA made iPSC with both c-Myc and Cyclin D1 (MH and DH iPSC) were 
able to give tissues from the three germ layers when generally differentiated after 
embryoid body (EB) formation. Generally differentiated cells were analyzed by RT-
PCR and by IF staining for markers for the three germ layers: SMA, AFP1 and Tuj1 
(Figure 2, C-D; Supplementary figure 3, A). In order to determine a more detailed in 
vitro pluripotency potential of DH iPSC, both MH and DH iPSC were differentiated 
into specific tissues from the three germ layers. Therefore, we performed a guided 
differentiation to Neural Stem Cells (NSC), Cardiomyocytes (CM) and Definitive 
Endoderm (ENDO) as described in the methods section. All these different cell types 
were analyzed for their specific markers by RT-PCR and IF (Figure 2, E-G; 
Supplementary figure 3, B-D). Videos of the beating cardiomyocytes are also given as 
support (Supplementary figure 3, E). Qualitatively no differences were found in their in 
vitro pluripotency potential, as both conditions were able to differentiate into all three 
germ layers cell types equally. As an internal control a commercial iPSC cell line 
reprogrammed with Episomal vectors containing c-Myc in the reprogramming cocktail 
was also differentiated into the mentioned cell types. 
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In vivo differentiation of DH iPSC into teratomas reduce the % of KI67. 
Athymic FoxN1 nu/nu mice were subcutaneously injected with both MH and DH iPSC 
to test and compare in vivo differentiation capacity. Teratomas were left to grow until a 
maximum volume of 2000mm^3 (Figure 3, A; Supplementary figure 4, A) and then 
were extirpated, fixed in paraformaldehyde and embedded in paraffin. Sections were 
made and stained for Hematoxylin/Eosin to determine three germ layer structures 
(Figure 3, B; Supplementary figure 4, B). Teratoma size was also affected by the 
reprogramming condition, two clones of DH iPSC gave rise to teratomas that stopped 
growing and stabilized their weigh. Despite this lack of growth, these clones also were 
able to form three germ layer structures in vivo. 
 
IPSC tumorigenic threat in vivo was assessed by analyzing KI67% in the teratomas. 
KI67 staining is usually evaluated for determining tumor potentiality of neoplasms. 
After counting more than 200 cells from five randomly picked images from each 
teratoma, we found that MH iPSC injected gave rise to teratomas containing around 
70% of KI67 positive cells in comparison with only 20% in DH teratomas (p=0.0097) 
(Figure 3, C; Supplementary figure 4, C). Even MH iPSC teratomas growth rate was 
higher in almost all three clones than DH iPSC teratomas. IPSC derived Neural stem 
cells were also analyzed in vitro for KI67% to compare MH and DH iPSC derived NSC 
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Figure 2. A new clinical grade method to generate human iPSCs replacing c-Myc with 
Cyclin D1.  
 
A) Messenger RNA reprogrammed clones characterization: bright field (BF), immunofluorescence for 
pluripotency markers (OCT4, SOX2, TRA1-81, SSEA4) and alkaline phosphatase (AP). Karyotype of 20 
metaphases per clone was also conducted; a representative image of normal karyotype is shown. One 
representative clone is shown for every condition (M9 and D5). Scale bars: 50µm. B) Real time PCR 
analysis of pluripotency markers OCT4, SOX2, NANOG, KLF4 and MYC. 3 clones per condition have 
been analyzed and compared with Episomal iPSCs. All values are relative expression levels to control 
HFFs and given in log scale. C) Immunofluorescence characterization of iPSCs general differentiation in 
vitro into MESODERM stained with alfa smooth muscle actin (SMA); ENDODERM, stained with alfa 1 
fetoprotein (AFP) and ECTODERM, stained with Tubulin 3 (TUJ1). Scale bars: 20µm. D) Real time 
PCR analysis of generally differentiated. MEF2C, FOX2A and TUBB3 were analyzed to determine 
mesoderm, endoderm and ectoderm expression levels. E) Characterization of hiPSCs differentiated into 
Neural Stem Cells (NSC) by immunofluorescence (Nestin and Tuj1) and by qPCR (Nestin, Tubb3, Sox1 
and Pax6). All values are relative expression levels to control HFFs and given in log scale. Scale bars: 
10µm. F) Characterization of hiPSCs differentiated into Cardiomyocytes (CM) by immunofluorescence 
(Gata4 and cTnT) and by qPCR (cTnT, Gata4 and MEF2C). All values are relative expression levels to 
control HFFs and given in log scale. Scale bars: 10µm. G) Characterization of hiPSCs differentiated into 
Endoderm (ENDO) by flow cytometry (CXCR4 positive cells) and by qPCR (CXCR4, C-KIT, SOX17, 
FOX2A, HNF4). All values are relative expression levels to control HFFs and given in log scale. 
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proliferative tumorigenic threat in vitro. Again, we saw significance between MH and 
DH clones (p=0.0311) (Figure 3, D).  
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Figure 3. Cyclin D1 made iPSCs have a lower tumorigenic threat (KI67%) in vitro and in vivo 
compared to c-Myc made iPSCs.  
 
A) In vivo pluripotency was tested with teratoma formation by injecting mRNA iPSCs from both conditions 
in athymic nude mice (Foxn1-/-) to examine the pluripotency potential into the three germ layers. Graph 
shows teratomas growth rates (volume in mm3) comparing c-Myc (M1, M6 and M9) and Cyclin D1 (D1, D3 
and D5) iPSCs teratomas. B) Teratomas were fixed in PFA 4%, embedded in paraffin and stained for 
hematoxylin/eosin (H/E). Representative three-germ-layer structures are shown for every condition. Scale 
bars: 100µm. C) Cell proliferation rate (KI67%) assessment in teratomas comparing every condition. MH 
clones presented a higher KI67% compared to DH clones (p value=0,0097). Scale bars: 50µm.D) KI67% was 
determined in neural stem cells (NSC) in vitro comparing MH with DH NSC clones. After counting 1000 
cells per condition, MH clones presented a higher KI67% compared to DH clones (p value= 0,0311). Scale 
bars: 100µm. 
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Cyclin D1 made human iPSC show a reduced % of DSB. 
3F+Cyclin D1 mouse iPSC presented a lower number of DSBs than 3F+c-Myc iPSC. 
Therefore, we also analyzed the human clinical grade iPSC for DSB %. Results show 
that human DH iPSC also present a lower percentage of H2AX than MH iPSC at 
passage 10 (Figure 4, A-B).  
 
Next, in order to corroborate that Cyclin D1 overexpression was promoting more DNA 
repair through homologous recombination, we assessed the levels of Rad51 in both 
conditions at passage 2, 10 and in NSC by counting the percentage of cells that their 
nucleus was positive for Rad51 (Figure 4, C-D). We have found that in early passage 2, 
MH clones display Rad51 in a major proportion in the cytoplasm than DH clones 
(Figure 4, B). It has been reported that homologous recombination is inhibited when 
Rad51 is retained in the cytoplasm as a consequence of AKT1 upregulation (Plo et al., 
2008). Therefore, we conclude that MH clones at passage 2 present a lower rate of 
homologous recombination than DH clones. 
 
Furthermore, Sirtuin 1 is recruited to the lesion site of DSBs and has been reported as 
necessary for initial DSB signaling event an DNA repair (Dobbin et al., 2013); 
correspondingly we found that sirt1 showed higher expression in MH than in DH iPSC 
as a consequence of the higher amount of DSBs. This increase in Sirt1 levels were only 
found during early passages (Figures 3, H), however, at passage 10, when Sirt1 levels 
had become already even, DSBs were still higher in MH iPSC. This could explain why 
Sirt1-/- MEFs couldn’t be reprogrammed with c-Myc. IPSC derived CM and NSC 
showed no differences in Sirt1 levels between conditions (Supplementary figure 4, F). 
 
As has been described in the introduction, c-Myc overexpression has been linked with 
promotion of alternative NHEJ repair mechanism. Thus, to check whether MH iPSC 
presented higher levels of alt-NHEJ than any other repairing type, we analyzed a battery 
of DNA damage response genes by RT-PCR: Rad51, Rad51B, Ku70, BRCA1, BRCA2, 
LIG3 and POLQ at different passages of iPSC made with Myc and Cyclin D1. Only 
LIG3 and RAD51B were found significantly different. The alternative NHEJ Ligase 3 
(LIG3) levels (Figure 4, D) show that LIG3 is significantly more expressed in MH 
clones during early passage 3 than DH clones, supporting our idea. Rad51B was also 
found significantly differently (p=0,024) in passage 3 iPSC (Figure 4, G). 
 
In order to find a possible footprint of the reprogramming process in any of the DNA 
damage repairing genes, we screened the methylation patterns by using the Infinium 
MethylationEPIC kit array. However, although we did not see differences globally 
between MH and DH clones, we checked for genes that are related with DNA repairing 
systems in iPSC (Figure 4, H). Interestingly differences (≥ 20%) between MH and DH 
clones were found in several CpG sites of RAD51B gene, however they all were located 
inside the body of the gene instead of in the promoter. XRCC6 and RAD50 genes also 
had a significantly different methylation status between MH and DH clones. However, 
after analyzing these same genes by real time PCR, expression levels were not found 
differently regulated for this two genes, only RAD51B was found differently expressed 
at passage 3 iPSC (Figure 4, G). 
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Cyclin D1 made human iPSC show a decreased % of MTS per chromosome. 
 
We wanted to investigate whether human iPSC reprogrammed with Cyclin D1 (DH 
iPSC) had an improved chromosomal stability as found in mouse iPSC. We thus 
repeated the telomere analysis through QFISH staining and determined the % of signal 
free ends and multitelomeric signals. In this case no differences were found in the % of 
signal-free ends between conditions. However, we show how MH iPSC and NSC carry 
a higher percentage of multitelomeric signal (MTS) per chromosome than DH iPSC and 
NSC (Figure 5, A and C). Therefore Cyclin D1 give raise to chromosomally more stable 
iPSC and NSC than MH. Number of free chromosome fragments was also analysed but 
no difference were seen between conditions for human iPSC (data not shown). 
 
Telomere length was higher in MH than in DH NSC clones (Figure 5, B). Since the 
absence of telomere maintenance has been proposed to act as a tumor-suppressive 
mechanism (Serrano and Blasco, 2007), cells differentiated from DH iPSC might be less 
tumor prone. 
 
Moreover, Sirt1 has been reported to be necessary for proficient telomere elongation 
and genomic stability of induced pluripotent stem cells (De Bonis et al., 2014). Sirt1 
also contributes to telomere maintenance and augments global homologous 
recombination. Sirtuin 1 null mouse embryonic fibroblasts (Sirt1-/-MEFs) were shown 
to express higher multitelomeric signals per chromosome (Palacios et al., 2010). 
 
Copy number variation (CNV), single nucleotide polymorphism (SNP) and 
methylome screening analysis. 
 
In order to deepen more into other genetic instability differences between MH and DH 
iPSC, we did a screening for Copy number variation (CNV), single nucleotide 
polymorphism (SNP) and methylation patterns of iPSCs and iPSC derived cells. Thus, 
we established collaboration with Dr. Manel Esteller and Dr. Raul Delgado’s laboratory 
from the Cancer epigenetics group in the Institut d’Investigacions Biomèdiques de 
Bellvitge (IDIBELL).  We collected the samples and they carried out the array analysis 
to study SNP, CNV and a methylome analysis in our new condition made iPSC.  
 
 
Figure 4. Cyclin D1 iPSCs have lower DNA double strand breaks (DSB) and a higher 
Homologous Recombination rate through Rad51 recuitment compared to c-Myc iPSCs.  
 
A) DNA double strand breaks (DSB) analysis of human iPSCs through H2AX immunofluorescence 
staining (B) showing less yH2AX signal in DH iPSCs and NSC than in MH. Scale bars: 20µm. C) Rad51 
immunofluorescence staining: MH P2 iPSC present higher cytoplasmic retention of Rad51 than DH P2 
iPSC. Scale bars: 10µm. D) Nuclear Rad51 protein % in MH and DH iPSC at passage 2, passage 10 and 
NSC. Passage 10 iPSC showed significant differences (p=0,0166) between conditions. E) Cell stress gene 
Sirtuin 1 is found significantly upregulated during early passages of MH iPSC compared with DH iPSC. 
However, after 10 passages Sirt1 levels equalize. F-G) RT-PCR analysis of ligase 3 (LIG3) and RAD51B 
in iPSC at passage 0, 3 and 10 compared with control HFFs. Three clones (n=3) per conditions were 
quantified. H) Methylation pattern of several CpG sites of the DNA repair genes: BRCA1, RAD50, 
RAD51, RAD51B and XRCC6, that were found differently methylated between MH and DH NSC. It is 
shown the position of the CpG on the gene (TSS1500, TSS200, 5’UTR and Body) and the % of diference 
between c-Myc and Cyclin D1. 
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Enlarged FISH HFF: 
Number of telomeres: 1768 
Telomere length: 8520,4 ± 4456,5 
Signal free ends: 0,68 ± 0,08% 
MTS/Chr: 2,9 ± 0,2% 
MH iPS P10: 
Number of telomeres: 5452 
Telomere length: 14647,5 ± 5849,4  
Signal free ends: 0,06 ± 0,01%  
MTS/Chr: 18,3 ± 2,7% 
DH iPS P10: 
Number of telomeres: 5392 
Telomere length: 13638,2 ± 5444  
Signal free ends: 0,06 ± 0,1%  
MTS/Chr: 10,6 ± 0,8% 
MH NSC: 
Number of telomeres: 6124  
Telomere length:  10868,4 ± 4744,3  
Signal free ends: 0,35 ± 0,26%  
MTS/Chr: 27,99 ± 4,64% 
DH NSC: 
Number of telomeres: 5628  
Telomere length: 7692,2 ± 3357,6 
Signal free ends: 0,36 ± 0,1%  
MTS/Chr: 16,1 ± 1,04% 
Telomere Fluorescence Intensity Units (TFU): 
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It is well established that replicative stress increases SNPs incidence, therefore first we 
screened in our human clinical grade iPSC from both conditions the presence of SNPs 
in comparison with control HFFs using the Omnis 5.0 Illumina array. In order to 
decrease clonal variability and increase sample size, we expanded and characterize 
(annexes figure 2) more clones for both MH (final n=6 clones) and DH (final n=5 
clones). We didn’t find differences in SNP incidence between conditions (Figure 5, D), 
although there was a trend of SNP upregulation after MH reprogramming comparing 
with DH. 
 
Chromosomal instability is characterized by chromosomal abnormalities and an altered 
gene expression signature. For example, c-Myc deregulation is directly linked with gene 
amplification. Hence, we assessed copy number variation (CNV) in our iPSC and NSC 
made with both conditions (Figure 5, E). CNVs were studied using the information 
gathered with a SNP array. When comparing conditions, we found a trend of decreased 
total amount of CNVs (both number of deletions and insertions) in DH clones. 
However, it wasn’t significantly different neither due to huge standard deviation 
differences because of clonal variability. Now, we are analyzing more clones to reduce 
variability.  
 
Furthermore, in order to compare if there was any differences at the genome 
methylation level between MH and DH iPSC we did a general methylome analysis 
between conditions. Correspondingly, analysis revealed no differences (data not shown, 
under analysis). 
 
 
Figure 5. Clinical grade human iPSCs replacing c-Myc with Cyclin D1 increase genetic 
stability.  
 
A) Telomere length analysis by quantitative fluorescence in situ hybridization (Q-FISH), using a Cy3 
labeled prove to detect CCCTAA palindromic repeats. Representative images of telomere Q-FISH in 
human cells are shown. Green squares are shown enlarged in the right column. Human foreskin 
fibroblasts (HFF) were reprogrammed into iPSC by weather MH or DH. IPSCs were passaged until 
passage 10, then cells were stained and analyzed for telomere length, signal free ends and 
multitelomeric signals per chromosome (MTS/Chr) %. IPSCs were differentiated into neural stem cells 
(NSC), then passaged 3 times and analyzed as in iPSCs. Three clones per condition with 10 metaphases 
per clone were studied. Blue: DAPI-stained chromosomes; red dots: telomeres; green arrows: 
multitelomeric signals (MTS); red arrows: signal free ends (SFE). B) Histograms showing frequency % 
of relative telomere lengths shown as telomere fluorescence units (TFUs). The medium telomere length 
(red bars on top of frequency graphs) is also shown as mean ± SE. Total numbers of telomeres analyzed 
per condition are shown. MTS/Chr% and signal free ends % values are also given. C) Graph presenting 
the % of MTS per chromosome in iPSCs and NSC made with both conditions. There’s an increase in 
the % of MTS per chromosome in MH iPSCs and derived NSC compared with DH iPSCs and NSC as a 
result of cell stress. On the other hand, in mouse cells differences were not detected in multitelomeric 
signals but in the percentage of signal free ends (data not shown), that on the contrary was almost 
identical in human cells (data not shown). D) Copy Number Variation (CNV) was studied for passage 
10 MH iPSCs (n=6 clones) and DH iPSCs (n=5 clones) with a human genome-wide array kit. Results 
are classified in function of the chromosome where they are located and the amount of copies of the 
segments analyzed. Garnet: 0-0,5 copies; yellow: 0,5-1,5 copies; green: 1,5-2,5 copies; blue: 2,5-3,5 
copies; purple: 3,5-4,5 copies. E) Total number of CNV variation taking into account deletions of one or 
two copies (0 + 1) and insertions of one or two copies (3 + 4), averaging five samples for control HFFs, 
three for MH iPSC and five for DH iPSC. 
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Global proteomic analysis of patient (F1) and iPSC-derived fibroblasts (F2). 
 
There is a clear need in the field to better understand the immune response of cells 
derived from reprogrammed cells before we board on extensive clinical trials to treat 
human disease. Therefore, in order to address this second aim of the thesis, we 
performed a detailed assessment comparing six patient fibroblast cell lines (termed F1) 
reprogrammed into iPSC and subsequently differentiated back to fibroblast cells 
(termed F2). 
 
Six human skin fibroblast cell lines (termed F1) that have previously been 
reprogrammed into iPSC, three by retroviral methods (Sanchez et al., 2012a; Sanchez et 
al., 2012b)  and three by non-viral Episomal methods (Briggs et al., 2013), then 
differentiated back to fibroblasts (termed F2) (Figure 6, A) were analysed for their 
potential immune response. First, in collaboration with Dr. Rafael Oliva group and Dr. 
Josep Mª Estanyol from the Molecular Biology Unit in the Medicine Faculty, they 
performed a global proteomic analysis comparing F1 cell lines to their paired F2 and 
mapped the protein expression profile.  
 
Overall, 1508 quantifiable proteins were detected with a confidence of 0.90 of which 87 
proteins with significantly different expression levels between F1 and F2 cells. 
Categorising proteins based on function, we first demonstrated no difference in 
fibroblast markers CD90, Fibronectin and CD44 between F1 and F2 cells indicating that 
they are similar fibroblast cell populations for both viral and non-viral made iPSC-
derived cells (Figure 6, B).  
 
The main differences in protein expression in F2 cells are signal transduction, cell cycle 
and immune system proteins (Figure 6, C-E). Interestingly, the proteomic screen 
revealed many proteins that have been shown to interact with the toll-like receptor 
TLR3 and TLR4 pathway (Figure 6, F-G).  
 
To verify the global proteomic analysis we performed flow cytometry analysis of the F1 
and F2 populations and confirmed that the two fibroblast cell populations are similar for 
two fibroblast cell markers CD90, CD44 and negative for stem cell marker CD34 
(Figure 6, I). This was the same for retrovirally made iPSC-derived cells or non-virally 
made iPSC-derived cells. Given that signal transduction proteins were the most 
represented differentially expressed proteins between F1 and F2 cells, we also verified 
that AKT signal transduction is overactivated in F2 cells compared to F1 cells by 
western blot analysis (Figure 6, H). 
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Adaptive immune response of human iPSC-derived cells. 
 
Analysis of HLA type by deep sequencing methods was performed to confirm HLA 
type for all cell types used (Figure 7, A). MHCI mRNA gene expression (HLA-A, B, C 
and B2M) for F1, iPSC and F2 cells by RT-PCR demonstrate that MHCI gene 
expression is down-regulated in iPSC, as previously published, but returns in F2 cells 
similar to F1 cells (Figure 7, B). We observed large variation between cell lines in 
MHCI gene expression, which has also been previously reported (Drukker et al., 2002). 
MHC1 protein expression was assessed by flow cytometry in all F1 and F2 cell lines 
and no difference in expression levels of MHCI was observed (Figure 7, C). Expression 
of MHC1 was the same for retrovirally made iPSC-derived cells (RV1-3) and non-
virally made iPSC-derived cells (Epi1-3). 
 
To mimic the possible in vivo functional response of MHCI expression to inflammation, 
MHC1 was stimulated with cytokine INF-gamma in F1 and F2 cells from both viral and 
non-viral made iPSC and MHC1 levels were measured by flow cytometry. Both F1 and 
F2 cells responded with an upregulation of MHCI expression in response to INF gamma 
and there was no difference indicating that the regulation of MHCI expression is not 
affected in iPSC derived cells (Figure 7, D). This suggests that MHCI expression is 
functionally normal in iPSC-derived cells.  
 
To further analyse the adaptive immune response we assessed by ELISA the expression 
of immune cytokines secretion in F1 and F2 cells in response to bacterial and viral 
insult. We found that, after Poly(I:C) stimulation, IL15 and RANTES expression was 
down-regulated in F2 cells compared to F1 cells in both viral and non-viral made iPSC 
(Figure 7, E) suggesting there will be altered immunogenicity of transplanted iPSC-
derived cells. However, due to huge variability among patient cells, standard deviation 
was too high to make differences significant. It was not the case for IL10, that was 
found upregulated in F2 after Poly(I:C) stimulation (Figure 7, E). Again, variability was 
too high to stablish significance.  
 
 
Figure 6:  Global proteomic analysis of patient (F1) and iPSCs-derived fibroblasts (F2).  
 
A) Panels left to right: photos representative of the patient fibroblasts, termed F1, iPSC clone, 
differentiation to embryoid bodies (EB) and iPSC-derived fibroblasts, termed F2, at two different 
passages (x100). Scale bars: 10µm. B) Table showing proteins characteristic of human mesenchymal 
stem cells (MSC), hematopoietic and fibroblasts that have either been identified or not in the F1 and F2 
cells. The p-value indicates that there is no difference in the amount of these proteins between F1 and F2. 
C) Table showing the differential proteins between F1 and F2 involved in Immune Response according 
to Reactome and Panther. D) Table showing the differential proteins between F1 and F2 involved in 
Signal Transduction according to Reactome. E) Schematic of Pathways overrepresented (in yellow)  of 
all proteins detected (Reactome). F) Interactions among the differential proteins involved in Signal 
Transduction and the TRL3, TRL4, IL6 and CCL2 proteins (highest confidence = minimum interaction 
score of 0.900). G) Interactions among the differential proteins involved in Immune System and the 
TRL3, TRL4, IL6 and CCL2 proteins (highest confidence = minimum interaction score of 0.900). H) 
Validation of proteomic screen. Western blot analysis of the PI3Kinase signal transduction pathway for 
total and phosphorylated AKT in F1 and F2 cells confirming overexpression of AKT signal transduction 
in F2 cells. I) Graph of flow cytometry for fibroblast markers CD90, CD44 and negative control marker 
CD34 (MSC marker) in F1 and F2 cells, demonstarting that the two populations of fibroblasts are 
similar. 
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Figure 7:  Adaptive immune response of human iPSC-derived cells.  
 
A) Genotype of the HLA of the patient fibroblasts used in this study. B) RT-PCR data for HLA A, B, C 
and B2M (MHC-1 components) expression levels in patient fibroblasts, subsequent iPSC clones and iPSC-
derived fibroblasts. C) Flow cytometry histograms of patient fibroblasts for MHC-I expression. D) 
Relative expression levels of MHC-I by flow cytometry for F1 cells and F2 cells stimulated with 
Interferon gamma. E) ELISA analysis graphs of expression levels of cytokines involved in the adaptive 
immune response: Rantes, IL15 and IL10. F) ELISA analysis graphs of expression levels of cytokines 
involved in inflammation and innate immune response of hiPSC-derived cells: MCP1 and IL6.  
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Inflammation and innate immune response in human iPSC-derived cells. 
 
We next analysed the innate immune response by assessing the expression of 25 
cytokines routinely assed by clinical immunologists by Elisa in viral or non-viral made 
iPSC derived cells, with or without viral ligand stimulation (Poly I:C) or bacterial 
ligand stimulation (LPS). We found no difference in expression of cytokines between 
viral and non-viral made F1 cells compared to F2 cells. Grouping viral made and non-
viral made cells together, two main cytokines involved in inflammation, MCP1 and IL6, 
were found to be upregulated in iPSC-derived cells compared to F1 cells both without 
stimulation (Figure 7, F). However, in response to bacterial LPS and viral Poly (I:C), 
normal MCP1 and IL6 secretion was found for both F1 and F2 cells. Again, variability 
was too high to stablish significance.  
 
Both IL6 and MCP1 are pro-inflammatory cytokines involved in the first steps of the 
innate immune response to recruit monocytes and neutrophils. Taken together the data 
indicates that higher levels of pro-inflammatory cytokines IL6 and MCP1 are being 
secreted by iPSC-derived cells (F2) at basal levels compared to F1 cells. However, F2 
cells behave normally increasing IL6 and MCP1 secretion in response to bacterial or 
viral insult. 
 
To investigate the mechanism underlaying the higher levels of pro-inflammatory 
cytokines being expressed in iPSC-derived cells, we hypothesised that the toll like 
receptor pathway is altered in F2 cells because it is the main pathway for cytokine 
secretion. Proteins associated with TLR3 had been found in the proteomic screen, 
prompting us to investigate toll-like receptor expression levels. By RT-PCR we show 
that TLR3 and TLR4 are more expressed in F2 than in F1 cells (Figure 8, A). This was 
confirmed by flow cytometry analysis for TLR3 protein expression, with 28.3% of F2 
cells expressing TLR3 receptor compared to only 5.1% of F1 cells (Figure 8, B), a 5-
fold higher number of cells with TLR3 receptor in iPSC derived cells. We then analysed 
our mouse C2C12 iPSC derived cells for TLR3 expression and found the same 
upregulation in F2 cells (Figure 8, C), confirming what we had observed in human 
iPSC-derived cells. No differences were found between MH and DH clones, thus data 
was grouped together. Data was taken from four iPSC clones differentiated into 
cardiomyocytes and compared with a control sample of mouse heart tissue from C3H 
mouse, the same mouse strain from where C2C12 cells were isolated. However, this 
time only TLR3 was found upregulated, as TLR4 showed the trend but was not 
significantly different (Figure 8, C).  
 
Then, we also studied TLR3 and TLR4 in the clinical grade mRNA reprogrammed iPSC 
derived cells. No differences were found between MH and DH iPSC, thus data was 
grouped together. Interestingly, this time only CM (F2) and not NSC or generally 
differentiated cells, had upregulated levels of TLR3 in comparison with original HFFs 
(F1) (Figure 8, D).  
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Figure 8: Mouse and human TLR3 and TLR4 in F1 and in iPSC-derived cells (F2).  
 
A) Graph of RT-PCR analysis of TLR3 and TLR4 gene expression levels in the patient human F1 and F2 cells. 
B) Representative flow cytometry histograms of F1 and F2 cells stained for TLR3 receptor expression 
confirming that TLR3 is overexpressed in F2 cells (from 5,1% to 28,3%). C) Graphs summarising RT-PCR 
analysis TLR3 and TLR4 gene expression levels in mouse iPSC-derived fibroblast like cells and 
cardiomyocytes compared to physiological normal mouse embryonic fibroblasts (MEF), mouse C2C12 skeletal 
muscle cells and mouse heart tissue. D) Human mRNA made iPSCs and iPSCs differentiated NSC, CM and 
general differentiation analysis for TLR3 and TLR4. 
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Three CpG sites are hypomethylated in isoform B TSS of TLR3 in NSC. 
 
In order to determine whether differences between F1 and F2 for TLR3 and TLR4 could 
be explained by an epigenetic mechanism, we used the methylome analysis done for the 
mRNA iPSC and their derived NSC in comparison with the original control HFFs. 
Furthermore, using the methylome analysis on the mRNA made iPSC is suitable to 
decrease variability issues associated with patient samples variation and to eliminate 
genetic background. 
 
The methylome array analysis examined several CpG sites inside the sequence of TLR3 
and TLR4. Results show no alteration at any CpG in the TLR4 promoter; however, we 
found hypomethylated CpGs inside the promoter of a short isoform of TLR3 (Figure 9, 
A). The array analyzed 4 CpG sites inside an alternative transcription start site (TSS) 
located in the promoter of this short TLR3 isoform B. These 4 CpG sites analyzed in the 
array were found hypomethylated in all iPSC clones (Figure 9, E). On the other hand, 
and most interestingly, in NSC we found that CpG site cg14827929 was highly 
hypomethylated and cg11273820 and cg00306510 were also hypomethylated in 
comparison with control HFFs (Figure 9, E). These CpG site are found inside the 
alternative TSS located inside the promoter of isoform B, a short isoform that differs 
from TLR3-FL at the protein level by lacking the first 8 leucine rich regions (LRRs) of 
the protein ectodomain responsible for the viral dsRNA recognition. 
 
 
TLR3 isoform B is upregulated in iPSC derived cells. 
 
To determine if the hypomethylation found in the TSS of the TLR3 isoform B promoter 
in NSC was affecting the expression of this isoform in iPSC derived cells, we analysed 
by qPCR several iPSC derived cell types: Neural Stem Cells, Cardiomyocytes and 
Endoderm cells differentiated from mRNA hiPSC. Specific primers were designed 
against the non-shared sequence of TLR3 isoform B transcript and it was compared 
with the TLR3 FL.  
 
RT-PCR results show that compared to control HFFs isoform B, relative expression 
levels are significantly upregulated in all iPSC and iPSC differentiated cells (n=6 
clones) (Figure 9, C). On the contrary, other F1 cell populations like mesenchymal stem 
cells (MSC) and umbilical cord blood (UCB) cells showed fewer or undetectable levels 
of isoform B TLR3 (Figure 9, D). 
 
Patient F1 and F2 cells were also analysed for full length and short isoform (Figure 9, 
B) and although in almost all clones there was an increase in expression in F2 
population, no significance was found due to high variation between patients.  
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TLR3 short isoform confers unresponsiveness to viral stimulation 
 
Functionally, homodimerization of TLR3 is essentially required for ligand binding 
(Wang et al., 2010b), and an intact binding site is required for dsRNA binding and a 
stable dimerization to activate the downstream signalling cascade to initiate pro-
inflammatory response (Figure 9, G). Consistently, after LPS and Poly(I:C) stimulation 
in HFFs, IL-6 is secreted (Figure 9, F). However, we found that after LPS and Poly(I:C) 
stimulation of NSC, IL-6 was not upregulated (p value= 0,0371 and p= 0,0001 
respectively) (Figure 9, F). Therefore, NSC were unresponsive to LPS and Poly(I:C) 
stimulation of TLR3. However nonstimulated F2 cells show higher level of IL6 
secretion (p value= 0,0001) (Figure 9, F). 
 
We hypothesize that his unresponsiveness can be explained taking into account that 
overexpression of the short B isoform found in all the different cell types differentiated 
from iPSC (Figure 9, C) was inhibiting TLR3 stimulation of the wild type TLR3-FL 
receptor, by competing with it in the dimerization process (Figure 9, G). Because an 
intact dimerization site is required for stabilization of the dsRNA/TLR3 dimer complex 
(Wang et al., 2010) the excess of isoform B might be competing with the FL-FL 
dimerization and therefore inhibiting the pathway signal transduction. 
 
 
 
 
 
 
 
 
 
Figure 9: Human TLR3 isoform B generates F2 cells unresponsive to Poly(I:C), gaining 
anti-inflammatory properties producing less IL6.  
 
A) Diagram of TLR3 gene exons and introns organization showing which exons are differentially 
expressed in full length isoform A and short isoform B. It is also shown the location of the alternative 
TSS found hypomethylated in NSC. Image kindly supplied by Dra. Jovita Mezquita. B) Raw RT-PCR 
expression levels of short TLR3 isoform in patient F1 and F2. Highlighted in red are the patient that 
presented an increase between F1 and F2. C) Relative expression levels of TLR3 full length (FL) and 
short isoform B determined by qPCR in mRNA made iPSCs and derived CM, NSC and Endoderm 
cells compared with control HFFs. D) Relative expression levels of TLR3 full length (FL) and short 
isoform B determined by qPCR in Bone marrow mesenchymal stem cells (BM MSC) and umbilical 
cord blood cells (USSC CB). E) Methylation state of 4 CpGs contained inside the alternative TSS that 
enables the transcription of the TLR3 short isoform B.F) Cytokine IL6 production (pg/ml expressed in 
log scale) comparing F1 (HFFs, n=2) and F2 cells (NSC, n=6 clones) without stimulation and after 
LPS and Poly(I:C) o/n stimulation. G) Graphical representation of the two hypothetical TLR3 
dimerization options: full length with full length (FL/FL) or full length with isoform B (FL/B) 
interacting with viral dsRNA. In the first case, dimer structure is stable and active and transduces 
signal to produce a pro-inflammatory effect through IL6 production in case there’s viral dsRNA. In 
the second case, an unstable dimer structure is nonfunctional and therefore unresponsive to dsRNA 
stimulation triggering an anti-inflammatory effect by the lack of signal transduction.  
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In vivo mouse model: immune response of transplanted syngeneic mouse iPSC and 
iPSC derived cells. 
 
To determine the immunogenicity generated by mouse iPSC derived cardiomyocytes 
(CM) (characterized by RT-PCR in Figure 10, A), a T cell kill assay was performed to 
assess survival. Cells were injected in vivo into syngeneic C3H mice. To investigate if 
an adaptive immune response was generated, a priming period of 7 days was left from 
the injection time point until the collection of the cytotoxic T lymphocytes (CTLs). Four 
different iPSC derived cardiomyocytes lines were injected in duplicate into the testis of 
mice. All animal experiments were approved by the ethics committee. 
 
Primed T cells degranulation activity was measured by flow cytometry by CD107a 
expression. The level of apoptosis of target iPSC and CM was determined by flow 
cytometry using Annexin V+PI. One week after cardiomyocytes injection, Cytotoxic T 
lymphocytes (CTLs) were isolated by FICOLL gradient from smashed spleens from 
mice. For T cell kill assay CTLs were added on top of the cardiomyocyte line that was 
injected in the mouse the CTLs were isolated from. Co-culture assay lasted 4h.  
 
Interestingly, the data shows that when the primed T cells are placed on the iPSC-
derived cardiomyocytes (CM) the level of CD107a or T cell activity, is reduced (Figure 
10, C) and apoptosis is not increased neither (Figure 10, D). CD107a reduction suggests 
that iPSC derived CM might be secreting cytokines that could reduce T cell activity. 
 
In conclusion, the data demonstrates that cell reprogramming process alters both the 
innate and adaptive immune response of iPSC-derived cells that provides an insight for 
future clinical applications of autologous human iPSC-derived cell transplantation. 
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Figure 10: In vivo mouse model: immune response of syngenic mouse iPSC-derived cells.  
 
A) RT-PCR characterization of C2C12 iPSCs derived Cardiomyocytes (CM) with cardiac markers: 
Nkx2.5, cTnT2 and Tbx5 for all 4 clones analysed compared with C2C12 negative control and mouse 
Embryonic Stem cells (mES) derived CM for positive control. B) RT-PCR characterization of C2C12 
iPSCs generally differentiated clone D1C3. Markers for Ectoderm (ISI1, SOX1 and ShcC), Mesoderm (T 
and Myf5) and Endoderm (AFP and HNF4) were analysed. C) T cells CD107a% degranulation in 
response to mouse IPSCs and mouse iPSCs derived CM coculture with primed T cells in syngeneic C3H 
mice. In all cases a significant decrease in CD107a was reported when co-culturing cytotoxic T 
lymphocytes (CTLs) with either iPSCs or CM. demonstrating reduction in T cell activity when plated with 
cardiomyocytes and no change in apoptosis (D) of cardiomyocytes as seen by Annexin V+PI %. Negative 
control for apoptosis are CMs alone and positive control are CM treated with 10% DMSO. 
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Neural Stem Cells (NSC) engraft and survive in a Spinal Cord Injury (SCI) rat 
model. 
 
Our laboratory is interested in finding a cellular therapy approach to study and treat 
spinal cord injury (SCI). Hence, we established collaboration with Dra Victoria Moreno 
from the Centro de Investigaciones Principe Felipe (CIPF) in Valencia where I stayed 
and received training to study our NSC using their SCI rat model. Therefore, we 
performed a practical test of the iPSC derived NSC by injecting them in a spinal cord 
injury (SCI) rat model in order to perform an in vivo functional assay to determine 
whether DH iPSC derived cells have an actual functional capability of survival and 
engraftment in vivo. We performed a spinal cord complete transection following 
published protocols (Lukovic et al., 2015). 
 
 
In a similar experiment using the same model of spinal cord injury of complete 
transection, it was reported that HESCs derived oligodendrocytes progenitors and motor 
neurons progenitors improved motor recovery 4 months after transplantation (Erceg et 
al., 2010). In this experiment however, we only assessed survival two months after 
injection and identify NSC differentiation capabilities towards their natural derivatives 
in a spinal cord injured niche. 
 
One clone of NSC differentiated from DH iPSC was chosen to test our new iPSC 
derived NSC capability of survival and engraftment in vivo. NSC tagged with cell 
tracker (Vybrant CFDA SE) were injected in this severe transection model into the 
spinal cord of four rats (Figure 11, A) as indicated in methods. To avoid rejection, 
cyclosporine was administrated through the water supply. At day 3 after injection one 
rat was sacrificed to see that cells were still alive and located near the injection site 
(Figure 11, B). 
 
Lesion site is delimited by the lack of GFAP positive astrocytes because of the scaring 
process happening after cord transection. We show how after two months, at day 60, 
cells survived, engrafted and migrated to the lesion site, as shown by the green tracker 
in all three rats (Figure 11, B and supplementary figure 11, A). Also, in all rats cells 
migrated towards the caudal side of the spinal cord (Supplementary figure 5, B). 
 
By studying colocalization of vibrant green marker with different antibodies we 
determined by immunofluorescence that NSC had differentiated 75,1% into mature 
neurons (MAP2-NSC colocalization), 1,9% immature neurons (Tuj1-NSC 
colocalization), 18,2% oligodendrocytes (OLIG2-NSC colocalization) and 5,2% mature 
astrocytes (S100-NSC colocalization) (Figure 5, C). These results reveal that Cyclin D1 
made iPSC derived NSC exhibit an in vivo differentiation potential similar to what has 
been published likewise with c-Myc iPSC. 
  
Results 
 
- 148 - 
 
 
 
 
 
  
Figure 11. Clinical grade human iPSCs derived NSC engraft and migrate to the lesion site in a 
Spinal Cord Injury (SCI) rat model.  
 
A) In a severe transection model in rats NSC were injected into the spinal cord in between segments T8-9, 
using a stereotaxic arm with an attached Hamilton. Cells, 2·10^6 in 10µl, were injected at two levels: rostral 
(5µl) and caudal (5µl) separated by 2-3 mm, at a speed of 2µl/min. B) Immunofluorescence of transection cuts 
of perfused spinal cords at day 3 after NSC injection, a control without cells at day 60 and a day 60 spinal cord 
after NSC injection and complete transection. Injected cells were tagged with cell tracker (Vybrant CFDA SE) 
to detect cells using a GFP detection wavelength. Tuj1 and GFAP were used to detect neurons and astrocytes 
respectively and DAPI to stain nuclei. A merge image is shown. Cells survived, engrafted and migrated as 
shown by the green tracker at day 3 and day 60. After injecting mRNA made iPSCs derived NSC in the spinal 
cord no neoplasm was formed. C) Colocalization study of vibrant green marker with different antibodies by 
immunofluorescence determines that NSC had differentiated 75,1% into mature neurons (MAP2), 1,9% 
immature neurons (Tuj1), 18,2% oligodendrocytes (OLIG2), 0% immature astrocytes (GFAP) and 5,2% 
mature astrocytes (S100).  
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Even though cell reprogramming is an established technique for production of induced 
pluripotent stem cells (iPSC), producing high quality patient specific iPSC suitable for 
cell therapy remains an important challenge, as there is a lack of clinical grade standard 
operating procedures.  About half human iPSC exhibit genetic and epigenetic variations, 
thought to result from incomplete reprogramming, mutation in somatic cells and cellular 
stress during reprogramming (Koyanagi-Aoi et al., 2013). Therefore, genetic instability 
are thought to be one of the potential barriers to clinical application of their derivative 
cells. A few months ago, the first iPSC clinical trial had to be stopped due to 
unexpected genetic instability found in the patient iPSC used in the trial, proving that 
genetic stability of iPSC is one major difficulty to elucidate before clinical application. 
Another of the major hurdles still to overcome is the tumorigenic threat associated with 
c-Myc pleiotropic effects. That’s why we proposed an alternative reprogramming 
cocktail to solve this issue. Indeed, factor based genetic instability remains an important 
issue to address, which is the reason why we have assessed Cyclin D1 as a candidate to 
substitute c-Myc in the reprogramming cocktail. Glis1 was also reported to be able to 
substitute c-Myc (Maekawa et al., 2011); however, it also promoted multiple pro-
reprogramming pathways, that were activated due to the upregulation of the 
transcription factors N-Myc, L-Myc, C-Myc, Nanog, ESRRB, FOXA2, GATA4, 
NKX2-5, as well as the other three reprogramming factors (Maekawa et al., 2011).  
An important feat in the reprogramming process is to bypass the cell cycle arrest in 
adult differentiated cells. For example, inhibition of the p53 and p21 pathway as well as 
the expression of Lin28 increases iPSC generation predominantly by acceleration of the 
rate of cell division (Hanna et al., 2009). Therefore, accelerated kinetics of iPSC 
formation was directly proportional to the increase in cell proliferation (Hanna et al., 
2009). C-Myc has been used classically for this purpose, as it is a transcription factor 
which regulates, among other functions, the expression of several genes involved in the 
control of cell proliferation like Cyclin D1. Then, we hypothesize that bypassing the cell 
cycle arrest by using Cyclin D1 would enable the replacement of c-Myc, removing all 
the other functions c-Myc has on the cell. Accordingly, we have found that without the 
acceleration of the cell cycle triggered by either c-Myc or Cyclin D1, 3F (Oct4, Sox2 
and Klf4) alone showed a very low efficiency with retroviral methods and a null 
reprogramming efficiency with mRNA transfections due to the incapacity to bypass cell 
cycle arrest. Maintaing efficiency is a challenge to solve, especially when dealing with 
reprogramming patient cells. 
 
It is unknown the minimum requirement tests for determining the clinically acceptable 
quality of iPSC. When assessing iPSC quality, the results of several tests are often 
qualitative, especially when dealing with epigenetic modifications, making it difficult to 
set thresholds for defining “normal” and “defective” cell lines. Another example is 
mutations; how many mutations and at what genes would classify iPSC defective? 
Since it is difficult to set the standards for quality of iPSC, these questions in turn raise 
another challenge, which is to what depth should the lines be analyzed, i.e. should we 
sequence the entire genome, epigenome and transcriptome of iPSC lines, and at what 
cost? 
 
In order to replace c-Myc oncogene in the reprogramming cocktail, here we have used 
the cell cycle gene Cyclin D1 in combination with the other three factors, Oct4, Sox2 
and Klf4 to reprogram somatic cells to pluripotency, showing a reduction in several 
genetic instability parameters. 
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In this study, we first tested reprogrammed mouse cells and assessed telomere length in 
the iPSC as a measure of genetic stability. Depending on the length, telomeres can be 
classified in long, short and signal-free ends (almost undetectable telomeres). Signal-
free ends have been associated with chromosomal t-loops formation and are considered 
a sign of genetic instability. As we have observed, 3F+Cyclin D1 clones have half the 
percentage of signal free ends than 3F+c-Myc clones (Figure 1, J); demonstrating that 
3F+Cyclin D1 mouse iPSC clones present a better quality telomere length. A 
comparison of chromosome instability between 3F+Cyclin D1 and 3F clones should 
have been assessed as control; however we were not able to grow iPSC clones from 
C2C12 with 3F transduction alone after picking them from the plate. 
 
Another chromosomal stability analysis that has been conducted is the determination of 
the number of chromosome free fragments present in the nucleus of the cells. The 
contribution of an increase in the number of chromosomal fragments to iPSC stability is 
poorly understood. However, an increase in the number of fragments was reported to 
occur after irradiation-induced lesions (Pantelias, 1986). CHO cells in metaphase 
exposed to 5Gy X-ray irradiation led to an increase of chromosome fragments, 
suggesting that it must be a feature of instability rather than a helpful acquisition 
(Pantelias, 1986). Those results are in accordance with the fact that in mouse cells, 
3F+c-Myc reprogramming increases the number of chromosomal fragments compared 
to 3F+Cyclin D1 (Figure 1, K), suggesting once more that c-Myc may be producing a 
higher stress in the cell than Cyclin D1.  
 
To determine whether Cyclin D1 can reduce cell stress in the reprogramming process a 
battery of genes associated with cell stress and DNA damage were evaluated (Figure 1 
and Supplementary Figure 1). ATM and p53 binding protein 1 (53BP1) are two DNA 
damage response genes. 53BP1 is a p53 binding protein that binds to the central DNA-
binding domain of p53. It relocates to the sites of DNA strand breaks in response to 
DNA damage. The well-known tumor suppressor p53 plays a central role in the 
response of mammalian cells to genotoxic stress (Iwabuchi et al., 1994). 53BP1 acts 
downstream of ATM in the DNA damage response pathway and is involved in tumor 
suppression in mice (Ward et al., 2003). Thus, defects in DNA damage recognition and 
repair mechanisms are associated with cancer predisposition, suggesting that cells might 
be more prone to tumorigenicity. On the other hand, ATM, the gene mutated in the 
disorder ataxia-telangiectasia, is a protein kinase that is a central mediator of responses 
to DNA double-strand breaks in cells (Kitagawa et al., 2005). But although ATM and 
53BP1 were less expressed in 3F+Cyclin D1 clones in C2C12, the difference was not 
significant enough. 
 
NFKB target genes such as inhibitor of apoptosis 2 (IAP2), manganese superoxide 
dismutase (MnSOD) and growth arrest DNA damage inducible gene 45 beta 
(GADD45b) were also evaluated. All they have protective effects against apoptosis. 
MnSOD for instance has been established to protect against oxidation induced apoptosis 
(Kasahara et al., 2005). The inhibitors of apoptosis (IAPs) antagonize cell death and 
regulate the cell cycle; IAPs are a family of proteins that suppress apoptosis triggered by 
a variety of stimuli (LaCasse et al., 1998; Hay, 2000). Induction of GADD45b by NF-
kappaB downregulates pro-apoptotic JNK signaling (De Smaele et al., 2001), 
functioning therefore as a protective mechanism as well. Interestingly, GADD45b and 
IAP2 genes transcripts levels are found upregulated in 3F+c-Myc clones compared to 
3F+Cyclin D1 clones (Figure 1, F-G). Thus, induction of Gadd45b and IAP2 
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functioning as a protective mechanism may suggest that c-Myc clones might require to 
be assisted or protected from DNA damage induced apoptosis. 
 
Finally, sirtuins 1, 3 and 6 levels were also analyzed, but only sirtuin 1 presented 
significant differences in expression (Figure 1, E). Sirtuins have been implicated in 
influencing a wide range of cellular processes like aging, transcription, apoptosis, 
inflammation and stress resistance. The role of Sirt1 in iPSC initially was thought to be 
important if not essential, as was reported to facilitate iPSC generation from mouse 
embryonic fibroblasts through deacetylation of p53, inhibition of p21 and enhancement 
of Nanog expression (Lau et al., 2012). But recently, Sirt1 has been actually described 
as necessary for proficient telomere elongation and genomic stability of induced 
pluripotent stem cells (De Bonis et al., 2014). In Lau’s paper it previously it was also 
found that knocking down sirtuin 1 with siRNA the number of iPSC colonies were three 
fold reduced. Here we’ve found that in MEFs null for sirtuin 1, the reduction is four fold 
when reprogramming with c-Myc (Figure 1, H). 
 
It has to be taken into account that the oncogene c-Myc and Sirt1 form a positive 
feedback loop both contribute to amplify each other. Sirt1 expression is increased by c-
Myc-dependent NAMPT activity and c-Myc function is enhanced by Sirt1 (Menssen et 
al., 2012). The fact that Sirt1 is not upregulated in 3F+Cyclin D1 clones as much as it is 
in 3F+c-Myc clones during early passage 1 (Figure 1, E), suggests that 3F+Cyclin D1 
clones might originate less genomic instability, preventing sirtuin 1 from increasing 
their levels to repair any damage. 
 
We wanted to understand whether Cyclin D1 could rescue iPSC from acquiring 
genomic instability during the reprogramming of MEFs lacking Sirtuin 1 (Sirt1-/-). 
Experiments performed show that 3F+Cyclin D1 can increase survival of cells during 
reprogramming to pluripotency. We propose that the absence of Sirtuin 1 does not 
prevent colonies from proliferating as if there were less alterations or instability than in 
3F+c-Myc and colony cells were not stopped to proliferate. Then, Cyclin D1 in Sirt1-/- 
MEFs appears to be rescuing reprogramming comparing to c-Myc, suggesting that 
Cyclin D1 functions independent of Sirtuin 1 during reprogramming. 
 
 
 
Human iPSC clinical grade reprogramming 
 
The next step in the process of developing a clinical grade protocol was to find a proper 
reprogramming method that could reduce the threat of insertional mutagenesis and 
transgene reactivation associated with retroviral vectors.  
 
It is widely accepted that reprogramming itself can induce both genetic and epigenetic 
defects in iPSCs (Doi et al.,2009; Kim et al., 2010; Polo et al., 2010; Lister et al., 2011). 
Even when using non-integrative virus-free methods as mRNA transfections (Gore et 
al., 2011) or episomal vectors (Taapken et al., 2011) approaches for reprogramming. 
The reprogramming method did not affect neither the frequency nor the type of genomic 
changes in hiPSCs (Taapken et al., 2011). Nevertheless, the three main non-integrative 
methods for reprogramming adult cells to iPSC in a clinical grade way that have been 
proposed to be clinically acceptable are:  synthetic mRNA transfections, Sendai virus 
and Episomal vectors.  
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Sendai virus has the advantages of wide host specificity and low pathogenicity, and the 
disadvantage of strong immunogenic response (Fusaki et al., 2009), triggering the 
applicability of this method to firstly require the development of less antigenic vectors. 
Episomal vectors consist of introducing episomal genes that are expressed and replicate 
when the host cell divides. Afterwards, the episomal vector is naturally gone when the 
iPSC multiply (Yu et al., 2009). Likewise, in the case of Sendai virus and episomal 
vectors, final clones have to be shown to be free of the original vector or virus. Still, it is 
always maintained the rare but potential chance of insertion of the Episomal vector 
DNA by homologous recombination. On the other hand, direct transfection of synthetic 
modified mRNA consists of the administration of mRNA modified to overcome innate 
antiviral immune responses. Although it is needed a daily transfection regimen to 
maintain a sustained expression, mRNA reprogramming allows a higher reprogramming 
efficiency (Warren et al., 2010).  
 
A comparison of Episomal vectors, Sendai virus, mRNA transfection, Retrovirus and 
Lentiviral methods demonstrated that mRNA transfection was the one showing a lower 
number of aneuploidies (Schlaeger et al., 2015). It offers the finest option for future 
clinical applications as expression is transient over 48 hours and dose and timing can be 
controlled as requested. Thus, we decided to proceed with mRNA transfections method.  
 
Messenger RNA made iPSC reprogrammed with c-Myc and Cyclin D1, here called MH 
and DH clones, gave a similar reprogramming efficiency percentage as with retroviral 
reprogramming (Supplementary figure 2, F), being Cyclin D1 half as efficient as c-Myc 
in the number of colonies. However and most importantly, we were not able to 
reprogram with 3F alone.  
 
Furthermore, after general and guided differentiation no qualitative differences were 
seen in terms of their in vitro pluripotency potential (Figure 2, C-G). Later, when in 
vivo pluripotency potential was assessed, all clones from both conditions were able to 
form teratomas containing structures of tissues from the three germ layers (Figure 3, B).  
 
 
Human iPSC tumorigenicity 
 
One of the main concerns about reprogramming is the tumorigenic potential of iPSC. 
IPSC have been shown to have a higher tumorigenic potential than ES cells (Miura et 
al., 2009; Okita et al., 2007), since they are made with the well-known oncogene c-Myc. 
C-Myc has been related with the activation of several pathways in the reprogramming 
process because of its pleiotropic effect, since it can cause permanent negative effects 
even with only transitory expression. 
 
An interesting difference was found in the tumorigenic marker KI67, which was found 
to be highly expressed in MH iPSC teratomas in comparison with DH iPSC teratomas 
(Figure 3, C). Following the same trend we found that neural stem cells derived from 
MH iPSC had as well higher values of KI67 in vitro in comparison with DH derived 
NSC (Figure 3, D). Neoplastic risk after transplantation of iPSC differentiated cells has 
been concerning since the discovery of iPSC. Here, we show how DH iPSC and derived 
NSC present lower levels of KI67, decreasing thus the associated tumorigenic threat. 
We thought that one possible explanation was that some of the genes that are found 
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amplified in the CNV array assay might be involved in the tumorigenic growth. 
However, cluster analysis revealed no big differences regarding cancer related genes 
amplified. Another possibility was that the small differences found at the methylome 
level could explain the highly aggressive growth rate found in MH clones. Nevertheless, 
after looking for similarities with methylation patterns from online databases no 
matches were found. 
 
Another evidence suggesting c-Myc iPSC higher tumorigenic risk, is that MH iPSC and 
NSC clones had longer telomeres than DH clones (Figure 5, B). Acquiring a certain 
telomere length is necessary for iPSC self-renewal capabilities; however long telomeres 
are also a hallmark of cancer. This is the reason why iPSC need to reach a balance 
between too short and too long telomeres. Nevertheless, telomere length in DH NSC are 
more similar to original HFFs than MH NSC, which are still too long for a 
differentiated cell type. This feature might also be relevant as cells that derive from 
iPSC should not retain any stem pluripotency property before they are transplanted into 
patients. Furthermore, in a recently published study after retrovirally made iPSC derived 
NSC injection into the spinal cord of injured rats, teratomas were formed (López-
Serrano et al., 2016, Supplementary Figure 5, C). In this publication iPSC was made 
with c-Myc in the reprogramming cocktail.  
 
 
DNA double strand breaks in human iPSC 
 
DNA double strand breaks (DSBs) are a consequence of oxidative and replicative stress. 
DSBs repair mechanisms are homologous recombination (HR) and non-homologous 
end joining (NHEJ). C-Myc expression has been reported to accumulate reactive 
oxygen species (ROS), which in turn generate DNA breaks (Khanna and Jackson 2001). 
Furthermore, c-Myc suppresses NHEJ (Li et al., 2012) and HR in various cancer cell 
lines (Luoto et al., 2010); contrarily to Cyclin D1 that has been linked with facilitating 
homologous recombination repair process by helping BRCA2 to recruit RAD51 in 
repairing DNA DSBs in the HR process (Chalermrujinanant et al., 2016). The fact that 
we found a higher percentage and intensity of H2AX positive DSBs in MH than in DH 
iPSC and NSC supports the idea that DH iPSC render a better genetic stability through a 
less stressful reprogramming process. 
  
NHEJ is the major pathway in mammalian cells for repairing DSBs (Hefferin et al., 
2005; Burma et al., 2006). Mechanistically, c-Myc binds to Ku70 protein through the 
Myc Box II (MBII) domain and therefore directly disrupts the Ku/DNA-PKcs complex 
suppressing thus the DSBs repair leading to genetic instability (Li et al., 2012). All Myc 
protein family (C-Myc, L-Myc and N-Myc) have the Box II domain involved in the 
inhibition of DSB repair. L-Myc has been proposed as an alternative to c-Myc for its 
increase in reprogramming efficiency and reduced tumorigenic threat compared with c-
Myc made iPSC (Nakagawa et al., 2010), however, Cyclin D1 is also a better choice 
since L-Myc Box II domain inhibits NHEJ repair (Li et al., 2012). 
 
Furthermore, Rad51 is found retained in the cytoplasm in a higher proportion in MH 
clones than in DH clones. Since Rad51 cytoplasmic retention has been linked with 
inhibition of homologous recombination (Plo et al., 2008), this results supports our 
hypothesis that Cyclin D1 is promoting DNA repair by helping to recruit Rad51 to the 
site of the DNA break during reprogramming to iPSC. 
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Rad51 is a central protein in homologous recombination repair mechanism and is 
therefore of great relevance in terms of genomic stability. Their family members are 
homologous to the bacterial RecA, Archaeal RadA and yeast Rad51. Therefore, it is an 
evolutionary conserved protein in most eukaryotes. Here we have observed that both 
MH and DH clones presented cytoplasmic distribution of Rad51. However, DH clones 
had a lower signal than MH clones (Figure 4). Correspondingly, RAD51 overexpression 
has been reported as a negative prognostic marker for colorectal adenocarcinoma 
(Tennstedt et al., 2013), in a study that analyzed 1,213 biopsies from colorectal 
adenocarcinomas. Strong RAD51 expression was observed in 1% of colorectal 
carcinomas, moderate in 11%, weak in 34% and no expressed in 44%. 
 
On the other hand, we have also found differences in RAD51B paralog in iPSC at 
passage 3. RAD51 paralogs are a family of five proteins (RAD51B, RAD51C, 
RAD51D, XRCC2 and XRCC3), that share at least 20% of sequence homology with 
RAD51. RAD51 paralogs are also important for homologous recombination (HR) since 
cells defective for them are sensitive to DNA-damaging agents like gamma radiation 
(Takata et al., 2001). Interestingly, RAD51B, has also been shown to be upregulated in 
MH clones at early passage 3, but not passage 10 (Figure 4, G). Consistently, it has 
been reported that expression of RAD51B paralog is de-regulated in several cancer cell 
types. For example, RAD51B expression is upregulated in gastric cancer tumours and 
correlates with a poor prognosis (Cheng et al., 2016); also overexpression of mutated 
versions of this gene have a high correlation with breast cancer predisposition (Golmard 
et al., 2013); as well as in chronic myelogenous leukemia (CML) cells (Albajar et al., 
2011), where Rad51B protein levels were upregulated and Myc was found at high levels 
correlating with a resulting imatinib drug resistance. Likewise, BCR/ABL tyrosine 
kinase fusion protein, which enhances c-Myc expression, is directly interacting and 
phosphorylating both RAD51 and RAD51B, which could be influencing the repair 
efficiency of HR (Slupianek et al., 2009; Rieke et al., 2016). It had been hypothesize 
that BCR/ABL mediated tyrosine phosphorylation of Rad51B may affect the interaction 
between the paralogs to enhance the efficiency and/or diminish the fidelity of 
homologous recombination in CML (Rieke et al., 2016). All this information as well 
corroborates what we hypothesized that MH iPSC present a higher tumorigenic 
potential and have a higher propensity to generate genomic instabilities than DH iPSC. 
 
Human ESC and iPSC have an altered cell cycle of 16-18h, with a short G1 phase with 
only 2,5h (Becker et al., 2006; Becker et al., 2007). Therefore, the cell has a short 
window of time to activate the repairing machinery for all damaged DNA DSBs 
acquired. The fact that LIG3 is significantly more expressed in MH clones during early 
passage 3 than DH clones (Figure 4, F), might link with the fact that c-Myc 
overexpression has been reported to promote the alternative NHEJ repairing mechanism 
rather than the classical NHEJ or Homologous Recombination. 
 
Human iPSC telomere stability 
 
Chromosome telomeres stability was also assessed with a QFISH analysis as in mouse 
cells. Multitelomeric signals (MTS) have been proposed to reflect increased breakage at 
chromosome termini and subsequent repair by homologous recombination mechanisms 
(Lydeard et al., 2007). Therefore multitelomeric signals are regarded as a type of 
genetic instability that are a result of telomere breakage during telomeres DNA 
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replication (Meeker et al., 2004; Muñoz et al., 2005; Blanco et al., 2007; Martinez et al., 
2009; Sfeir et al., 2009; Tejera et al., 2010; Bosco et al., 2012).  
 
Sirtuin 1 also contributes to telomere maintenance and augments global homologous 
recombination. Sirtuin 1 null mouse embryonic fibroblasts (Sirt1-/-MEFs) were shown 
to express a higher number of multitelomeric signals per chromosome (Palacios et al., 
2010). Here we show how during the early passaging of MH iPSC Sirt1 levels are 
higher than DH iPSC (Figure 3, F). This fact, could be explained by the necessity of 
Myc made iPSC to restore all DNA damage caused by the stress c-Myc is driving on 
cells undergoing reprogramming, as shown by the increase in the MTS/Chr %. 
 
While differences in signal free ends percentage were found in mouse iPSC between 3F 
+ c-Myc and 3F + Cyclin D1, these differences were not found in human iPSC; 
however, differences were found in MTS/Chr percentage (Figure 5, A). This might be 
explained as fundamental differences exist between human and mouse telomere biology 
(Wright et al., 2000). The fact that c-Myc reprogramming increases the percentage of 
MTS/Chr supports our hypothesis that DH iPSC hold a greater chromosome stability 
than the classical MH iPSC. 
 
BRCA2 and Rad51 are required for telomere length maintenance in MEFs (Badie et al., 
2010).  BRCA2 deletion and Rad51 inhibition led to telomere shortening and increased 
number of MTS in MEFs (Badie et al., 2010). Correspondingly,  we see a decrease in 
Rad51 nuclear expression in MH clones, that might explain why we also see an increase 
in MTS in Myc made clones, since Rad51 was reported to be essential for facilitating 
telomere replication and capping and an alteration in normal levels could have affected. 
 
 
Copy Number Variation in human iPSC 
 
To advance iPSC technology we assessed CNV to see whether reprogramming with 
Cyclin D1 could lower the increase in CNV after reprogramming. Results showed that 
reprogramming increased CNV in both conditions; still MH presented a higher rate than 
DH iPSC clones, (Figure 5, D-E). However, no significance was found due to clonal 
variation. The fact that c-Myc containing cocktail has led to a higher trend of CNVs can 
be explained as it has been reported to be involved in gene amplification (Denis et al., 
1991; Mai et al., 1994; Mai et al., 1996). It has been published that Myc overexpression 
elevates DHFR gene copy number within 3 weeks by 10 fold (Denis et al., 1991) or 
even just within 72h after overexpression (Mai et al., 1994; Mai et al., 1996). Indeed, 
every single cell expressing the conditional Myc gene had DHFR amplification (Mai et 
al., 1994). DHFR gene encodes for a protein that provides methotrexate (MTX) dug 
resistance; therefore also related with tumorigenic threat increase. Thus, Myc 
deregulates the normal “once per cycle” replication initiation, forcing several initiations 
of replication forks. Therefore, amplification of genes involved in DNA synthesis and 
cell-cycle progression provide a proliferative advantage to cells that harbour it (Kuschak 
et al., 2002).  
 
C-Myc dysregulation is associated with illegitimate recombinations and long-range 
chromosomal rearrangements rather than single nucleotide polymorphism (Rockwood et 
al., 2002). Nevertheless in the case of mRNA reprogramming, c-Myc overexpression 
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lasted for 12 days on a row, which in turn might have been enough to cause CNVs 
differences found between MH and DH iPSC. 
 
It was shown that reprogramming with protein transfections of the reprogramming 
factors led to lower increase in CNV in comparison with retroviral and lentivirally made 
iPSC (Park et al., 2014). Correspondingly, our result shows how the non-integrative 
method of mRNA transfection reprogramming does not present a significant increase in 
CNV between HFFs and iPSC. 
 
Genomic alterations can also be selected during differentiation of PSC. For example, an 
abnormal subpopulation of ESC with multiple duplications in chromosome 20, after 
only 5 days, was selected in a cardiac differentiation experiment (Laurent et al., 2011). 
Interestingly, multipotent adult stem cells also show frequent typical chromosomal 
abnormalities, like duplication of chromosome 19 in neural stem cells (NSC) or a 
deletion of chromosome 13 in mesenchymal stem cells (MSCs) (Ben-David et al., 
2011a).   
 
CNV itself is not necessary a risky trait, as mounting number of papers show somatic 
mosaicism as a common feature of the human body, since there is already a 
considerable variation in the genomes of ordinary cells within our bodies (Chen et al., 
2013; Lupski et al., 2013; Poduri et al., 2013; Biesecher et al., 2013). However, the 
more CNV a cell undergoes the more chances it is going to affect a relevant set of genes 
to promote transformation. 
 
IPSC derived cells immune response 
As the field grows and moves closer to clinical application the need to understand what 
will be the immune response of transplanted human iPSC-derived cells becomes 
paramount. Is autologous iPSC derive cells going to be a main source of cells for future 
cell therapies? Or maybe allogeneic iPSC derived cells HLA matched? Personalized 
againsts off the shelf cell sources needs to be devated over the next years. 
 
The interaction of the human immune system with autologous reprogramed human cells 
remains an unexplored question. Four recent publications in animal studies (mice and 
non-human primates) indicate that there may be some immune response of autologous 
reprogramed cells (Liu et al., 2013; Zhao et al., 2011; Guha et al., 2013; Morizane et al., 
2013). Data from human transplanted autologous reprogramed cells in vivo is limited 
and only one current clinical trial for iPSC-RPE cells exists with no immune response 
data available (Kamao et al., 2014; Alvarez et al., 2015). As the field grows and moves 
closer to clinical application the need to understand what will be the immune response 
of transplanted human iPSC-derived cells becomes paramount. 
 
Patient cells that have been reprogrammed into iPSC and then differentiated to tissue 
specific cells can be considered artificial stem cells and many questions still exist about 
their function including genetic stability, ability to heal an injured tissue and their 
immune response. Artificially made stem cells provide a viable source of cells for cell 
replacement therapy. Therefore, they remain a prominent potential source of cells for 
the rapidly growing field of regenerative medicine. 
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Toll-like Receptor 3 (TLR3) short isoform overexpression in F2 
 
Here, we have compared a population of patient cells (F1) with a population of iPSC 
derived cells (F2). Global proteomic analysis revealed that the two populations of 
fibroblast cells were mainly similar and no differences between viral made and episomal 
made iPSC was observed neither. However, there were differences in signal 
transduction and immune cell protein expression.  
 
Central to the finding that iPSC-derived cells have altered immunogenicity is the 
sustained toll like receptor TLR3 expression. Double-stranded RNA (dsRNA), a 
frequent by-product of virus infection, is recognized by toll-like receptor 3 (TLR3) to 
mediate innate immune response to virus infection. The PI3K-Akt pathway plays an 
essential role in TLR3-mediated gene induction (Sarkar et al., 2004). We have found 
that both TLR3 and the Akt pathway is highly expressed in iPSC-derived cells and is 
most likely regulating expression of inflammatory cytokines IL6 and MCP1 as well as 
secondary adaptive immune system cytokines such as IL15 and RANTES. Increased 
levels of IL6 and MCP1 secretion by transplanted F2 cells (Figure 7, F) could cause 
recruitment of monocytes and neutrophils to further complicate a long-term 
inflammation response.  
 
However, the down-regulation of IL15 and RANTES may result in a possible reduction 
of secondary T cell mediated response. This observation among others brings forward 
the interesting possibility that iPSC-derived cells may benefit from a suppressed 
immunogenic microenvironment favouring initial survival and subsequent engraftment 
and tissue regeneration. Interestingly, a recent study found that differentiation of human 
iPSC results in a loss of immunogenicity and leads to the induction of tolerance, despite 
expected antigen expression differences between iPSC-derived versus original somatic 
cells (De Almeida et al., 2014). In further agreement with this study it has also been 
demonstrated that neural progenitor cells from human induced pluripotent stem cells 
generated less autologous immune response (Huang et al., 2014). 
 
Lee et al. found that the toll-like receptor 3 (TLR3) pathway enable efficient induction 
of pluripotency by viral or non-viral approaches (Lee et al., 2012b). Stimulation of 
TLR3 causes rapid and global changes in the expression of epigenetic modifiers to 
enhance chromatin remodelling and nuclear reprogramming. Furthermore, they 
conclude that activation of inflammatory pathways is required for efficient nuclear 
reprogramming in the induction of pluripotency (Lee et al., 2012b). Our finding 
suggests that this essential TLR3 pathway for achieving cell pluripotency is not re-set to 
the correct levels in iPSC-differentiated cells (F2) that then results in altered AKT 
signalling and cytokine secretion (Figure 6, H; Figure 7, E-F; Figure 9, E). 
 
TLRs are expressed in the membrane of immune and non-immune cells (Delneste et al., 
2007; Lafon et al., 2006). However, neurons also express TLRs, specifically TLR3 in 
order to have the ability to mount a strong inflammatory response by expressing 
inflammatory cytokines like TNF-α and IL-6 in absence of glia (Lafon et al., 2006). 
TLR3 recognizes dsRNA, produced by most viruses at some stage in their lifecycles, 
being a potent indicator of viral infection. Nevertheless, homodimerization of TLR3 is 
essentially required for ligand binding (wang et al., 2010b), and an intact binding site is 
required for dsRNA binding and stable dimerization to activate the downstream 
signalling cascade. TLR3 ectodomain, which is made by 23 LRR, bind as dimers to 45 
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bp segments of dsRNA, the minimum length required for TLR3 binding and activation 
(Wang et al., 2010b). The dsRNA interacts at two sites on each TLR3-ECD, one near 
the N-terminus (comprising LRR-NT and LRRs 1–3), and one near the C-terminus 
(comprising LRRs 19–23) (Liu et al., 2008). Mutational analyses (Wang et al., 2010b) 
have established that these three sites individually interact weakly with their binding 
partners but together form a high affinity receptor-ligand complex. Simultaneous 
interaction of all three sites at the same time is therefore required for stable and 
functional binging of TLR3/dsRNA. In the cell, two TLR3 ectodomains interacting on 
the luminal side of an endosome bring the two TIR domains together on the cytoplasmic 
side, forming a dimeric scaffold on which adaptor molecules could bind and initiate 
signalling cascade (Figure 10, F). When TLR3 dimerizes, it is recruited TICAM1 for 
the production of pro-inflammatory cytokines (Brikos et al., 2008). 
 
TLR3 activation triggers a signal transduction that activates IL6 production. Therefore 
the fact that iPSC derived cells seem to express more TLR3 isoform B and the fact that 
this isoform blocks the correct function of the wild type full length isoform suggests 
that iPSC derived cells might be more prone to have anti-inflammatory properties 
(Figure 9, F) after being stimulated with pathogen associated molecular patterns 
(PAMPs), such as LPS and Poly(I:C) (Figure 9, E). Lack of IL6 cytokine excesive 
inflammatory response might be a positive property of iPSC derived cells. Nevertheless, 
there’s no complete lack of IL6 secretion, since control basal levels of NSC without 
stimulation are higher than original HFFs. This small but stable level of IL6 secretion 
might be enough to maintain a desirable immune response in front of possible infections 
in transplanted iPSC derived cells inside patients.   
 
Regarding the T cell kill assay, we have shown how after in vivo priming cytotoxic T 
lymphocytes (CTLs), not only there has not been an increase in CTLs cytotoxic 
degranulation, but a significant decrease (Figure 10, C). Interestingly after priming 
CTLs against iPSC, the decrease in CD107a degranulation marker was higher than 
when priming CTLs with CM, probably because of the decrease of MHC1 receptor 
expression reported in iPSC (Figure 8, B). Correspondingly, other studies showed that 
iPSC derived retinal pigmented epithelial cells (iPSC-RPE) have also been shown to 
inhibit T cell activation in vitro through TGF-β secretion (Sugita et al., 2015). 
Moreover, no increase in apoptosis was observed in CM co-cultured with primed CTLs 
against CMs, showing a lack of immunogenicity against syngeneic cells. Corneal 
Epithelial-like cells derived from hESC have been also reported to be less responsible 
for T cell proliferation and NK cell lysis in vitro (Wang et al., 2016). Moreover, in the 
paper, Wang et al. show that the immunological properties were not affected by 
interferon-γ. All these results indicated a low immunogenicity of ESC-CECs 
corroborating our findings.  
 
The altered cytokine microenvironment of hiPSC-derived cells raises a number of issues 
to be considered for future cell transplantation. This may allow for hiPSC-derived cells 
to be used not only as an autologous cell therapy but also in a limited capacity as an 
allogeneic cell therapy. Recent work testing the allogeneic capacity of iPSC-derived 
cells in pig and rat models has revealed that this may not be the case and allogeneic 
iPSC-derived cells die in vivo at an early stage post transplantation (Sohn et al., 2015; 
Conradi et al., 2015).  
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Taken together the data demonstrate that the cell reprogramming process alters specific 
aspects of both the innate and adaptive immune response resulting in a reduction of 
immunogenicity, supporting similar findings recently described for human iPSC derived 
cells (de Almeida et al., 2014; Huang et al., 2014). 
 
 
 
Cyclin D1 iPSC functional assay with NSC. 
 
Keeping in mind that the final aim is the clinical application of iPSC derived cells, early 
this year, it has been published the first human clinical trial for iPSC transplantation 
therapies in the RIKEN institute, Japan (Mandai et al., 2017). It has consisted on iPSC 
derived retinal pigmented epithelial (RPE) cells transplantation in two age-related 
macular degeneration (AMD) patients. Therefore, an important challenge before iPSC 
can be used in the clinic is the survival and engraftment of iPSC derived cells in a 
hostile tissue environtment in vivo without evidence of pathology. Thus, in order to test 
engraftment of our new DH iPSC derived cells in vivo in an animal model, we explored 
injecting neural stem cells (NSC) into a Spinal cord injury (SCI) rat model. Hence, this 
functional assay of NSC injection resulted in a positive result of engraftment and 
survival. NSC not only survived 2 months after injection into rat spinal cords, but also 
migrated to the lesion site, which is delimited by the lack of astrocyte marker GFAP 
(Silver et al., 2004).  
 
Hematoxylin eosin staining showed a recovery of the spinal cord tissue without any 
neoplasm. However, in order to determine whether this synaptic connection between the 
central nervous system (CNS) above and below the lesion is helping to recover the 
injury a longer period of time than two months and a larger number of animals would be 
required to be able to detect a significant quantifiable mobility improvement. 
 
IPSCs can be differentiated to neural precursor cells, neural crest cells, neurons, 
oligodendrocytes, astrocytes, and even mesenchymal stromal cells. In SCI these can 
produce functional recovery by replacing lost cells and/or modulating the lesion 
microenvironment. Interestingly, after injecting DH iPSC clone DH1 derived NSC in 
the spinal cord of rats, no pathological neoplasm was formed; in contrast with our 
previous results where Retrovirally made iPSC (reprogrammed with c-Myc) derived 
Neural Stem Cells formed teratomas when injected into rat spinal cords in a similar 
model (López-Serrano et al., 2016). Remarkably, NSC differentiated in vivo into their 
derivatives: mature neurons (75,1%), oligodendrocytes (18,2%) and mature astrocytes 
(5,2%) (Figure 5, C). 
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 Cyclin D1 accelerates the reprogramming process by increasing pluripotency markers as 
shown by alkaline phosphatase in mouse and Tra-1-81 in human cells.  
 
 
 Cyclin D1 decreases cell stress response genes during early reprogramming passages, 
such as IAP2, Gadd45b and Sirt1 in mouse cells and 53BP1, sirtuin 1 and Sirt6 in 
human cells. Furthermore Cyclin D1 rescued reprogramming in mouse Sirt1-/- MEFs 
compared to c-Myc, indicating it functions independent of Sirt1. 
 
 
 Cyclin D1 made iPSC maintain the same pluripotency and differentiation potential in 
vitro and in vivo than c-Myc made iPSC. 
 
 
 Cyclin D1 mouse made clones show a significant decrease in percentage of telomere 
signal-free ends and a trend of a lower number of chromosomal fragments in the 
nucleus. On the other hand, human DH iPSC show a decrease in % of multitelomeric 
signals per chromosome (MTS/Chr) in comparison with MH iPSC.  
 
 
 Double strand breaks (DSBs) acquired during the reprogramming process and passaging 
until passage 10 and after differentiation to NSC are significantly lower when 
reprogramming with Cyclin D1 than with c-Myc. 
 
 
 Cyclin D1 promotes DNA repair by enhancement of homologous recombination by 
helping to recruit Rad51, as has been recently reported (Chalermrujinanant et al., 2016). 
Here, MH clones show high levels of cytoplasmic Rad51 than DH clones; furthermore 
DH clones have higher nuclear Rad51. 
 
 
 Gene copy number variation (CNV) is not significantly increased from HFFs to iPSC 
using synthetic mRNA transfections method. 
 
 
 DH iPSC and NSC present significantly lower KI67 levels in vitro and in vivo 
compared with MH clones, demonstrating thus a lower tumorigenic threat of Cyclin D1 
as a new component of the reprogramming cocktail as a substitute for c-Myc. 
 
 
 In the in vivo spinal cord injury rat model, we demonstrated that DH iPSC derived NSC 
survive, engraft and differentiate into their derivatives 2 months after being injected into 
the spinal cord near the lesion site. 
 
 
 Overall, results indicate that using Cyclin D1 for cell reprogramming is a better method 
to generate higher quality iPSC than using the classical c-Myc. 
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 Cell reprogramming process alters specific aspects of both the innate and adaptive 
immune response of iPSC-derived cells resulting in a reduction of immunogenicity, 
providing an insight for future clinical applications of autologous human iPSC-derived 
cell transplantation. 
 
 
 We have described an upregulation of a short isoform (isoform B) of Toll-Like 
Receptor 3 (TLR3) in all iPSC derived cells as a consequence of the hypomethylated 
CpG sites found in the alternative transcription start site of the gene, not seen in normal 
endogenous cells. 
 
 
 IPSC derived Neural Stem Cells remain unresponsive to Poly(I:C) stimulation and 
uncapable to secrete IL-6. 
 
 
 We suggest that TLR3 short isoform B competes with the full length wild type isoform 
distabilitzing the essentially required dimerization process, for processing the signal 
transduction to create an inflammatory response.  
 
 
 Lack of proinflammatory response may lead to beneficial consequences of future 
transplants of iPSC derived cells. 
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Future work/new directions: 
 
 
 To increase the detection threshold of small CNV, we will perform a whole 
genome sequencing of the iPSC and NSC samples.  
 
 
 Transfect an MMEJ reporter plasmid (pSV40-MMEJ), from Kostyrko et al., 
2016, to iPSC to determine the actual levels of alternative NHEJ in both MH and 
DH iPSC. 
 
 
 Apply for “La Marató” grant to perform a larger experiment in vivo with more 
rats to see whether NSC can help rescuing the mobility of rats in the long term. 
Then, rats would not be sacrificed until 3-4 months after injecting the cells to be 
able to detect functional recovery. 
 
 After defining this protocol to obtain better quality iPSC, we want to focus on 
developing differentiation protocols into several cell types, such as 
motorneurons to assess an SMA mice model. 
 
 
 Explore why after differentiating reprogrammed cells the epigenetic status of the 
alternative transcription start site for TLR3 remains hypomethylated. Try to 
remethylate this CpG with the CRISPR Cas9 technology. 
 
 
 Increase the number of patients studied from 6 to larger cohorts to better define 
the TLR3 status in iPSC derived cells, to see whether it is a phenomena all 
across patients with very diverse genetic backgrounds. Furthermore, exploring 
other cell types derived from iPSCs a part from NSC, like CM or Endoderm, 
among others. 
 
 
 Overexpress full length TLR3 with lentiviral vectors to overcompete with the 
short TLR3 isoform and show a recovery of response to LPS and Poly(I:C) 
stimulation. 
 
 
 Analyze IL10 secretion levels of mouse iPSC derived cardiomyocytes as a 
measure of a possible explanation of the protective effect of CM over the CTLs. 
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Suplementary figure 1.  Mouse C2C12 iPSCs reprogramming and cell stress genes.  
 
A) GFP reporter gene expression after transduction of reprogramming factors in Ecotropic Phoenix virus producing cells and 
infected mouse C2C12. B) Oct4 and Cyclin D1 protein expression level was checked by western blot to corroborate that the 
transgene was functionally producing protein. C) Alkaline phosphatase was shown positive for colonies picked after 
reprogramming C2C12 with 3F+c-Myc and 3F+Cyclin D1. D) C2C12 infected cells starting to form colonies both for 3F + c-
Myc and 3F + Cyclin D1. Reporter GFP expression was detected at passage 1 meaning the transgene was on. At passage 3, the 
transgene was silenced as GFP expression was off. E-I) Other cell stress genes levels were checked by real time PCR at 
passage 1 and 5 and compared with control C2C12 and mouse Embryonic Stem cells levels: p53 binding protein 1 (53BP1), 
The protein kinase ataxia-telangiectasia mutated (ATM) implicated in the regulation of oxidative stress, Manganese 
superoxide dismutase (MnSOD) also implicated in oxidative stress and Sirtuin 3 (Sirt3) and Sirtuin 6 (Sirt6). No significant 
differences were found. 
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Supplementary figure 2.  Cyclin D1 and c-Myc HFF iPSCs characterization. Retroviral transduction and mRNA transfection 
were used as reprogramming methods.  
 
A) GFP reporter gene expression after transduction of reprogramming factors in human foreskin fibroblasts (HFFs) iPSCs 
colonies reprogrammed retrovirally with 3F + c-Myc and 3F + Cyclin D1. B) Immunofluorescence images showing a 
positive expression of Oct4 and Sox2 in human iPSCs at passage 5 made both with 3F+c-Myc and 3F+Cyclin D1. Nuclei 
were stained with DAPI. C) FACS analysis of Tra-1-81 staining of retrovirally infected HFFs cells with 3F + c-Myc (1,3%) 
and 3F + Cyclin D1 (5,6%) compared to a non-infected control (0,5%). A polyclonal scrape of randomly picked colonies 
was stained two weeks after the cells were cultured onto a feeder layer of irHFFs in hES medium. D) Messenger RNA 
reprogrammed clones characterization: bright field (BF), immunofluorescence for pluripotency markers (OCT4, SOX2, 
TRA1-81, SSEA4) and alkaline phosphatase (AP). Karyotype of 20 metaphases per clone was also conducted; a 
representative image of normal karyotype is shown. Four clones are shown, two for c-Myc (M1 and M6) and two for Cyclin 
D1 (D1 and D3). E) Cyclin D1 mRNA functional test. Graph shows the % of EdU positive HFFs after transfection of 
different concentrations of mRNA (0, 50, 100, 250 and 500ng/well). Cells were transfected in 2% FBS. As positive control 
cells were cultured in 30% FBS. F) Reprogramming efficiency and nº of colonies of HFFs reprogrammed with retroviral 
transduction and mRNA transfections comparing conditions: base factors (BF: OSKL), BF+c-Myc and BF+Cyclin D1.  
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Supplementary figure 3.  Cyclin D1 and c-Myc mRNA iPSCs derived Neural Stem Cells (NSC) and 
Cardiomyocytes (CM) characterization and videos for beating CM.  
 
A) Immunofluorescence of generally differentiated iPSCs stained for endoderm (SMA), mesoderm (AFP) and 
ectoderm (Tuj1). Four clones are shown, two for c-Myc (M1 and M9) and two for Cyclin D1 (D3 and D5). 
Nuclei were stained with DAPI. B) Immunofluorescence of guided differentiation of iPSCs into Neural Stem 
Cells (NSC), stained for NESTIN, TUJ1, MAP2 and SOX2. Four clones are shown, two for c-Myc (M1 and M9) 
and two for Cyclin D1 (D3 and D5). Nuclei were stained with DAPI. C) Immunofluorescence of guided 
differentiation of iPSCs into Cardiomyocytes (CM), stained for GATA4 and cTnT. Four clones are shown, two 
for c-Myc (M6 and M9) and two for Cyclin D1 (D1 and D5). Nuclei were stained with DAPI. D) Flow cytometry 
analysis histograms of guided differentiation of iPSCs into definitive endoderm. Cells were stained for CXCR4. 
Four clones are shown, two for c-Myc (M6 and M9) and two for Cyclin D1 (D3 and D5). E) Videos of all clones 
(M1, M6, M9, D1, D3 and D5) differentiated into beating CM. As positive control Episomal iPSCs were also 
differentiated into CM.  
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Supplementary figure 4. In vivo pluripotency differentiation potential assessment to teratomas and cell 
proliferation rate (KI67%).  
 
A) Teratomas of mRNA made iPSCs injected in athymic nude mice (Foxn1-/-) to test the in vivo 
pluripotency potential into the three germ layers. B) Other examples of different tissues found in Cyclin 
D1 teratoma (D3): ciliated respiratory epithelium (endoderm) and muscle and adipose tissue (mesoderm). 
C) Immunohistochemistry staining of KI67 for each teratoma to assess proliferation. Five different fields 
were picked randomly for counting the % of positive cells per each teratoma. Two images per clone are 
shown. D-E) Other cell stress genes levels were checked by RT-PCR at passage 0, 3 and 10 and 
compared with control HFFs. P53 binding protein 1 (53BP1) and Sirtuin 6 (Sirt6). F) Sirtuin 1 levels by 
qPCR in iPSCs differentiated cells. After iPSCs differentiation into neural stem cells (NSC) and 
Cardiomyocytes (CM) Sirtuin 1 levels are not different between conditions. 
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Supplementary figure 5. Clinical grade human iPSCs derived NSC engraft and migrate to the lesion site in a Spinal 
Cord Injury (SCI) rat model.  
 
A) Immunofluorescence of transection cuts of perfused spinal cords at day 60 after NSC injection of three rats 
(SC #1, 2 and 3). Injected cells were tagged with cell tracker (Vybrant CFDA SE) to detect cells using a GFP 
detection wavelength. Tuj1 and GFAP were used to detect neurons and astrocytes respectively and DAPI to stain 
nuclei. A merge image is shown. Cells survived, engrafted and migrated as shown by the green tracker at day 3 
and day 60. After injecting mRNA made iPSCs derived NSC in the spinal cord no neoplasm was formed. B) NSC 
tracking show migration preferences towards the lesion site and the caudal side of the spinal cord. C) Image 
extracted from López-Serrano et al., 2016. Retrovirally made iPSCs derived NSC were injected into the spinal 
cord. Grafted cell survival and localization in the injured spinal cord. The amount of grafted cells along 1 cm of 
the injured spinal cord was studied at 7, 21, and 63 dpt by immunolabeling with human marker SC121. The 
grafted cells occupied the main part of the spinal cord at 63 dpt, filling an area that was significantly increased 
compared to the area at 7 and 21 days (G, H). ***p < 0.001. Acute and subacute transplanted groups: at 7 dpt (n = 
3), 21 dpt (n = 4), and 63 dpt (n = 6). Thus, retrovirally made iPSCs derived NSC gave raise to a tumour mass in 
the spinal cord. 
C 
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Annexes Figure 1. Messenger RNA transfection protocol. 
 
A) Synthetic messenger RNA degradation is checked by agarose gel. Oct4, Sox2, Klf4, Lin28 and Cyclin D1 are shown. 
B) GFP expression after mRNA transfection of a transcript coding for the green fluorescent protein. Every 
reprogramming experiment was done in parallel with a mGFP transfected HFFs control. C) Diagram showing Cyclin D1 
mRNA template production. ORF was cloned with a 5’ and 3’ UTR by splint ligation. D) Messenger RNA levels in the 
cell obtained by RT-PCR 24, 48 and 72h after transfect mouse fibroblasts with 200ng of Cyclin D1 and Oct4 compared 
with an untransfected control (0h). E) Schematic timeline of the mRNA transfection protocol. Different ng and different 
densities were tested, transfecting every 24h during 14-17 days. To increase reprogramming efficiency we added VPA, 
and SB431542, and PD0325901 (Zhang et al., 2011). To avoid immune response cells were pre-treated from day 1 
onwards with siRNA against IFNb1, Stat2, Eif2ak2 (Angel et al., 2010). F) Protein expression levels determined by 
Western Blot of lysates from MEFs 24h after transfecting 200ng of mRNA coding for Oct4, Sox2 and Cyclin D1. Actin 
was used as loading control. Positive control are untransfected mouse embryonic stem cells. G) Partially reprogrammed 
iPSC colonies obtained from mRNA transfected MEFs. Scale bars, 100µm. 
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Annexes Figure 2. Characterization of pluripotency of the extra clones. 
 
A) RT-PCR analysis of pluripotency markers Oct4, Sox2 and Nanog for M3, M4, M5, D2 and D4 clones 
compared with control HFFs. B) Alkaline Phosphatase staining of M3, M4, M5, D2 and D4 clones. 
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HUMAN 
GENES 
FORWARD PRIMER REVERSE PRIMER 
hGAPDH GCACCGTCAAGGCTGAGAAC AGGGATCTCGCTCCTGGAA 
hOCT4 GGAGGAAGCTGACAACAATGAAA GGCCTGCACGAGGGTTT 
hSOX2 TGCGAGCGCTGCACAT TCATGAGCGTCTTGGTTTTCC 
hNANOG ACAACTGGCCGAAGAATAGCA GGTTCCCAGTCGGGTTCAC 
hKLF4 ACGATCGTGGCCCCGGAAAAGGACC CAACAACCGAAAATGCACCAGCCCCAG 
hC-Myc GCGTCCTGGGAAGGGAGATCCGGAGC TTGAGGGGCATCGTCGCGGGAGGCTG 
hMEF2C CTGGCAACAGCAACACCTACA GCTAGTGCAAGCTCCCAACTG 
hFOX2A CTGAAGCCGGAACACCACTAC CGAGGACATGAGGTTGTTGATG 
hTUBB3 GGCCAAGTTCTGGGAAGTCA CGAGTCGCCCACGTAGTTG 
hNestin CAGGAGAAACAGGGCCTACA TGGGAGCAAAGATCCAAGAC 
hSox1 TACAGCCCCATCTCCAACTC GCTCCGACTTCACCAGAGAG 
hPax6 GCTTCACCATGGCAAATAACC GGCAGCATGCAGGAGTATGA 
hcTNT GGCAGCGGAAGAGGATGCTGAA GAGGCACCAAGTTGGGCATGAAC 
hGata4 AGGCCTCTTGCAATGCGGA CTGGTGGTGGCGTTGCTGG 
hCXCR4 TGTTGTCTGAACCCCATCCT CTGTGAGCAGGTCCAG 
hc-KIT TTCTCTGCGTTCTGCTCCTAC CCCACGCGGACTATTAAGTC 
hSox17 TGGCGCAGCAGAATCCA CCACGACTTGCCCAGCAT 
hHNF4 CTGCAGGCTCAAGAAATGCTT CTGCAGGCTCAAGAAATGCTT 
hChat AACGAGGACGAGCGTTTG TCAATCATGTCCAGCGAGTC 
hHoxB4 GTCGTCTACCCCTGGATGC TTCCTTCTCCAGCTCCAAGA 
hNkx6.1 ATTCGTTGGGGATGACAGAG CCGAGTCCTGCTTCTTCTTG 
hPeripherin AGACCATTGAGACCCGGAAT GGCCTAGGGCAGAGTCAAG 
hHLA A TCCTTGGAGCTGTGATCGCT AAGGGCAGGAACAACTCTTG 
hHLA B TCCTAGCAGTTGTGGTCATC TCAAGCTGTGAGAGACACAT 
hHLA C TCCTGGTTGTCCTAGCTGTC CAGGCTTTACAAGTGATGAG 
hB2M TGACTTTGTCACAGCCCAAGATA AATCCAAATGCGGCATCTTC 
hTLR3 CCTGGTTTGTTAATTGGATTAACGA TGAGGTGGAGTGTTGCAAAGG 
hTLR4 CCAGTGAGGATGATGCCAGAAT GCCATGGCTGGATCAGAGT 
hTLR3 
isoform B 
AAGACACAACCAGGAACTGCC GCTTCTCTGACCTTCCAGTCC 
h53BP1 GTCAGGTCATTGAGCAGTTACCTC TCCTCCACAGCAGGAGCAG 
hATM CCGTGATGACCTGAGACAAG AACACCACTTCGCTGAGAGAG 
hIAP2 ATGCTTTTGCTGTGATGGTG TGAACT TGACGGATGAACTCC 
hMnSOD TGGCCAAGGGAGATGTTACA TGATATGACCACCACCATTGAAC 
hGADD45b TCGGATTTTGCAATTTCTCC GACTCGTACACCCCCACTGT 
hSIRT1 TGGGTACCGAGATAACCTTCT TGTTCGAGGATCTGTGCCAA 
hSIRT3 GCATTCCAGACTTCAGATCGC GTGGCAGAGGCAAAGGTTCC 
hSIRT6 GCAGTCTTCCAGTGTGGTGT AAGGTGGTGTCGAACTTGGG 
hLIG3  GAAGAGCTGGAAGATAATGAGAAGG AGTGGTTGTCAACTTAGCCTGG 
hPOLQ CAGCCCTTATAGTGGAAGAAGC GCACATGGATTCCATTGCACTC 
hRad51 CAATGCAGATGCAGCTTGAA CCTTGGCTTCACTAATTCCCT 
hRad51B TTTCCCCACTGGAGCTTATG CTTCGTCCAAAGCAGAAAGG 
hBRCA1 ACAGCTGTGTGGTGCTTCTGTG CATTGTCCTCTGTCCAGGCATC 
Annexe Table 1. RT-PCR forward and reverse primers used for human and mouse qPCR. 
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hBRCA2 CTTGCCCCTTTCGTCTATTTG TACGGCCCTGAAGTACAGTCTT 
hKu70 ATGGCAACTCCAGAGCAGGTG AGTGCTTGGTGAGGGCTTCCA 
D1 ORF GAACACCAGCTCCTGTGCTGCG TCAGATGTCCACGTCCCGCAC 
 
Xu-F1 TTGGACCCTCGTACAGAAGCTAATACG     (Mandal et al., 2013) 
Xu-T120  T(120)CCTACTCAGGCTTTATTCAAGACCA    (Mandal et al., 2013) 
5' splint D1 CGCAGCACAGGAGCTGGTGTTCCATGGTGGCTCTTATATTTCTT 
3' splint D1 CCCGCAGAAGGCAGCTCAGATGTCCACGTCCC 
5' UTR TTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAG
AAGAGTAAGAAGAAATATAAGAGCCACCATG  (Mandal et al., 2013) 
3' UTR GCTGCCTTCTGCGGGGCTTGCCTTCTGGCCATGCCCTTCTTCTCTCCCTTGCACCTGTA
CCTCTTGGTCTTTGAATAAAGCCTGAGTAGGAAGTGAGGGTCTAGAACTAGTGTCGA
CGC   (Mandal et al., 2013) 
MOUSE 
GENES 
FORWARD PRIMER REVERSE PRIMER 
mGAPDH CATGGCCTTCCGTGTTCCTA CCTGCTTCACCACCTTCTTGAT 
mOCT4 TAGGTGAGCCGTCTTTCCAC GCTTAGCCAGGTTCGAGGAT 
mSOX2 TGCGAGCGCTGCACAT TCATGAGCGTCTTGGTTTTCC 
mNANOG AAACCAGTGGTTGAAGACTAGCAA GGTGCTGAGCCCTTCTGAATC 
mRex1 ACGAGTGGCAGTTTCTTCTTGGGA TATGACTCACTTCCAGGGGGCACT 
mUtf1 GGATGTCCCGGTGACTACGTCTG GGCGGATCTGGTTATCGAAGGGT 
mNkx 2.5 GACAGGTACCGCTGTTGCTT AGCCTACGGTGACCCTGAC 
mTbx5 TGACTGGCCTTAATCCCAAA ACAAGTTGTCGCATCCAGTG 
mcTnT2 GGAGGAGTACGAGGAGGAA CTCCTTGGCCTTCTCTCTC 
mTLR3  GAAGCAGGCGTCCTTGGACTT TGTGCTGAATTCCGAGATCCA 
mTLR4 CAGTGGTCAGTGTGATTGTGG TTCCTGGATGATGTTGGCAGC 
m53BP1 GTTACCTCAGCCAAACAGGACAAGCA CCCTTCCTTCTCCTCCTCTAACTC 
mATM TGCACATACAAGGTGGTTCCC CCACTCGAGAACACCGCTTC 
mIAP2 GCTCAGAATCAAAGGCCAAG CACCAGGCTCCTACTGAAGC 
mMnSOD TTAACGCGCAGATCATGCA GGTGGCGTTGAGATTGTTCA 
mGADD45b TCCTGGTCACGAACTGTCAT GATGTTTGGAGTGGGTCTCA 
mSIRT1 CTTGCACTTCAAGGGACCAA GTATACCCACCACATCTGAG 
mSIRT3 GCTGCTTCTGCGGCTCTATAC GAAGGACCTTCGACAGACCGT 
mSIRT6 GACCTGATGCTCGCTGATG GGTACCCAGGGTGACAGACA 
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